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Abstract
Background and Objective: High blood uric acid (hyperuricemia) is a common
phenomenon in populations with hypertension, hyperglycemia, obesity and/or
dyslipidemia. This study was to investigate the effects of quercetin supplementation
on blood uric acid level and the biochemical mechanism behind it.
Methods: A pilot trial confirmed the delivery of quercetin from a supplement tablet
in healthy males (n=6). Randomised, double-blind, cross-over, placebo-controlled 4-
week dietary intervention trial with the same supplement tablet containing 500 mg
quercetin d-1 was conducted in selected healthy males (n=22, with higher blood uric
acid but within normal range). Changes of uric acid and glucose were analysed in
fasting blood plasma at 0, 2 and 4 weeks. Plasma metabolomics were profiled by 1H-
NMR. Where quercetin and its metabolites may affect in the pathway of uric acid
metabolism was investigated in vitro and ex vivo.
Results: At the end of the 4-week trial, plasma uric acid levels were significantly
reduced (mean change -26.5 µM, 95% CI -7.6 to -45.5, P = 0.008, n=22), as were
diastolic blood pressures in normotensive subjects (-3.1 mm Hg, -0.5 to -5.8, P =
0.048, n=10). Paired plasma 1H-NMR spectrum showed lowered glutamine (P =
0.008), acetoacetate (P = 0.005) and lactate (P = 0.03) after quercetin treatment. A
dose-dependent inhibition of quercetin, quercetin-3'-O-sulfate and 3,4-
dihydroxyphenylacetic acid on xanthine oxidase in vitro and a mild inhibitory effect
of quercetin on plasma adenosine deaminase was found.
- iii -
Conclusions: Quercetin supplementation can maintain blood uric acid level and
blood pressure within a low-risk range. It is probably a result of regulated purine
metabolism by quercetin, its microbial derivatives and their metabolites.
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Chapter 1. Introduction
1.1 Hyperuricemia and metabolic syndromes
1.1.1 Epidemiology of hyperuricemia
Abnormally high blood uric acid (hyperuricemia) is the most determinant risk factor
for gout, an inflammatory arthritis caused by uric acid crystals (1). Patients who
develop diabetes (2), obesity (3), hyperglycemia (4, 5), hypertension (6), stroke (7),
heart disease (8, 9), kidney dysfunction (10, 11) and cancer (12), often display
hyperuricemia, although this often is not noticed until their first, if any, gout attack.
Gout prevalence increased from ~0.5 to ~3% between 1960 and 2010 in the US (13)
and other areas (14) accompanied by a parallel increase in the number of individuals
with hyperuricemia (15, 16). The prevalence of gout is much higher in men than in
women and rises with age (17). Data show a rise in the prevalence of gout that is
potentially attributable to shifts in diet and lifestyle, improved medical care, and
increased longevity (18). Interestingly, allopurinol, a uric acid lowering agent in gout
therapy, also has a protective effect on hypertension (19), which suggests that excess
uric acid synthesis is associated with hypertension (20, 21). The fact that 25-34 is the
age group with highest blood uric acid level (22) may suggest that hyperuricemia
precedes the development of metabolic syndromes (23).
1.1.2 Epidemiology of metabolic syndromes
Metabolic syndrome consists of dyslipidemia (i.e., high triglycerides and lipoproteins
containing apolipoprotein B and low high-density lipoproteins), hypertension,
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hyperglycemia, hyperinsulinemia and obesity (24). The prevalence of metabolic
syndrome in patients with gout has been reported to be as high as 62% (25). Results
of animal studies suggest that hyperuricemia might play a part in development of
metabolic syndrome (26). Hyperuricemia often precedes development of diabetes
(27), obesity (28) hyperinsulinemia (20). Elevated blood uric acid has been shown to
be an independent predictor of mortality in high-risk groups including populations
with hypertension (29, 30) and coronary heart disease (31), stroke (32), diabetes (33),
heart failure (34) and renal hypertension (35). A meta-analysis review showed that
high blood uric acid levels increase all-cause mortality in patients with heart failure,
and that this increase in risk seems to start at an uric acid level of 420 µM (36).
Growing number of experimental and clinical evidences proposed uric acid as having
a causal role in hypertension (37). Hypertension is commonly associated with
hyperuricemia (38). For example, hyperuricemia has been reported in nearly 90% of
children with newly diagnosed untreated hypertension, and uric acid concentrations
were directly related to systolic and diastolic blood pressure in these patients (39).
Normotensive men with hyperuricemia but not metabolic syndrome showed a higher
risk of hypertension than those with a uric acid concentration within the normal
range (23). Men with gout have a two-fold higher risk of kidney stones than do
patients without gout (40). Cardiovascular diseases are the greatest threat for patients
with gout. Evidence from prospective and interventional studies suggests that
hyperuricemia is an independent risk factor for cardiovascular diseases (41).
However, an elevation of uric acid in hypertension could be a consequence of
reduced renal function, the use of diuretics, the presence of hyperinsulinemia and
oxidative stress, or elevated renal vascular resistance, which are commonly present in
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this condition (42). As such, hyperuricemia is not considered a true metabolic
syndrome.
1.1.3 Pathophysiology of uric acid metabolism
The human diet contains little uric acid. It is produced in the liver and to a lesser
extent in the small intestine from the metabolism of purines. Purines come
exogenously from specific foods and endogenously from cellular metabolism. Uric
acid is a weak acid with pKa of 5.75. At a physiological pH of 7.4 in the extracellular
compartment, 98% of uric acid is present as monosodium urate, with a low solubility
limit of about 380 µM (43). Humans and higher primates do not have the enzyme
uricase that degrades uric acid to the highly soluble allantoin. Consequently, the
physiological concentration of urate in blood is close to its limit of solubility. When
urate concentration exceed 380 µM, risk of monosodium urate crystal formation and
precipitation increase (1, 44). In urine, which is acidified along the renal tubule,
urinary urate is converted to low solubility uric acid. Therefore, humans are
particularly susceptible to changes induced by diet which parallels hyperuricemia,
causing gout, arthritis, and/or kidney stone (45). Uric acid level in blood depends on
the balance between purine ingestion, synthesis in cells recycling and the degradation
function of xanthine oxidase at the end of the purine pathway (Figure 1-1).
Figure 1
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oxidised
purine metabolism in humans. The majority of uric acid is excreted by the kidney
and the rest in feces, but a substantial amount of uric acid is reabsorbed at the
proximal tubule of the kidney. Figu
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purine nucleoside phosphorylase, PNP) and dehydrogenase (xanthine
oxidoreductase, XOR or IMP dehydrogenase), end up to uric acid. Figure is
personally drawn by Yuanlu Shi.
Some dietary factors, including purines, alcohol and fructose, were critical in
elevating blood uric acid level (48-51). Persons with gout may benefit from limiting
dietary purines. Serum uric acid levels are increased with increasing total meat or
seafood intake and decrease with increasing dairy intake. In an observational study of
47 150 men, the risk for gout increased by 21% for each additional portion of meat
(such as beef, pork, lamb, broth, gravy, sweetbreads, liver and kidney) per day and
by 7% for each additional portion of seafood (such as shrimp, anchovies, mussels,
scallops, sardines, herring, fish roe, canned tuna, shrimp and lobster) per week (17).
It is important to note that moderate consumption of purine-rich food, such as
mushrooms, was not associated with an increased risk for gout (52). Furthermore, the
incidence of gout reversely associates to intake of dairy products. Protein from dairy
products does not seem to carry the same risk as protein from meat or fish sources
(52). In comparison to men who did not drink alcohol, the multivariate relative risk
of gout increased from 1.25 (95% CI, 0.95 to 1.64) for alcohol consumption of 5 to
9.9 g per day to 2.53 (95% CI, 1.73 to 3.70) for 50 g per day or more (P<0.001).
This risk varied substantially according to the type of alcoholic beverage: beer
conferred a larger risk than liquor, whereas moderate wine drinking did not increase
the risk (53).
Chronic exposure to fructose can lead to development of hyperuricemia (54).
Fructose phosphorylation by fructokinase causes intracellular phosphate depletion
leading to the activation of AMP deaminase (AMPD1), which converts the adenosine
monophosphate to inosine monophosphate. As illustrated by Figure 1-3, fructose
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enters hepatocytes and other cells (including tubular cells, adipocytes, and intestinal
epithelial cells), where it is completely metabolised by fructokinase with the
consumption of ATP; unlike in glucose metabolism, there is no negative regulatory
mechanism to prevent the depletion of ATP. Rapid conversion of fructose to fructose
1-phosphate catalysed by fructokinase results in decreased ATP and inorganic
phosphate (Pi) levels. Intracellular Pi has a regulatory effect on urate production in
the liver by inhibiting AMP deaminase. In addition, ATP levels have a regulatory
effect on 5′-nucleotidase. Thus, fructose induces acute depletion of ATP and Pi and 
causes increased activity of the enzymes involved in the degradation of purine
nucleotides to urate. This leads to the activation of AMP deaminase, which converts
the AMP to IMP, inosine and eventually uric acid (55).
As a consequence, uric acid is generated in the process, and uric acid concentrations
may rise by 60-240 µM after the ingestion of a large fructose-based meal (56).
Chronic hyperuricemia may reversely up-regulate fructokinase expression thus
leading to the amplification of the lipogenic effects of fructose in human hepatocytes
(55). Cohort studies found that fructose-sweetened beverages have a notable effect
on increased levels of BMI and serum uric acid level in adolescents (49) and adults
(50). Results from intervention studies are in accordance with this finding. An acute
hyperuricemic response was observed (P<0.01) after a 64 g fructose load in healthy
humans (48). It was widely believed that intake of polyphenol rich beverages can
increase antioxidant capacity in plasma (57, 58), but was later proven to be the effect
of fructose on plasma uric acid production (59, 60) since uric acid behaves like
antioxidant in these assays. The concentration of plasma uric acid at the end of a 1
week treatment of ~213 g d-1 (26% energy in take) of fructose is significantly higher
than that of control group in healthy young males (P<0.05) (61). However this effect
can only be confirmed in long
(62) while others fail to prove the relationship between fructose and gout
Figure 1
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1.1.4 Hyperuricemia and metabolic syndromes
A proposed causal relationship between hyperuricemia and metabolic syndromes is
shown in Figure 1-4. Insulin resistance seems to be the core reason for the
association of hyperuricemia and metabolic syndromes (65). Studies in healthy
humans (66, 67) and animal models (68) substantiate an explicable role of increased
insulin resistance to hyperuricemia, and vice versa. Over production of uric acid
could be a sign of over production of free radicals which induce oxidative
metabolism (69, 70), and uric acid itself may also inhibit nitric oxide production
(71). The combined result would be insulin resistance and platelet aggregation (72)
and pro-inflammatory activity (73). Then hypertension is caused via pathways that
involved a reduction in nitric oxide synthase in the macula densa of the kidney,
stimulation of renin-angiotensin system and reduction of renal perfusion (73).
Importantly, each of these effects was ameliorated by uric acid lowering drugs (74).
Figure
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(
1.2 Quercetin
Diabetes and diabetic complications
with lower incidence of type 2 diabetes
quercetin was conducted in 34
neuropathy
reported
quercetin, ascorbyl palmitate
mix of
1-4 Proposed causal relationship between hyperuricemia, metabolic
16, 65).
and
, a reduction in the severity of numbness, jolting pain, and irritation was
following four weeks of treatment
chlorogenic acid, myricetin,
Figure is p
metabolic
-
ersonally drawn by Yuanlu Shi and partially adapted from
syndromes
: H
patients
and vitamin D
quercetin
10 -
igher dietary flavonol intake is associated
(75). A h
with type 1 or 2 diabetes and diabetic
topically
3 (76).
and
uman interven
with a mixture
When regularly
metformin for 1 week, fasting
tion study using
that co
administered
ntained
a
- 11 -
blood glucose, 2 h postprandial, actual peak glucose and AUC (post-50 g) were
decreased in 40 diabetic patients (77).
Hypertension: Quercetin also appears to have effects on lowering blood pressure in
overweight or obese (78, 79) subjects, smokers (80) and hypertensive (81) but not
normotensive (healthy) (82, 83) individuals. Evidence from human intervention
studies suggests that the antihypertensive effect of quercetin might involve improved
endothelial function, since a single 200 mg dose of quercetin augmented nitric oxide
status and reduced endothelin-1 concentrations (84).
Metabolic syndrome traits and obesity: In animal studies, quercetin tends to
improve overall status of diet-induced problematic animals. For example, to the diet
of obese Zucker rats, quercetin was added at a dose of 2 or 10 mg kg-1 body weight
for 10 weeks, and this improved total cholesterol, triglycerides and insulin levels and
decreased inflammatory molecules produced by visceral adipose tissue (85). In a 8-
week study, quercetin (1.2% of the diet) was not effective in preventing hepatic
insulin resistance caused by a high-fat diet in mice (86). However another 20-week
study reports that mice fed by a diet high in fat, cholesterol and sugar induced
increases in visceral and hepatic fat, cholesterol, triglycerides, blood glucose, insulin
and inflammatory adipokines but their changes were partially prevented if quercetin
was administered (0.5% of the diet) (87). Quercetin was reported to be effective in
reducing high-fat induced elevations in cholesterol and triglyceride levels and
associated with a reduced formation of atherosclerotic plaques in the aorta and
carotid artery in rabbits over 12 weeks (88).
Mixed results have also been reported in human studies. Two weeks of
supplementation with doses of quercetin ranging from 50-150 mg d-1 had no effect
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on serum uric acid, lipids/lipoproteins, body composition or resting energy
expenditure (89). A supplement containing 100 mg d-1 quercetin along with 128 mg
of other mixed flavonoids (composition not specified) or placebo was given to male
smokers for 10 weeks significantly decreased total cholesterol, LDL and serum
glucose, as well as increases in HDL compared to placebo group, triglycerides, body
mass index and waist circumference did not change (80). Quercetin supplementation
(150 mg d-1) decreased blood pressure and HDL-cholesterol concentrations while
having no effect on total cholesterol or triglycerides in overweight and obese subjects
(78). The effect on aspects of metabolic syndrome might be influenced by
apolipoprotein E (apoE) genotype. A dose of 150 mg d-1 for 6 weeks decreased
systolic blood pressure by 3.4 mm Hg in the apoE3 group, but had no effect in the
apoE4 group. Quercetin decreased HDL and apoA1 and increased the LDL:HDL
cholesterol ratio in the apoE4 subgroup, but the apoE3 subgroup experienced no
significant changes in these variables (79). In a study with 1 002 subjects receiving
either 500 mg quercetin or 125 mg vitamin C with 5 mg niacin, this efficiently led to
a small decrease in blood pressure, and the group treated with double of that dose
also had a small decrease in HDL levels (90). Healthy men and women received
either 1 000 mg d-1 quercetin or placebo for 28 days but quercetin did not modify
total cholesterol, LDL, HDL, triglyceride levels, blood pressure, resting heart rate or
thrombogenic risk factors (platelet aggregation and platelet thromboxane B2
production) (83).
Hyperuricemia: An extensive amount of in vivo human and animal researches have
focused on the uric acid lowering effect of quercetin. An inverse association of blood
uric acid level with vitamin C supplementation (91), orange juice intake (92) or
coffee intake (93) was confirmed. However mixed results have been reported from
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epidemiology studies and intervention trials with quercetin and effect on blood uric
acid level. For example, among 50 healthy Japanese females (aged 53 ± 9.7 years),
flavonoids were found not to be associated with blood uric acid level (94). 6 cups of
black or green tea daily during a 4-week period had no effect on plasma uric acid on
healthy smokers (95). 400 g onion with 6 cups of tea daily providing 76-110 mg of
flavonols (mostly quercetin) for 2-week had no effect on plasma uric acid level in 10
stable type 2 diabetic patients (96). 2-week of consumption of red grape juice did not
affect concentrations of uric acid in both haemodialysis patients and healthy subjects
(97). 4-week of 15 mg d-1 quercetin glucoside from blueberry-apple juice gave no
significant difference of the uric acid levels between before and after
supplementation in 4 females and 3 males (98). 2-week of quercetin supplementation
in capsule with doses up to 150 mg d-1 had no effect on serum uric acid in human
(89). However, animal evidence suggests the uric acid lowering effects of quercetin
affords protection for both healthy and induced-hyperuricemia cases. 2-week of
quercetin treatment (5 mg kg-1) significantly reduced serum uric acid levels in
normal and induced-hyperuricemia rats (99). Oral administration of quercetin, morin,
myricetin, kaempferol, apigenin and puerarin at 50 and 100 mg kg-1 for 3 d was able
to elicit hypouricemic actions in hyperuricemic mice induced by potassium oxonate
(100). A crude apple polyphenol extract and low-viscosity apple fibres isolated from
cider apples were administered separately or in association with the diet of
apolipoprotein E deficient mice. After 4 months of supplementation, uric acid
concentrations and antioxidant capacity (Ferric reducing ability of plasma, FRAP) in
plasma were reduced in all groups supplemented with polyphenols or fibre (101). 3-
week supplementation of procyanidins from grape had no significant effect on
plasma uric acid level in both young and aged rats (102).
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1.3 Quercetin
Flavonoids, including quercetin, are molecules that have been largely studied for
their numerous biochemical and physiological activities (103, 104). Apparently, a
habitual diet approach allowing maintenance of health has been of interest to
researchers for a long time, since quercetin has an in vivo effect on biomarkers and
other metabolic syndromes that have been proven to associate with hyperuricemia
such as hypertension, diabetes and limited evidence on oxidised LDL. Quercetin is
the main flavonol in the human diet, present in many fruits, vegetables and
beverages. It is particularly abundant in onions and black tea (105). Quercetin
usually occurs as O-glycosides, with D-glucose as the most frequent sugar residue.
Quercetin is particularly interesting since it was proven to inhibit xanthine oxidase
(106). Quercetin can also inhibit enzymes responsible for superoxide anion
production, such as NADPH oxidase (107), superoxide dismutase (108) and
lipoxygenase (109). As shown in Figure 1-5, chemical structure of quercetin is
compared to that of fabuxostat, an sythesised inhibitor of xanthine oxidase. It works
by non-competitively blocking the molybdenum pterin center which is the active site
on xanthine oxidase. In particular, the dihedral angle O1C2C1′C2′ of quercetin, is in 
good agreement with the previous calculated values for distinguishing the important
aspects in the inhibition of xanthine oxidase: attraction inside the cavity and
anchorage (110).
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Table 1-1 HPLC–tandem MS (MS2) identification of quercetin metabolites detected in plasma and urine (112).
Note: Retention time is not necessarily related to indicated group position and structures with peak number with *are proposed structures.
Abreviations: Glc, glucosyl unit; GlcUA, glucuronyl unit; SO3, sulfate; [M-H]-, negatively charged molecular ion; Rt, retention time.
Peak
Rt
(min)
Skeleton
Conjugation position [M-H]-
(m/z)
MS2 fragments ions (m/z) Location
3 4' 3'
01 43·2 Quercetin OH OH OH 301 179, 151 Plasma
02 47·9 Quercetin OH OH SO3 381 301 ([M-H]--SO3) Urine, plasma
03* 48·3 Quercetin OH SO3 OH 381 301 ([M-H]--SO3) Plasma
04 28·4 Quercetin Glc OH OH 463 301 ([M-H]--Glc) Plasma
05 28·4 Quercetin GlcUA OH OH 477 301 ([M-H]--GlcUA) Urine, plasma
06 33·2 Isorhamnetin Glc OH methyl 477 315 ([M-H]--Glc) Plasma
07 34·4 Quercetin OH GlcUA OH 477 301 ([M-H]--GlcUA) Urine
08 36·3 Quercetin OH OH GlcUA 477 301 ([M-H]--GlcUA) Urine, plasma
09 34·1 Isorhamnetin GlcUA OH methyl 491 315 ([M-H]--GlcUA) Urine, plasma
10 37·2 Isorhamnetin OH GlcUA methyl 491 315 ([M-H]--GlcUA) Urine, plasma
11* 29·6 Quercetin OH Glc SO3 543 463 ([M-H]--SO3), 381 ([M-H]--Glc), 301 ([M-H]--SO3-Glc) Urine
12* 30·6 Quercetin Glc OH SO3 543 463 ([M-H]--SO3), 381 ([M-H]--Glc), 301 ([M-H]--SO3-Glc) Urine
13* 30·1 Quercetin GlcUA OH SO3 557 477 ([M-H]--SO3), 381 ([M-H]--GlcUA), 301 ([M-H]--SO3-GlcUA) Urine
14* 30·3 Quercetin OH GlcUA SO3 557 477 ([M-H]--SO3), 381 ([M-H]--GlcAU), 301 ([M-H]--SO3-GlcUA) Urine, plasma
15 22·8 Quercetin Glc Glc OH 625 463 ([M-H]--Glc), 301 ([M-H]--Glc-Glc) Plasma
16* 21·5 Quercetin Glc GlcUA OH 639 477 ([M-H]--Glc), 463 ([M-H]--GlcUA), 301 ([M-H]--GlcUA-Glc) Urine
17* 26·2 Quercetin Glc OH GlcUA 639 477 ([M-H]--Glc), 463 ([M-H]--GlcUA), 301 ([M-H]--GlcUA-Glc) Urine
18* 27·0 Quercetin GlcUA Glc OH 639 477 ([M-H]--Glc), 463 ([M-H]--GlcUA), 301 ([M-H]--Glc-GlcUA) Urine
19* 15·6 Quercetin GlcUA GlcUA OH 653 477 ([M-H]--GlcUA), 301 ([M-H]--GlcUA-GlcUA) Urine
20* 24·8 Quercetin GlcUA OH GlcUA 653 477 ([M-H]--GlcUA), 301 ([M-H]--GlcUA-GlcUA) Urine
21* 27·4 Quercetin OH GlcUA GlcUA 653 477 ([M-H]--GlcUA), 301 ([M-H]--GlcUA-GlcUA) Urine, plasma
22* 20·4 Methylquercetin GlcUA methyl GlcUA 667 491 ([M-H]--GlcUA), 315 ([M-H]--GlcUA-GlcUA) Urine
23* 22·7 Methylquercetin GlcUA GlcUA methyl 667 491 ([M-H]--GlcUA), 315 ([M-H]--GlcUA-GlcUA) Urine
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1.3.1 Absorption, bioavailability and biotransformation
Quercetin bioavailability may vary depending on the food or the conjugation and
may vary among people due to the diverse amount of transporters. The maximum
concentration in plasma can reach up to 1 to 2 µM and the excretion in urine may
typically range from 0.5 to 1.4 % as portion of intake (113). Figure 1-8 summarises
the proposed metabolic fate of quercetin once is ingested. To date, no enzymes
involved in the biotransformation of flavonoid glycosides were identified in the
stomach, however 50% of quercetin was hydrolysed there (114). Once it enters the
small intestine, quercetin may undergo deglycosylation by β -glucosidase present on 
the outer surface of the intestinal brush border or microbial enzymes in colon (115).
The quercetin-glucoside can alternatively be absorbed intact by passive diffusion and
then the glycosylated quercetin is hydrolysed in enterocytes by cytosolic β-
glucosidases (116). Based on the fact that glycosylated quercetin is more
bioavailable than quercetin, it was suggested that a glucose transport system may be
involved in the absorption of quercetin-3-O-glucoside (117). The liberated quercetin
is then glucuronidated, sulfated and/or methylated by UDP-glucuronyltransferases
(UGTs), sulfotransferases (SULTs) and catechol-O-methyl transferases (COMT), all
of which are found in human intestine. A significant amount of conjugated
flavonoids are re-secreted by enterocytes via multidrug resistance-associated protein
2 (MRP2) or breast cancer resistance protein (BCRP) into the intestinal lumen (118).
The large intestine is by far the most colonised region of the digestive tract, with a
total population of 1011-1012 CFU mL-1 of contents with more than 500 bacterial
species, of which over 99% are anaerobic (119). Intestinal bacteria also play an
important role in quercetin metabolism. Quercitin-3-O-glucoseide can be hydrolysed
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by Enterococcus casseliflavus and the released aglycone can be degraded to 3,4-
dihydroxyphenylacetic acid and phloroglucinol (120). However, flavonoids in
general are further degraded into numerous phenolic and carboxylic acid products
(121), as well as to carbon dioxide (122). As shown in Figure 1-9, the proposed
pathway for colonic bacterium-mediated catabolism of quercetin in the human large
intestine results in the production of 3,4-dihydroxyphenylacetic acid (DOPAC) and
phloroglucinol (123), smaller quantities of 3,4-dihydroxybenzoic acid, 4-
hydroxyphenylacetic acid (124) and 3-hydroxyphenylacetic acid. Like intact
quercetin, those microbial-derived phenolic metabolites are readily conjugated by
glucuronidation, sulftation, and methylation in the small intestine, liver and other
organs (Figure 1-6, Figure 1-7). The polyphenol molecule provides multiple potential
sites for these reactions and the extent of these reactions depends on substrate
specificity of the enzyme that determines the reactivity and the position of the
conjugation and the availability of the conjugation enzymes and their respective
cofactors that are affected by the proteome and metabolome.
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1.4 Objectives and methodology
Quercetin intake has been shown to affect various biomarkers of metabolic
syndromes in human. A few studies have reported the inhibition effect of quercetin
and related metabolites on xanthine oxidoreductase, the main enzyme on uric acid
production, in vitro. Quercetin treatment has significantly improved blood uric acid
level in induced-hyperuricemic mice, but it has not been established so far in humans
(see Section 1.2: Hyperuricemia). Because of the relatively lower bioavailability of
quercetin, the dosage in those human studies may not be able to deliver a decent
amount of quercetin into target organs. For the same reason, the treatment period of
2-weeks may not be long enough to allow a consistent amount of quercetin being
accumulated in blood. Therefore, a human study with a higher dosage and a longer
treatment period is necessary.
The aim of the current study is to test the hypothesis that chronic oral
supplementation of quercetin can modify the blood uric acid level in healthy men
(Figure 1-10).
Experimental Hypotheses:
1) Quercetin or its metabolites inhibit the enzymes that are involved in uric acid
metabolic pathway. They are adenosine deaminase (ADA), purine nucleoside
phosphorylase (PNP) and xanthine oxidoreductase (XO).
2) Quercetin reduce blood uric acid in human volunteers.
3) Quercetin affects fasting glucose and/or blood pressure.
4) Quercetin reduces blood uric acid by inhibiting uric acid production and/or other
mechanism, such as increasing kidney excretion.
Figure 1
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2) Development of an enzymatic assay to quantify uric acid level in biological
samples (urine, plasma, cell tissue extract or cell culture medium) aiming to detect
plasma uric acid changes.
3) Development of HPLC-DAD method that accurately quantify purine derivatives
in biological samples (plasma, cell tissue extract or cell culture medium) aiming
to evaluation the validity of in vitro enzyme kinetic assay and the effects of
quercetin and its metabolites on uric acid production.
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Chapter 2. Materials and Methods
2.1 Uric acid assay
Uric acid in plasma samples and urine samples was determined by a specific coupled
enzyme reaction, followed by a colorimetric determination at 520 nm (128). The
protocol was modified for use in a 96-well plate reader for high-throughput and
improved accuracy. Within-run variation was 1.99 ± 1.20%, and between-run
variation was 2.17 ± 0.52%. Recovery was 92.8 ± 1.6% for plasma and 80.4 ± 3.8%
for 10-fold diluted urine. Calibration curve was prepared for each plate, with a
regression curve of 0.550 ± 0.003 mM-1 uric acid and a maximum concentration of
1.0 mM with R2 ≥ 0.999. 
2.1.1 Introduction
In this assay, uric acid concentration is determined selectively by a coupled enzyme
reaction, which results in a red dye (520 nm). 8 μL of sample (serum/plasma/10-fold 
diluted urine/working standard) is needed per test. The reaction is carried at room
temperature (25 ̊C) for 15 min in 96 well plate reader. Protocol is modified according 
to Fossati et al. (128).
Figure 2-1 shows the enzymatic reaction sequence of this assay. In brief, the amount
of H2O2 produced by uricase selectively from uric acid would be detected by a
colorimetric quantification of the product of peroxidase which is proportional to the
uric acid concentration. Modifications from the original protocol include standard
curve being made by at least 5 points (including blank), instead of 2 points (including
blank). 3,5
dichloro-2
read on a 96 well plate and plate reader instead of cuvette and spec
ensures the accuracy and increases throughput.
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2.1.3 Reagents and standards
Buffer/enzymes/4-aminoantipyrine reagent Phosphate buffer, 200 mM, pH 7.0;
horseradish peroxidase, > 0.20 kU L-1; ascorbate oxidase, > 0.20 kU L-1; 4-
aminophenazone, 0.33 mM; and potassium hexacyanoferrate (II) trihydrate, 40 µM.
This reagent is stable for six weeks at 2-8 ̊C 
DHBS Sodium 3,5-dichloro-2-hydroxybenzenesulfonate 8 mM and Triton X-100, 5
g L-1. This reagent is stable for months at room temperature if protected from direct
light.
Uricase reagent Uricase, 6 kU L-1, in doubly-distilled water. This is stable for
months at room temperature, barring bacterial contamination.
Working reagent Mix the buffer/enzymes/4-aminoantipyrine, DHBS and uricase
reagents in the ratio 1.5:0.5:0.02; store in an amber glass bottle. The mixture was
used during one working day.
Standards 0.168 g of uric acid and 0.102 g of lithium carbonate were dissolved in
100 mL of Milli-Q water. To achieve this, add 30 mL of Milli-Q water and keep in
60 ̊C water bath for 20 minutes till totally dissolve and then bring the volume to 100 
mL after cooling to room temperature. Aliquots of this stock were protect from light,
stored in -20 ̊C and used within one month. 
2.1.4 Procedure
For 100 assays (96-well plate), prepare working reagent by mixing 24 mL of
Buffer/enzymes/4-aminophenazone, 8 mL of DHBS, and 320 μL of uricase reagents 
in an amber glass bottle. Quickly mix 8 μL of sample or working standards and 320 
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μL working reagent to each well. Multi-dispenser pipette is an ideal alternative to 
multi-channel pipette since reverse pipetting is recommended for avoiding bubbles.
Shortly shake the plate before incubating and let stand in dark without lid for 15 min
at 25 ̊C. Shortly shake the plate before reading the absorbance at 520 nm. When 
preparing samples into well plates, substitute H2O for urine or plasma in the first and
last sample in each plate to produce blank samples. This provides a check for carry-
over between samples.
2.1.5 Linearity and sensitivity
A moderate increase in the reagent′s pink colour does not influence the results. The 
background for the assays is the value obtained for the uric acid standard 0 (blank).
Correct for the background by subtracting the standard 0 (blank) value from all
readings. Background values can be significant and must be subtracted from all
readings. Use the values obtained from the appropriate uric acid standards to plot a
standard curve.
Calibration curve (Figure 2-2) gives a conversion k value for each plate and it is
0.550 ± 0.001 mM-1 uric acid (mean ± SEM, n=10). Recovery was calculated from
pooled plasma spike with 300 µM standards of each plate and it is 92.8 ± 0.5%
(mean ± SEM, n=10). Concentration was corrected by the corresponding recovery
value.
Figure 2
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2.2.1 Introduction
This method for measurement of D-glucose in plasma is based on the detection of
absorbance at 340 nm of NADH produced using the hexokinase assay from Sigma-
Aldrich (USA) with modification in use of 96-well micro-plate reading which
increases the amount of sample analysed in time, as well as reduces the amount of
plasma required, from 1 mL to as little as 10 μL. 
The first reaction is catalysed by the hexokinase, where glucose is phosphorylated by
adenosine triphosphate (ATP):
Glucose + ATP  G-6-P + ADP (non-selectively)
The glucose-6-phosphate (G-6-P) formed is then oxidised to 6-phosphogluconate (6-
PG) in the presence of nicotinamide adenine dinucleotide (NAD+). This reaction is
catalysed by glucose-6-phosphate dehydrogenase (G-6-PDH):
G-6-P + NAD+  6-PG + NADH (selectively)
During this oxidation, an equimolar amount of NAD+ is reduced to NADH. The
consequent increase in NADH concentration is directly proportional to the glucose
concentration and can be measured at 340 nm.
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2.2.2 Chemicals and equipment
Glucose (hexokinase) assay kit was purchased from Sigma-Aldrich (St. Louis, MO,
USA). The working reagent contains the following lyophilised compounds: 1.5 mM
of NAD+, 1.0 mM of ATP, 1.0 unit mL-1 of hexokinase (1.0 unit is defined to
phosphorylate 1.0 μmol of D-glucose per min at pH 7.6 at 25 ̊C; rate of 
phosphorylation: Km, 0.12 mM, pH 7.5, 30 ̊C), and 1.0 unit mL-1 of glucose-6-
phosphate dehydrogenase (1.0 unit is defined to convert 1.0 μmol of glucose-6-
phosphate to 6-phospho-D-gluconate per min in the presence of NADP at pH 7.4 at
25 ̊C) with sodium benzoate and potassium sorbate as preservatives. D-glucose was 
from Fisher Scientific (UK) and 96-well plate compatible for UV reading was from
Greiner bio-one (Austria). A micro-plate reader modelled PHERAstar FS
(BMGlabtech, Germany) was used for UV absorbance reading.
2.2.3 Procedure
A series of concentrations of standard solutions at 1.5, 1.0, 0.5, 0.25, 0.025 and 0 mg
mL-1 (0 mg mL-1 was used to create reagent blank) of D-glucose were prepared
freshly for each set of experiment. Mix 10 µL of standard or sample with 250 µL of
working reagent or Milli-Q water (as blank). Incubate the 96-well micro-plate for 15
min in a 30 ̊C incubator and read the absorbance at 340 nm. 
2.2.4 Linearity and sensitivity
Background values can be significant and were subtracted from all readings. The
background for the assays is the value obtained from the reagent blank, and for each
plasma sample is the value obtained from the corresponding plasma blank. Correct
for the background by subtracting the reagent blank value and their sample blank
values from all readings. Use the values obtaine
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2.3 Quantification of quercetin content in food
This method was modified and shared between group members with purpose driven
modification specified to various food type. Modification for onion extraction was
also contributed by Dr. Patthamawadee Charoensuk.
2.3.1 Sample preparation
The quercetin content of the red onion soup and of the supplement tablet was
determined by HPLC-diode-array analysis. To 5 g of frozen red onion, 5 mL of
absolute methanol was added and to 0.4 g soup powder, 5 mL of 70% methanol was
added. Extraction was performed using ultra sonication and vortex. The samples
were centrifuged (3 000 g, 4 ̊C, 10 min) and the supernatant was collected. The 
extraction was repeated twice with 5 mL of 70% aqueous methanol (containing 0.1
mM ascorbic acid, pH 5.08). 1 mL of the combined extracts was fully dried in a
centrifugal evaporator (Genevac Ltd, Ipswich, UK), and then reconstituted with 1
mL of 50% aqueous ethanol containing 100 µM daidzein as internal standard. Before
HPLC analysis, the samples were filtered through polytetrafluoroethylene (PTFE)
membrane syringe filter (pore size of 0.2 µm). Extraction was performed in duplicate
for each food sample.
2.3.2 HPLC analysis of quercetin and its conjugates
The reconstituted samples were analysed on an Agilent HPLC 1200 instrument
(Agilent Technologies, Waldbronn, Germany) equipped with C18 column
(ZORBAX Eclipse XDB-C18, 4.6×50 mm, 1.8 µm particle size, rapid resolution
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high throughput, 600 bar column, Agilent, USA) and a pre-column (Eclipse XDB-
C18, 4.6×12.5 mm, 5 µm, analytical guard cartridge, Agilent, USA).
A modified version of the analytical HPLC method from (131) and (132), was used.
Solvents A (water with 0.1% of formic acid, v/v) and B (acetonitrile with 0.1% of
formic acid, v/v) were run at a flow rate of 0.5 mL min-1. The chromatographic
conditions of elution were as follows: 0-2 min, 15% solvent B; 2-22 min, increase
solvent B from 15% to 40%; 22-24 min, isocratic for 2 min. A post-run column clean
up procedure was applied by increasing B to 90% in 1 min, isocratic for 3 min and
finally rapidly returning to initial conditions with re-equilibration at 29 min for 5 min
of 15% B. Each sample (10 µL) was injected and analysed twice. A column clean-up
stage maintained B at 90% (30 min) which was followed by a re-equilibration at 15%
B (30 min) to initiate each new batch of analysis. Diode array detection monitored
the eluent at 255 nm and 370 nm. A standard curve ranging from 15.6 to 1 000 pmol
quercetin equivalents was produced using standard solutions of quercetin 3,4′-O-
diglucosides (AUC370nm of 0.736 pmol-1), quercetin 4′-O-glucoside (AUC370nm of
1.49 pmol-1), daidzein (AUC255nm of 1.68 ± 0.01 pmol-1), and quercetin (AUC370nm of
1.26 pmol-1), with retention times of 3.20, 9.44, 12.6 and 14.3 min, respectively.
HPLC chromatograms of standard mix, supplement extract and red onion extract are
shown in Figure 2-4.
After HPLC analysis to confirm that the supplement contained pure quercetin (Figure
2-4), the quantification was performed by spectrophotometry using the extinction
coefficient (ε) at λmax (quercetin) 19.95 mM-1 cm-1 (257 nm) and 21.88 mM-1 cm-1
(376 nm) against 95% aqueous ethanol (133). In brief, 5 tablets were finely ground in
an electric coffee grinder and about 2 mg of the powder was accurately weighed and
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fully dissolved in 95% ethanol. Absorbance spectra were compared with quercetin
standards prepared in 95% ethanol.
Figure 2-4 HPLC chromatograms of (A) quercetin standards (B) supplement extracts
and (C) onion extracts at 255 nm (dash line) and 370 nm (solid line): (1)
quercetin 3,4′-O-diglucoside; (2) quercetin 4′-O-glucoside; (3) daidzein (added
as internal standard); (4) quercetin.
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2.4 HPLC-ESI/MS analysis of metabolite
2.4.1 Chemicals and enzymes
Absolute methanol, ethanol, acetonitrile (LC-MS grade) and ethyl acetate were from
VWR international, France; ascorbic acid was from MP Biomedicals, LLC, France;
formic acid, sodium acetate trihydrate, acetic acid, hydrochloric acid, β-
glucuronidase from Helix pomatia, and sulfatase from Helix pomatia, were
purchased from Sigma-Aldrich, USA. Standards of quercetin dihydrate, quercetin-4′-
O-glucoside (spiraeoside), quercetin-3,4′-O-diglucoside, isorhamnetin (3-O-
methylquercetin), tamarixetin (4′-O-methyquercetin ), daidzein and taxifolin, are all
HPLC grade and were purchased from Extrasynthese, France.
2.4.2 Processing of urine samples and analysis of quercetin
24-h urine was collected into a 3 L sterile urine storage container with 3 g of ascorbic
acid added. Once the sample arrived at the laboratory, the weight was measured and
two 45 mL aliquots were taken into 50 mL falcon tubes, then centrifuged at 2 000 g
at 4 ̊C for 10 min. The supernatant was stored at -20 ̊C until analysis. 
2.4.2.1 Enzyme hydrolysis of quercetin conjugates and liquid phase extraction
Metabolites of methyl-, glucuronyl-, glucosyl- and sulfo-conjugates of quercetin in
human urine were hydrolysed to quercetin and the monomethylated derivatives
isorhamnetin (3-O-methylquercetin) and tamarixetin (4′-O-methylquercetin) using β-
glucuronidase and sulfatase (112). To 200 µL of urine, 20 µL of 0.2 M sodium
acetate - acetic acid buffer, pH 5.0 containing 200 units β-glucuronidase and 5 units 
- 38 -
of sulfatase were added; 2 µL of 100 µM taxifolin was added as internal standard,
then incubated in a shaking water bath at 37 ̊C, 100 rpm for 1 h. The completion of 
hydrolysis of all quercetin conjugates was assured by parallel experiments running
from 1 h every 0.5 h up to 3 h (Figure 2-5). Results showed that hydrolysis was
complete within 1 h. The pH of the hydrolysis mixture was adjusted to 2.0 by
addition of 30 µL of 0.1 M HCl. To the hydrolysis mixture (about 250 µL), 500 µL
of ice-cold ethyl acetate was added, mixed vigorously by vortex for 2 min, followed
by standing on ice for 2 min and centrifugation at room temperature at 17 000 g for 2
min. The procedure was repeated twice and 3 supernatants pooled. Extracts were
fully dried by nitrogen gas, then reconstituted with 150 µL of 50% ethanol and
filtered through 0.2 µm PTFE filters before analysis. An enzyme unit was defined at
37 ̊C at pH 5.0 according to the manufacturer: one unit of β-glucuronidase liberates 
1.0 μg of phenolphthalein from phenolphthalein glucuronide per h; one unit of 
sulfatase hydrolyses 1.0 μmol 4-nitrocatechol sulfate per h. Extraction was 
performed in duplicate for each biological sample.
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Figure 2-5 Enzymatic hydrolysis of urinary quercetin conjugates against incubation
time.
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2.4.2.2 HPLC-ESI/MS
Analysis of urine concentrations of quercetin and of the monomethylated derivatives:
isorhamnetin (3-O-methylquercetin) and tamarixetin (4′-O-methylquercetin) was
performed by HPLC (detailed in Section 2.3.2) with mass spectrometry using a
Shimadzu LC-2010C HT with single ion monitoring (Shimadzu, Tokyo, Japan)
operated in negative electrospray ionization (-ESI) mode. Nitrogen was used both as
drying and nebulising gas at a flow rate of 15.0 L h-1 and 1.5 L h-1. The DL
temperature was maintained at 250 ̊C with detector voltage set at 1.80 kV and 
interface voltage at -3.5 kV. The standard curve was 0.05 - 2.00 µmol, within-run
variance was 6.8 ± 5.6% and between-run variance was 14.5 ± 8.2%. The recovery of
quercetin extraction from urine was calculated using the yield of taxifolin (internal
standard, 111 ± 14.3%, n=92). All chromatograms in the same batch were processed
automatically by software (Labsolutions, ver. 5, Shimadzu, Tokyo, Japan) using the
same processing parameters, such as integration, peak-to-peak amplitude, and peak
detection. Manual integration was performed only rarely when necessary.
Figure 2-6 shows a typical LC-MS Chromatogram of quercetin and conjugates after
enzymatic hydrolysis of urine. The retention times of quercetin (m/z 301),
isorhamnetin (m/z 315), tamarixetin (m/z 315) and taxifolin (m/z 303) are 16.1 min,
20.4 min, 20.6 min and 8.8 min, respectively.
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Figure 2-6 LC-MS chromatogram of quercetin and methylquercetin after β-
glucuronidase and sulfatase hydrolysis of urine.
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2.5 Proton nuclear magnetic resonance (1H-NMR) spectroscopy
Method is detailed in Section 5.2.
2.6 Development of HPLC method of analysing adenosine, inosine,
hypoxanthine, xanthine, uric acid and adenine simultaneously
A method that can accurately measure the product of these enzymes: inosine (of
ADA), hypoxanthine (of PNP) and uric acid (of XOR) without interference of their
enzymatic substrate adenosine (of ADA), inosine (of PNP) and hypoxanthine (of
XOR), of tested compounds (in this case, quercetin and its metabolites) or of plasma
contents was built. This method can be used for investigating interaction of interested
compounds on these enzymes by which the uric acid was produced. The HPLC
reverse phase separation was achieved on a C18 column, using a mobile phase
consisting of water containing 3- 20% methanol, at a flow rate of 0.6 mL min-1. The
column effluent was monitored by UV detection referencing to 450 nm. A linear
response was achieved over the concentration range 50 - 500 pmol. The analytical
method LOQ was below 50 pmol. This method is standardised for enzyme activity
study both of purified (or) recombinant enzymes and of delicate samples, such as
plasma or cell extract.
2.6.1 Introduction
Uric acid production results from endogenous purine degradation in hepatocyte, by
adenosine deaminase (ADA; E.C.3.5.4.4), purine nucleoside phosphorylase (PNP;
E.C.2.4.2.1) and xanthine oxidoreductase (XOR): xanthine oxidase (XO,
E.C.1.17.3.2) or xanthine dehydrogenase (XD, E.C. 1.17.1.4)
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The traditional way of separating purine nucleosides is with HPLC on a C18 column
in 8% aqueous methanol containing 30 mM of phosphate, pH 5.5 (135). Mei et al.
have reported an ideal HPLC method (136) that is satisfactory for our purpose of
separating inosine from adenosine, hypoxanthine from inosine, uric acid from
hypoxanthine and xanthine, and adenine (added as internal standard). Current
method was built by employing a combination of HPLC method using methanol (7%
- 30%) to separate inosine and adenosine (137) and one to separate inosine and
hypoxanthine (138). In our present method, a C18 column 150 mm × 4.6 mm is
equipped with a gradient combination of solvent A: 0.1% formic acid in deionised
water at pH 2.2 and solvent B: absolute methanol with reverse-phase gradient from
3% to 20% methanol. A 95% methanol cleaning step is adopted to application on
plasma samples.
2.6.2 Chemicals and methods
With adenine added as internal standard, the metabolites of adenosine, inosine,
hypoxanthine, xanthine and uric acid were analysed by HPLC-diode-array 1200
Series (Agilent Technologies) equipped with a C18 column (150 × 4.6 mm 125 Å,3
µm, Phenomenex Aqua). Solvents A (water with 0.1% v/v of formic acid) and B
(methanol) were run at a flow rate of 0.6 mL min-1. The chromatographic conditions
of elution were as follows: 0 - 2 min, 3% solvent B; 2 - 14 min, increase solvent B
from 3% to 20%. A post-run column clean up procedure was applied by increasing B
to 95% in 1 min, isocratic for 2 min and finally rapidly returning to initial conditions
with re-equilibration at 18 min for 2 min of 3% B. Each sample (10 µL) was injected
and analysed twice. A column clean-up stage maintained B at 95% (30 min) which
was followed by a re-equilibration at 3% B (30 min) to initiate each new batch of
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analysis. A photo diode array detector (DAD) was used to simultaneously record
chromatograms at 260 nm (adenosine and adenine), 250 nm (inosine and
hypoxanthine), 270 nm (xanthine) and 292 nm (uric acid) with a reference
wavelength of 450 nm.
2.6.3 Result and discussion
2.6.3.1 HPLC chromatogram
HPLC chromatogram of standards was as shown in Figure 2-8. Adenine (4.50 min),
adenosine (8.52 min), inosine (9.84 min), hypoxanthine (6.37 min) and uric acid
(6.27 min) were well separated. The retention times of hypoxanthine and uric acid
are similar therefore the two peaks overlap at 250 nm at low concentration (Figure
2-8 B). However the uric acid can be identified at 292 nm exclusively (Figure 2-8 A,
C) from the rest metabolites which compromised to the interference from
hypoxanthine (Figure 2-9). Hypoxanthine cannot be quantified for this reason but as
substrate, it is not important in quantifying reaction progress as long as it is certain
that it does not interfere with product (uric acid ) quantification.
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Figure 2-8 HPLC chromatogram of standards of (A) uric acid (6.27 min) at 292 nm,
of (B) adenine (4.50 min), adenosine (8.52 min), inosine (9.84 min) and
hypoxanthine (6.37 min) at 250 or 260 nm, (C) Peak identification of uric acid
by zoom in from 5 min to 7 min. Overlap of the peaks of uric acid and
hypoxanthine does not interfere the quantification of uric acid due to the
difference of wavelength of maximum absorbance
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Figure 2-9 Overlay of UV spectra of adenosine, inosine, adenine, xanthine,
hypoxanthine and uric acid. At 292 nm, only uric acid absorb extensively.
2.6.3.2 Linearity and sensitivity
Linearity of reagent responses was assessed by use of aqueous solutions of
adenosine, inosine, hypoxanthine, xanthine and uric acid at concentration up to 500
pmol, or to 4 000 pmol. The responses are linear within this range, with a linear
regression equation presented in Figure 2-10.
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2.6.3.3 Limit of detection and quantification
Limit of detection (LOD) and limit of quantification (LOQ) were calculated
according to the equations below
LOD=3Sa/b,
LOQ=10Sa/b,
where Sa is the residual standard deviation of the linear regression of the response
and b is the slope of the calibration curve (AUC pmol-1).
The calculation of LOD and LOQ are presented in Table 2-1. Data suggests that the
accuracy of detection is excellent for detecting small difference of product when
conduct enzyme kinetic experiment.
Table 2-1 Limit of detection and limit of quantification of compounds with this
HPLC method.
Compound b(pmol-1) Sa
range
(pmol)
LOD
(pmol)
LOQ
(pmol)
Adenosine 0.829 33.6 500-5000 122 405
Inosine 0.672 2.86 50-500 12.8 42.5
Adenine 0.632 6.38 1000 30.3 101
Xanthine 0.581 45.6 500-5000 236 785
Hypoxanthine 0.617 1.26 50-500 6.13 20.4
Uric acid 0.631 4.93 50-4000 23.4 78.2
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Figure 2-10 Calibration curve of purine derivatives quantified by HPLC-DAD at 260
nm (adenosine and adenine), 250 nm (inosine and hypoxanthine), 270 nm
(xanthine) and 292 nm (uric acid).
- 50 -
2.6.4 Conclusion
We have developed a new HPLC method for quantitatively studying the kinetics and
inhibition of human (mammalian) enzymes using body fluids (and pure enzyme
system or using cell extracts). The same method can also be extended for screening a
large number of compounds for the discovery of enzyme inhibitors.
2.7 Statistical analysis
All statistical analyses were performed using the SPSS statistics software (version
21; International Business Machines Corp., New York, USA). Normality of data
distribution was checked with the Shapiro-Wilk test and data are normally
distributed; independent samples t test was used to compare means between
treatments. Data that were not normally distributed were compared using the
Wilcoxon signed-rank tests. Relationships between variables were evaluated using
Pearson′s correlation coefficient. All calculations were carried out with CI 95%, and 
differences were considered significant at P<0.05. Correlation coefficient r was
calculated by the Pearson test. Unless otherwise indicated, the results were reported
as mean values with their standard deviations.
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Chapter 3. Comparison of the Urinary Excretion of Quercetin
Glycosides from Red Onion and Aglycone from Dietary
Supplements in Healthy Subjects a Randomised, Single-blinded,
Cross-over Study
Abstract
Some intervention studies have shown that quercetin supplementation can regulate
certain biomarkers, but it is not clear how the doses given relate to dietary quercetin
(e.g. from onion). We conducted a two-period, two-sequence cross-over study to
compare the bioavailability of quercetin when administered in the form of fresh red
onion meal (naturally glycosylated quercetin) or dietary supplement (aglycone
quercetin) under fasting conditions. Six healthy, non-smoking, adult males with BMI
22.7 ± 4.0 kg m-2 and age 35.3 ± 12.3 y were grouped to take the two study meals in
random order. In each of the 2 study periods, one serving of onion soup (made from
100 g fresh red onion, providing 156.3 ± 3.4 µmol quercetin) or a single dose of a
quercetin dihydrate tablet (1800 ± 150 µmol of quercetin) were administered
following 3 d washout. Urine samples were collected up to 24 h, and after enzyme
deconjugation, quercetin was quantified by LC-MS. The 24-h urinary excretion of
quercetin (1.69 ± 0.79 µmol) for 100 g of red onion in soup was not significantly
different to that (1.17 ± 0.44 µmol) for 500 mg quercetin supplement tablet (P =
0.065, paired t-test). This means that in practice, 500 mg of quercetin supplement can
provide bioavailable quercetin comparable to ~100 g fresh red onion. These data
allow intervention studies on quercetin giving either food or supplements to be more
effectively compared.
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3.1 Introduction
Quercetin is a flavonoid (class: flavonol) that is present at high levels in onions,
apples and tea, in the form of a 3-O-glucoside, 4′-O-glucoside or 3,4′-O-diglucoside.
Intervention studies using those foods to examine long term effects are rare, not only
because of the extensive food preparation required with consistent composition, but
also that volunteers grow tired of the same food for months which limits compliance.
Many studies using quercetin supplements (aglycone) in humans indicate effects on
antioxidant status, oxidised LDL, inflammation and metabolism (summarised in
Table 3-1). 500 mg quercetin supplementation twice per day improved the NIH
(National Institution of Health) prostatitis symptom score after 30 d in 30 men with
chronic pelvic pain syndrome (139) and improved cystitis symptoms after 28 d in 22
interstitial cystitis patients (140). 150 mg of quercetin significantly affected
expression of key genes, glycolipid catabolism, cell proliferation and apoptosis after
42 d intake in 20 subjects with a cardiovascular risk phenotype (141), and decreased
systolic blood pressure, serum HDL-cholesterol, and plasma concentrations of
atherogenic oxidised LDL in 96 healthy subjects (78). Daily consumption of 100 mg
quercetin for 70 d reduced serum total and LDL/HDL cholesterol, glucose and
systolic and diastolic blood pressure in 49 health subjects (80). 14 d of daily dose of
30 mg quercetin improved the oxidative resistance of LDL (109) and significantly
decreased tissue inhibitor of metallopeptidase-1 (TIMP-1) in plasma and lymphocyte
mRNA (142) in healthy subjects.
Whether dietary quercetin could achieve the same effects remains unknown since the
bioavailability of quercetin aglycone in supplements is much lower than quercetin
glucoside (143) and this makes interpretation and comparison of studies using
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supplements or foods difficult. Although studies have delaminated the correlation
between quercetin intake and urinary excretion (112, 116, 127, 143-150), it was
never done with quercetin dihydrate supplements at dosage up to 500 mg or in a
crossover trial in comparison to onion meal. Previous data suggests that a 10-fold
dosage difference might yield similar urinary excretion and thus present study
adopted 500 mg quercetin tablet and 47 mg quercetin from 100 g of fresh red onion.
Although limited, clinical data relating to the safety of quercetin were available from
studies in which quercetin or plant extracts containing quercetin glycosides were
provided to study subjects for oral ingestion for periods of up to 12 weeks at dose
levels ranging between 3 and 1000 mg quercetin d-1 (139, 151-153). None of them
reported significant adverse health effects following oral administration of quercetin
to humans at doses up to 1000 mg d-1 for up to 12 weeks (154). This randomised,
single-blind, two period, two sequence, cross-over intervention study, conducted
under fasting conditions with a 3 d washout period, compared different dosages of
quercetin from dietary supplements (aglycone) and fresh red onion (naturally
conjugated as glucosides). This comparison allows to calculate the dosage of
different quercetin sources needed to achieve similar effective absorption in healthy
subjects to aid in the design of meaningful intervention studies.
Table 3-1 Human intervention studies on quercetin supplementation a
dose per day b days
No. of subjects per
group c
Biomarkers significantly affected Biomarkers not significantly affected Ref
500 mg x 2 30 30 men with chronic
pelvic pain
syndrome
Improvement in NIH prostatitis symptom score (139)
500 mg x 2 28 22 interstitial cystitis
patients
Improvement in cystitis symptoms No side effects or adverse reactions (140)
250 mg x 4 21 63 Blood antioxidant capacity or plasma lipid
during ultramarathon
(141)
150 mg 14 12  Serum uric acid, plasma α- and γ -tocopherols, 
oxidised LDL, tumour necrosis factor-α, serum 
lipids and lipoproteins, plasma antioxidant
capacity, body composition, or resting energy
expenditure supplementation
(89)
150 mg 42 42 with
cardiovascular risk
phenotype
Gene expression of C1GALT1, O-glycan biosynthesis;
GM2A, glycolipid catabolism; HDGF, cell
proliferation; SERPINB9, apoptosis
Gene expression of the other target genes (155)
150 mg 42 93 overweight or
obese
Decrease of systolic blood pressure, serum HDL,
plasma concentrations of atherogenic oxidised LDL
Total cholesterol, TAG, LDL/HDL, TAG/HDL,
TNF-α, C-reactive protein, nutritional status, 
blood parameters of liver and kidney function,
haematology or serum electrolytes
(78)
150 mg 56 49 men Decrease of waist circumference, postprandial systolic
blood pressure and postprandial triacylglycerol
concentrations; increase of HDL-cholesterol and TNFα 
Endothelial function (156)
100 mg 70 49 Increase of HDL; decrease of serum total cholesterol
and LDL; decrease of systolic and diastolic blood
pressure, blood glucose
Inflammatory IL-6, sVCAM-1 (80)
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(continued from Table 3-1)
dose per day b days
No. of subjects
per group c
Biomarkers significantly affected Biomarkers not significantly affected Ref
30 mg 14 10 Improved oxidative resistance of LDL Plasma triglycerides, HDL or LDL (109)
30 mg 14 4 Decrease in TIMP-1 plasma protein and
lymphocyte mRNA
TIMP-2 and matrix metalloprotein-2
lymphocyte mRNA or plasma protein
(142)
500 mg quercetin-3-O-
glucoside
7 15 Repeated-sprint performance, percent fatigue
decrement, blood XO activity, IL-6 or uric acid
(157)
250 mg quercetin and
other polyphenols
28 27 HDL/LDL cholesterol, platelet aggregation,
plasma thromboxane B2, blood pressure,
resting heart rate
(83)
100 mg of quercetin
with 50 mg of each
[resveratrol,pterostilbe
ne, δ-tocotrienol, 
nicotinic acid]
28 81 Elderly with
normal total
serum
cholesterol
decreased serum nitric oxide, C-reactive protein,
uric acid levels, and γ-glutamyltransferase activity 
(158)
100 mg [curcumin, 400
mg]
1 15 renal
transplant
recipients
Improved renal function only in patients with
elevated serum creatinine, improved urine output
and lowered isoprostanes in patients with delayed
graft function
Blood pressure, calcineurin levels (159)
a Some of the entries were derived from (160)
b Quercetin aglycone, unless otherwise stated.
c Healthy subjects, unless otherwise stated.
Abbreviation: NIH, national institution of health; C1GALT1, Core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase; GM2A, ganglioside
monosialic 2 activator; HDGF, hepatoma-derived growth factor; SERPINB9, Serpin B9; IL-6, Interleukin 6; sVCAM-1, soluble vascular cell adhesion molecule 1;
TIMP-1, tissue inhibitor of metallopeptidase -1; TIMP-2, tissue inhibitor of metallopeptidase-2.
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3.2 Subjects and methods
3.2.1 Subjects
Six healthy male volunteers participated in the present study. They were non-
smokers, not on any medication, aged 35.3 ± 12.3 y (range 20.0 - 48.9) and had a
BMI of 22.7 ± 4.0 kg m-2 (range 18.5 - 29.9). Exclusion criteria were metabolic and
endocrine diseases, malabsorption syndromes, alcohol abuse, use of dietary
supplements or any form of regular medication. All subjects were asked to maintain
their normal lifestyle and usual extent of physical activities throughout the study.
This study was conducted according to the guidelines laid down in the Declaration of
Helsinki and all procedures involving human subjects were approved by the MaPS
and Engineering joint Faculty Research Ethics Committee (MEEC 12-019),
University of Leeds, UK. Written informed consent was obtained from all subjects.
3.2.2 Study design
The study was conducted with a single-blinded (researcher blind), diet-controlled,
cross-over design. Subjects were required to avoid flavonols in the diet for 3 d
washout prior to the breakfast and for 1 d during 24-h urine collection. For this
purpose, a list of food items rich in flavonols was given to each participant as a
guideline. This diet excluded vegetables like onion, spring onion, shallots, leeks,
chives, spinach, kale, endive, lettuce, broccoli, asparagus, tomato, olive, pepper,
courgette, green beans, broad bean, common bean and galangal; all types of berries
and currants, apple, apricot, grape and plum; all types of alcoholic beverages and tea;
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and propolis supplements. On the morning of the study, baseline urine was collected
immediately before breakfast and 24-h urine was collected following the breakfast.
The six participants were randomly assigned to treatment group A or B (n=5 and 1).
Group A ingested one quercetin supplement (1800 ± 150 µmol quercetin
equivalents) with a standard breakfast; after another 3 d washout, they ingested
onion-enriched soup (156.3 ± 3.4 µmol quercetin equivalents). Group B had
treatments in reverse order to Group A. The baseline urine was used as compliance
control and no apparent deviation from the low-quercetin diet was observed.
Accordingly, the concentrations of quercetin were very low (0.095 ± 0.037 µM,
SEM) in baseline urine.
3.2.3 Preparation of standard breakfasts
Red Onion Soup Fresh local red onions were washed, skinned and sliced after
removing the top and bottom of the bulb. The slices were frozen at -20 ̊C for 1 h and 
quickly minced with a kitchen electronic blender while still frozen. 100 g of the
onion mince was stored individually at -20 ̊C until the day of the human study. A 
breakfast was freshly made consisting of one portion of instant tomato soup mix 52 g
(Slim a Soup, Batchelorsrange, UK) and 100 g of frozen onion by adding hot water
and stirring into a soup-paste after heating in a 800 W microwave for 1 min. The
standard meal was served with buttered white bread. The soup powder did not
contain any quercetin.
Supplement Quercetin dihydrate tablets (500 mg) were Purchased from Nature′s Best 
(Kent, UK) without further processing. One tablet was consumed with buttered white
bread and instant tomato soup as above.
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3.2.4 Laboratory analysis
Method of quantification of quercetin in study food was detailed in Section 2.3.
Protocol for processing of urine samples and analysis of quercetin was as described
in Section 2.4.
3.2.5 Statistical analysis
All statistical analyses were performed using the SPSS statistics software (version
21; International Business Machines Corp., New York, USA). Normality of data
distribution was checked with the Shapiro–Wilk test and data are normally
distributed; independent samples t test was used to compare means between
treatments. All calculations were carried out with CI 95%, and differences were
considered significant at P < 0.05. Unless otherwise indicated, the results were
reported as mean values with their standard deviations.
3.3 Results
3.3.1 Control variables and intervention compliance
The baseline urine was used as compliance control and no deviation from the low-
quercetin diet was observed. Accordingly, the concentration of quercetin was very
low 0.095 ± 0.037 µM (SEM) in baseline urine.
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3.3.2 Quercetin content of the study meals
Based on individual analysis of compounds, red onion soup contained 156.3 ± 3.4
µmol quercetin equivalents per portion made from 100 g fresh red onion (quercetin
3, 4′-O-diglucoside 59.3% and quercetin 4′-O-glucoside 40.7%, substance
equivalents). Quercetin dihydrate tablets contained 1800 ± 150 µmol of quercetin
(100% quercetin aglycone).
3.3.3 Urinary excretion of quercetin
The LC-MS chromatogram of quercetin and methylquercetin after β-glucuronidase 
and fulfatase hydrolysis of human urine can be found in Section 2.4.2.2, Figure
Figure 2-6. The 24-h urinary excretion of quercetin for each individual after
consuming a meal of 100 g red onion or a single study tablet is shown in Table 3-2
and Figure 3-1. 24-h urinary excretion of quercetin after consuming red onion soup,
made from 100 g fresh red onion, was 1.69 ± 0.79 µmol (of which 72.9 ± 6.0% of
quercetin, 7.70 ± 5.92% of isorhamnetin and 19.4 ± 5.95% of tamarixetin), and that
from the 500 mg quercetin supplement was 1.17 ± 0.44 µmol (71.4 ± 11.1%, 7.54 ±
6.38% and 21.0 ± 11.7%). No significant difference in quercetin excretion was
observed within subject (P = 0.065, paired t test) or among populations (P = 0.189,
independent t test, n=6) for the total quercetin.
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Table 3-2 Total urinary excretion of quercetin and methyl quercetin (mean ± SEM)
and the proportion of each metabolites (%)
Subject Treatment
Total
quercetin,
(µmol)
24-hour urinary excretion,%
Quercetin Isorhamnetin Tamarixetin
369
Supplement 1.43 ± 0.11 74.6 ± 6.9 4.69 ± 2.77 20.7 ± 2.43
Onion soup 1.73 ± 0.12 82.5 ± 6.3 3.22 ± 2.01 14.2 ± 1.91
434
Supplement 1.07 ± 0.03 83.3 ± 1.8 12.1 ± 2.53 4.58 ± 2.89
Onion soup 0.87 ± 0.06 71.1 ± 6.9 13.0 ± 7.54 15.9 ± 9.20
442
Supplement 0.82 ± 0.05 77.4 ± 6.3 7.77 ± 2.73 14.9 ± 2.81
Onion soup 1.72 ± 0.08 71.8 ± 3.5 8.57 ± 0.38 19.6 ± 1.58
569
Supplement 1.85 ± 0.18 54.8 ± 5.3 17.5 ± 0.85 27.8 ± 3.74
Onion soup 3.17 ± 0.33 65.8 ± 9.3 15.6 ± 0.92 18.6 ± 2.11
723
Supplement 1.17 ± 0.13 60.9 ± 9.6 0.00 ± 0.00 39.1 ± 1.65
Onion soup 1.37 ± 0.12 69.1 ± 7.8 0.00 ± 0.00 30.9 ± 1.32
959
Supplement 0.66 ± 0.06 77.7 ± 8.0 3.18 ± 1.94 19.1 ± 5.31
Onion soup 1.26 ± 0.06 76.9 ± 3.9 5.74 ± 0.24 17.3 ± 0.72
Mean ± SD
Supplement 1.17 ± 0.44 71.4 ± 11.1 7.54 ± 6.38 21.0 ± 11.7
Onion soup 1.69 ± 0.79 72.9 ± 6.0 7.70 ± 5.92 19.4 ± 5.95
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Figure 3-1 Urinary excretion of quercetin and methyl quercetin (mean ± SEM). 1800
± 150 µmol quercetin from supplements or 156.3 ± 3.4 µmol quercetin from
red onion soup was provided to each individual on separate occasions.
Metabolites of methyl-, glucuronyl-, glucosyl- and sulfo-conjugates of
quercetin in human urine were hydrolysed to quercetin and the
monomethylated derivatives isorhamnetin (3′-O-methylquercetin) and
tamarixetin (4′-O-methylquercetin) using β-glucuronidase and sulfatase 
(detailed in Section 2.4.2).
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3.4 Discussion
The aim of the present randomised, single-blind, two-period, two-sequence, cross-
over intervention study, conducted under fasting conditions with a 3 d washout
period, was to compare the absorption of quercetin from fresh red onion (156.3 ± 3.4
µmol, naturally conjugated) and dietary supplements (1800 ± 150 µmol, aglycone) in
healthy subjects. This resulted in similar amounts of quercetin being absorbed as
assessed by quantifying 24-h urinary excretion of quercetin.
Quercetin supplementation dose-dependently increases plasma quercetin
concentrations in healthy humans (89), and incorporation of the washout period was
designed to diminish the impact of carry-over effects. According to other reports, the
plasma concentrations after quercetin-4′-O-glucoside supplementation (equivalent to
100 mg quercetin) reached a peak after 0.7 ± 0.3 h and the apparent elimination half-
life was about 11 h (149). Quercetin accumulated in plasma after repeated intake of
onion (elimination half-life of 28 h), apples (elimination half-life of 23 h) and tea
(143), but a steady state concentration in plasma was reached after about 4 d (147)
and so plasma concentrations would reflect the intake of only the previous 3 d. For
this reason, the length of the washout period was designed to be 3 d.
24-h urinary excretion of quercetin after consumption of red onion (mainly glucoside
conjugated quercetin) and supplement (quercetin aglycone) was significantly
different when compared by percentage dose (P<0.0001, paired t test, 1.08 ± 0.51%
and 0.065 ± 0.024%). These values are consistent with other human studies. For
example, 24-h urinary excretion of quercetin as a proportion of intake after
consumption of conjugated quercetin from fried onion was 0.8 ± 0.4% (116) and 1.1
± 0.5% (145). 13-h urinary excretion of quercetin as a proportion of intake from
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onion was 0.31 ± 0.14% and that from 100 mg quercetin aglycone was 0.12 ± 0.08%
(148). A systematic review confirmed that the correlation between the dose of
quercetin ingested and its recovery in 24-h urine samples in humans is on average 1.5
% but with recovery ranging from 0.07 to 8.4% (161). Table 3-3 summarises the
maximum plasma concentration and the urinary excretion of quercetin after
consuming quercetin rich food, quercetin-3-O-rutinoside supplement or quercetin
supplement and Figure 3-2 shows the relevance between urinary excretion and
quercetin intake, within category of each form. It should be noted that the amount in
urine reflects the minimum amount of quercetin absorbed, and other experiments
such as intestinal perfusion show that the actual amount absorbed is considerably
higher (162). Nevertheless, the amount in urine is a suitable biomarker for some
polyphenols since it allows comparisons between different foods or supplements, and
between individuals for the same compound (143, 163). The low amount of
compounds such as quercetin in the urine means that the remainder of the dose is
either excreted in the bile, in the feces or may end up as chemically-altered microbial
metabolites, which can then be absorbed in the colon (164). Typical microbial
metabolites of quercetin are 3,4-dihydroxyphenylacetic acid, 3,4-dihydroxybenzoic
acid and 3-hydroxyphenylacetic acid (114). After absorption, these compounds
participate in metabolism and so may ultimately contribute to the physiological
effects of quercetin (122). Even though the amount of intact quercetin in urine after
these dosages of supplementation and onion intake were similar, it is likely that the
supplement could deliver higher concentrations of microbial metabolites to the
blood.
Supplements have consistent quality and a relatively long shelf life, and are preferred
in many intervention studies since they remove the complication of the activity of
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other components in the food, and are well tolerated long-term by volunteers.
However, it is important to know the bio-equivalence of quercetin-containing foods
and supplements, to allow for future design and to compare existing studies.
According to the result of this study in practical terms, 100 g of onion gives a
comparable amount of quercetin in the urine to a 500 mg quercetin aglycone
supplement. Based on this data, we can compare reported intervention studies on
quercetin from onions and from supplements (Table 3-4), which lists the human
intervention studies using dietary sources of quercetin. The obvious difference
between the dose ranges between Table 3-1 and Table 3-4 may explain, for example,
why plasma LDL/HDL reduction after 14 d administration was observed by Kim et
al. (165) but not by Egert et al. (89) or Chopra et al. (109). This pilot study provides
a guideline for design of future human studies when using supplements and foods,
and also facilitates comparison of studies in existing literature.
Figure 3-2 Comparison of bioavailability among human trials. 24-h (or 13-h) urinary
excretion of quercetin from onion or supplement. Data were extracted from
(112, 116, 127, 143-150) and present study (red circled).
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Table 3-3 Bioavailability of quercetin from onion or supplement.
Quercetin
intake
(µmol)
24 h Urinary
excretion (µmol)
Urinary
excretion as
portion of
intake (%)
ref
Juice 15.9 0.046 0.29 (144)
Juice 31.8 0.149 0.47 (144)
Onion 43 0.45 ± 0.22 1.1 ± 0.5 (145)
food mix 69.5 1.43 2.06 (146)
Onion 156.3 ± 3.4 1.69 ± 0.79 1.08 ± 0.51 Present
study
Onion 225 ± 43 3.22 ± 1.6 1.39 ± 0.49 (143)
Onion 252 0.62 ± 0.17 0.24 ± 0.07 (147)
Onion 275 ± 8.8 12.9 4.7 (112)
Onion (13h) 295 ± 46 0.911 ± 0.427 0.31 ± 0.14 (148)
Onion 331 21.2 ± 8.3 6.4 ± 2.5 (149)
Quercetin-4′-glucoside 331 14.9 ± 5.6 4.5 ± 1.7 (149) 
Onion 364 0.87 ± 0.27 0.24 ± 0.07 (147)
Onion 411 ± 74 3.29 ± 0.59 0.8 ± 0.4 (116)
Quercetin-3-O-rutinoside 176 1.04 ± 0.04 0.59 ± 0.02 (127)
Quercetin-3-O-rutinoside 331 ± 7 1.17 ± 1.34 0.35 ± 0.41 (143)
Quercetin-3-O-rutinoside (13h) 331 ± 17 0.241 ± 0.629 0.07 ± 0.19 (148)
Quercetin-3-O-rutinoside 662 5.96 ± 5.96 0.9 ± 0.9 (149)
Quercetin aglycone 107.6 8.18 7.6 (150)
Quercetin aglycone (13h) 331 ± 17 0.381 ± 0.248 0.12 ± 0.08 (148)
Quercetin dihydrate 1800 ± 150 1.17 ± 0.44 0.065 ± 0.024 Present
study
Note: All data are presented by mean ± SD.
Table 3-4 Human intervention studies on dietary quercetin a
Dose per day b Supplement
equivalent c
Days No. of subjects
per group d
Biomarkers significantly affected Biomarkers not significantly affected Ref
76-110 mg quercetin
and other flavonols
from 400 g onion
(with tomato sauce) +
6 cups of tea
1200-1800 mg
with other
14 10 type 2
diabetic
patients
Decrease oxidative damage to
lymphocyte DNA
Fasting plasma glucose, fructoseamine,
vitamin C, carotenoids, α-tocopherol, urate, 
albumin and bilirubin
(96)
200 g onion 1500 mg 1 6 female Increase resistance of
lymphocyte DNA to strand
breakage, decrease in urinary 8-
hydroxy-2′-deoxyguanosine 
Urinary malondialdehyde (166)
21 mg dietary
quercetin, 9 mg
dietary kaempferol
350 mg with
other
1 19 female Increase in erythrocyte
superoxide dismutase activity,
decrease in lymphocyte DNA
damage (tail moment)
Plasma α-tocopherol or β-carotene (146) 
51 mg quercetin from
4.3 g onion extract
850 mg 30 23 male with
oral maltose
load induced
postprandial
endothelial
dysfunction
Increase postprandial flow-
mediated vasodilation (FMD)
responses
Fasting FMD systemic or forearm
hemodynamic
(167)
100 mg quercetin +
128 mg other
flavonoids, onion peel
extract
1660 mg with
other
14 12 female Decrease total cholesterol level,
LDL cholesterol and atherogenic
index
Erythrocyte antioxidant enzymes, lipid
peroxidation markers, plasma antioxidant
vitamin (retinol, tocopherol, carotenoids,
coenzyme Q10), ex vivo H2O2-provoked
oxidative DNA damage
(165)
a Some of the entries were derived from (160)
b Quercetin aglycone, unless otherwise stated.
c Calculation is based on 16.6-fold since 100 mg quercetin aglycone equivalents from onions would be comparable to about 1660 mg quercetin aglycones from
supplements, according to this study.
d Healthy subjects, unless otherwise stated.
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Chapter 4. Effect of Quercetin Supplements on Healthy Males: a
Four-Week Randomised Cross-Over Trial
Abstract
Hypertension, diabetes and obesity are often accompanied by hyperuricemia, which,
if left unattended, may lead to gout. Allopurinol is usually administered to mediate
hyperuricemia during gout treatment but is associated with side effects including
joint problems and rashes. We explored non-drug strategies to reduce plasma uric
acid using the naturally occurring biologically active molecule, quercetin, which
inhibits XO, a key enzyme in the production of uric acid. To determine effects of one
month oral supplementation of quercetin on plasma uric acid level, on blood pressure
and on fasting glucose, a randomised, double-blinded, placebo-controlled, cross-over
trial (between February 2013 to April 2014) involving 22 healthy males aged 19 to
60 years with baseline plasma uric acid concentration in the higher range (but still
considered healthy; 339 ± 51 µM) was conducted with one quercetin tablet
containing 500 mg quercetin daily for 4 weeks, compared to placebo (one lactose
tablet), once daily for 4 weeks, with a 4-week washout period between treatments.
The order of the treatments was randomised. At the end of 4 weeks of daily
supplementation of quercetin, plasma uric acid levels were significantly lowered by -
26.5 µM (95% confidence interval [CI], -7.6 to -45.5 µM; P=0.008), without
affecting fasting glucose, urinary excretion of uric acid or blood pressure. In
conclusion, daily supplementation of 500 mg quercetin for 4 weeks significantly
reduces plasma uric acid concentrations in healthy males.
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4.1 Introduction
Hyperuricemia is the strongest determinant risk factor for gout, an inflammatory
arthritis caused by uric acid crystals (1). Hyperuricemia is common in patients who
develop diabetes (2), obesity (3), hyperglycemia (4, 5), hypertension (6), stroke (7),
heart disease (8, 9), kidney dysfunction (10, 11) and cancer (12), although it is often
unattended until their first, if any, gout attack. Gout prevalence increased from ~0.5
to ~3% between 1960 and 2010 in the US (13) and other areas (14) accompanied by
a parallel increase in the number of individuals with hyperuricemia (15, 16). The fact
that 25-34 is the age group with highest blood uric acid level (22) may suggest that
hyperuricemia precedes the development of metabolic syndromes (23). Interestingly,
allopurinol, a uric acid lowering agent in gout therapy, has a protective effect on
hypertension, which suggests that excess uric acid synthesis is a casual factor in
developing hypertension (20).
Some dietary factors, including purines, alcohol and fructose, also elevate blood uric
acid (48-51). For example, chronic exposure to fructose can lead to development of
hyperuricemia (54). Fructose phosphorylation by fructokinase causes intracellular
phosphate depletion leading to the activation of deaminase, which converts the
adenosine monophosphate to inosine monophosphate, inosine, and hypoxanthine,
xanthine and ultimately uric acid through XOR (Figure 1-3). Chronic hyperuricemia
may also up-regulate fructokinase expression therefore leading to the amplification
of the lipogenic effects of fructose in human hepatocytes (55). Apparently, fructose
induced insulin resistance occurs as a result of fructose-induced hyperuricemia (168,
169). Studies in healthy humans (66, 67) and in animal models (68) substantiate the
importance of increased insulin resistance to hyperuricemia, and vice versa.
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Recently, quercetin was identified to be able to induce insulin secretion (170),
protect INS-1 pancreatic β-cells against oxidative damage (171) and reduce insulin 
resistance in adipose tissue and skeletal muscle (172).
Apparently, XOR, as the major enzyme in uric acid production, became an
extensively pharmacologically targeted enzyme in extensive exploration of inhibition
strategies, including allopurinol (173). The plant-derived flavonoid, quercetin, and its
metabolites inhibit XO in vitro (111) and regulate blood uric acid level in vivo in
animal studies (99-101), yet whether uric acid metabolism could be similarly
affected in humans is still highly debatable (89, 94-98).
Therefore, we performed this randomised, double-blindeded, placebo-controlled,
cross-over trial to test the hypothesis that habitual 500 mg d-1 of oral quercetin
supplementation might result in a long-term reduction in plasma uric acid in subjects
with non-optimal blood uric acid.
4.2 Materials and methods
4.2.1 Sample size calculation
A sample size of 17 was estimated to be required to detect a 10% difference for the
primary efficacy variable, plasma concentration of uric acid, and to achieve 80%
power to meet the two-tailed equality criteria between quercetin and placebo. A
significance level of 0.05 from paired 2-sample t test was set for this two-sequence,
two period cross-over design (174). Coefficient of variation of blood uric acid level
among population was about 20% according to previous cohort reports (78, 175,
176) and 10% of coefficient of variation among study population was estimated since
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we pre-screened and selected the upper 50% of the volunteers in plasma uric acid
concentration. About 50 ± 10 volunteers shall be screened in the first stage. The
volunteers with plasma uric acid level exceeding 300 μM would be selected. 
4.2.2 Subjects
22 healthy males were eligibly assigned and successfully compliant to the complete
study. Selection criteria included being apparently healthy, age between 19 to 65,
BMI between 18.5 and 29.9 kg m-², non-smoking and not a heavy drinker (less than 3
units of alcohol regularly per day). Volunteers with diagnosed gout and/or kidney
stone, who were experiencing intestinal disorders, or whose plasma uric acid
concentration was lower than 300 µM, were excluded. The study was conducted
according to the guidelines laid down in the declaration of Helsinki of 1975 as
revised in 1983 and all procedures involving human subjects were in accordance
with the ethical standards of the University of Leeds, MaPS and Engineering joint
Faculty Research Ethics Committee (MEEC12-019), UK. Written informed consent
was obtained from each of the subjects before commencement of the study. All data
were collected and analysed in the School of Food Science and Nutrition in the
University of Leeds, UK.
4.2.3 Study design
The main goal of the present study was to examine the chronic effect of quercetin on
plasma uric acid concentration, as well as on biochemical markers associated with
chronic pre-diabetes and hypertension. For this purpose, the study was a randomised,
double-blinded, placebo controlled, cross-over, 4-week intervention trial with 2
treatment groups, with daily consumption of either quercetin dihydrate tablet (500
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mg stated, actual measured 544 mg, purchased from Nature′s Best, Kent, UK) (177) 
or placebo (the placebo formulation is a white oval tablet and contain lactose
monohydrate, magnesium stearate and cellulose, purchased from Fagron, Barsbuttel,
Germany). There was a 4-week washout period between each treatment. Blood and
urine samples were taken before, during and the end of each study phase (Figure
4-1). Each participant was independently and randomly assigned in one of two
groups, receiving both treatments in one order or another.
During the protocol, volunteers made 6 visits to the research unit at day 0, 14 and 28
of each experimental period for measurement and sample collection. In practice, with
24-hour urine collected at home during the day and night before the visit, overnight-
fasted subject arrived at the research unit between 7-10 am. A fasting blood sample
was collected, followed by questionnaires and measurements of weight, height and
blood pressure. Subjects received a light meal and the study tablets before leaving
the research unit. All participants were assured not to exceed the dosage described in
this study. Subjects were asked to maintain their lifestyle and their normal dietary
habits from 4 weeks before the first visit till the end of the entire study. Compliance
was assessed at the end of each 4-week period by call back questionnaires recording
date of missing dose, changes of physical activity and intensity, use of exotic diet or
non-routine medications, and the occurrence of any side effects. Subjects were also
asked to return the unconsumed tablets at each follow-up visit.
Intervention was randomised independently by a coin toss for each volunteer who
received a random 3 digital code. A decode list (participant identification and subject
code) was kept by a third person in order to blind the researcher assessing outcomes.
The size and shape of study tablets were the same and of different colour, and
participants were not aware of the identification of the two types of study tablets.
Figure 4
4.2.4 Sample collection
Blood pressure was measured on the left upper arm in a quiet room at normal
temperature 25
(Panasonic Co., Tokyo, Japan). Before blood pressure recording were made,
participants rested 15 min in a seated position. At each assessment, 3 consecutive
blood pressure readings were recorded at 5 min interv
measures was used for analysis.
Venous blood was collected following a standard venepuncture protocol into a
sodium fluoride/potassium oxalate blood collection tube (Greiner
Blood samples were immediately centri
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were stored at -80 ̊C until analysis. 24-hour urine samples were collected by 
volunteers in 3 L sterile urine container (Simport, Beloeil, Canada) which contained
3 g of L-ascorbic acid (MP Biomedicals, France). The urine samples were weighed
before centrifugation at 2 000 g, 4 ̊C for 10 min before storage at -20 ̊C. Urine 
samples for uric acid assay was 10-fold diluted before storage at -80 ̊C. Urinary 
quercetin was quantified by HPLC-ESI/MS as previously described in Section 2.4
(177).
4.2.5 Uric acid assay
Assessment of uric acid in plasma and urine samples was by a specific coupled
enzyme reaction, followed by a colorimetric determination at 520 nm (128). The
protocol was modified for use in a 96-well plate reader (BMGlabtech, Germany) for
high-throughput and improved accuracy. Within-run variation was 1.99 ± 1.20%, and
between-run variation was 2.17 ± 0.52%. Recovery was 92.8 ± 1.6% for plasma and
80.4 ± 3.8% for 10-fold diluted urine. Calibration curve was prepared for each plate,
with a regression curve of 0.550 ± 0.003 mM-1 uric acid with R2 > 0.999 and a
maximum concentration of 1.0 mM. The protocol is detailed in Section 2.1.
4.2.6 Measurement of blood glucose
Plasma glucose was measured with a commercial hexokinase assay kit for D-glucose
(Sigma-Aldrich, St. Louis, USA). The protocol was modified for use in a 96-well
plate reader. Within-run variation was 4.29 ± 2.21% and between-run variation was
3.33 ± 2.51%. Recovery was 104 ± 8%. Calibration curve was prepared for each
plate, with a regression curve of 0.923 ± 0.006 per mg mL-1, D-glucose with R2 ≥ 
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0.999 and a maximum concentration of 1.5 mg mL-1. The protocol is detailed in
Section 2.2.
4.2.7 Statistical analysis
Normality of data distribution was tested by Shapiro-Wilk tests. The paired 2-sample
t test was used for comparison of normally distributed data. Data that were not
normally distributed were compared using the Wilcoxon signed-rank tests.
Relationships between variables were evaluated using Pearson′s correlation 
coefficient. In all cases, a value for P ≤ 0.05 (2-tailed) was taken to indicate a 
significant effect. Unless otherwise indicated, results are expressed as mean values
and standard deviations (SD). All statistical analyses were performed using the SPSS
statistics software (version 21; International Business Machines Corp., New York,
USA).
4.3 Results
4.3.1 Subjects
During the recruitment, among the potential volunteers who expressed their interest
in participation, 54 provided contact information, measurements of height and
weight, age, history of disease, and written consent. 2 failed to donate blood at this
stage because of fear of needles or difficulty in locating vein, so they were no longer
continuing in the following study. 52 of them successfully donate a single fasting
blood sample for uric acid assay. They aged 28.6 ± 11.6 years (ranging 19-60 years),
with a body mass index of 24.2 ± 3.36 kg m-2 and plasma uric acid at 316 ± 56.5 µM
(ranging 194
completed the study (
Figure 4-2
to the CONSORT statement. (Consolidated standards of reporting trials
-472 µM,
Flow diagram for
n=52) (Table
Figure 4-2).
current
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Table 4-1 Physical characteristics of volunteer participants at screen visit, n=52
Variable Mean SEM SD Min Max
Age (years) 28.6 1.62 11.6 19.0 60.0
Body mass index (kg m-2) 24.2 0.43 3.36 18.5 32.7
Uric acid (µM) 316 7.92 56.5 194 472
The study recruitment attracted mostly adults in their early 20s (Figure 4-3) since the
advertisement was posted around the campus of the University of Leeds. However,
among the volunteers who made contact (n=54) and donated blood sample (n=52), a
strong correlation was found between age and BMI (Figure 4-3), while no correlation
was found between blood uric acid level and BMI or between that and age (Figure
4-4). This finding confirmed the necessity of screening subject by blood analysis.
Figure 4-3 Correlation between age and BMI.
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Figure 4-4 No correlation can be found between concentration of plasma uric acid
with either age (A) or BMI (B) (n=52).
The study population (n=22) selectively contains volunteers with a relatively high
uric acid level after exclusion. Comparison of the histogram between populations
included and excluded shows a clear shift of the main range (Figure 4-5).
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Figure 4-5 Histogram of plasma uric acid concentration at screening visit.
The distribution of volunteers who were excluded because of either low plasma uric
acid level or other personal reasons. Figure at bottom shows the plasma uric acid
concentration distribution of the 22 volunteers who successfully complete the study.
The upper shift of normal curve suggested that selection in this stage is efficient.
They were healthy adult males aged 29.9 ± 12.9 y with BMI of 24.8 ± 3.0 kg m-2,
blood pressure of normal to (pre-) hypertensive (Systolic 123 ± 8 mm Hg, Diastolic
74.3 ± 9.0 mm Hg), and fasting blood glucose of normal to impaired fasting
glycemia of 5.04 ± 0.56 mM and plasma uric acid of 339 ± 51 µM (Table 4-2). The
BMI of the study subject are distributed across normal weight and overweight. The
age of the study subjects is mainly young adults and ranges up to 60 year however an
age gap between younger and elder was observed (Figure 4-6).
Table 4-2
n=22
Age (y)
BMI (kg m
Heart rate (beats min
Systolic blood pressure (
Diastolic blood pressure (
Plasma uric acid (µM)
Fasting glucose (mM)
Figure 4-6
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glucose, uric acid, age, BMI, DBP and SBP. Significant correlations were found
between age and fasting glucose (Pearson correlation = 0.666, P<0.01), age and DBP
(Pearson correlation = 0.611, P<0.01), age and BMI (Pearson correlation = 0.559,
P<0.01); and between DBP and BMI (Pearson correlation = 0.470, P<0.05), DBP
and fasting glucose (Pearson correlation = 0.811, P<0.01), DBP and SBP (Pearson
correlation = 0.548, P<0.01). No other significant correlation was found. No
significant correlation between plasma uric acid with any other factors were found,
although this contradicts a previous publication (179).
It is important to notice the correlation between DBP and fasting glucose at baseline
visit (Pearson correlation = 0.811, P<0.01), as shown in Figure 4-7 E and another
three following visits (Figure 4-8). This may be an observation confirming the
correlation between pre-hypertension and pre-diabetes (impaired glucose tolerance).
Table 4-3 Correlations of baseline biomarkers, n=22.
Glucose
(mM)
Uric acid
(µM)
Age
(year)
BMI
(kg m-2)
SBP
(mm Hg)
Uric acid (µM) .285
(.198)
-- -- -- --
Age (year) .666
(.001) **
-.038
(.866)
-- -- --
BMI (kg m-2) .315
(.153)
.080
(.572)
.456
(.033) *
-- --
SBP (mm Hg) .202
(.366)
.056
(.806)
.119
(.596)
.326
(.139)
--
DBP (mm Hg) .811
(<.001) **
.184
(.412)
.611
(.003) **
.470
(.027) *
.548
(.008) **
Note: Data presented in Pearson Correlation (P value, 2-tailed). * indicates a trend
(P<0.1) and ** indicates P<0.05.
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Figure 4-7 Correlations among age, BMI, fasting glucose, DBP and SBP in all
subjects (n=22) at baseline visit.
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A B
C D
E
Figure 4-8 Strong correlation between DBP and fasting glucose was confirmed
repeatedly in all 4 different visits with 4 weeks interval (panel A, B, C, D) of
22 subjects. Overlay of 4 measurements is shown in panel E.
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4.3.3 Intervention compliance
The study population was homogenous because strict eligibility criteria and
participant surveillance were used to prevent confounding influences of gender,
medications, diet, or other lifestyle factors. The BMI of each subject was consistent
compared to previous visits and this suggests the consistency of physiological status
during the whole study as the subjects were required to avoid vigorous change of
physical activity or dietary habits (Table 4-4). According to participant′s reports, no 
significant change of lifestyle or medication occurred during the study on lifestyle
maintenance questionnaire and no adverse event for receiving quercetin or placebo
was reported (Table 4-5). 24-h urinary excretion of quercetin was 0.810 ± 0.704
µmol during quercetin treatment and 0.200 ± 0.366 µmol during placebo treatment
(Figure 4-9, Figure 4-10). According to the returned unconsumed tablets, participant
self-reports and significant difference of the uptake of quercetin during interventions,
none of the participants was classified as non-compliant.
Table 4-4 BMI change during the study (n=22)
BMI (kg m-2)
Time Mean SEM
1st arm
Baseline
Endpoint
24.9
25.1
0.6
0.6
2nd arm
Baseline
Endpoint
25.1
25.1
0.6
0.6
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Table 4-5 Summary of questionnaire of lifestyle maintenance, number of Yes (parts
out of 22)
1st arm 2nd arm
Baseline Endpoint Baseline Endpoint
Change of physical activity 3 (13.6%) 2 (9.09%) 3 (13.6%) 0
Change of dietary habits 0 1 (4.55%) 2 (9.09%) 0
Non-routine medication 4 (18.2%) 3 (13.6%) 2 (9.09%) 1 (4.55%)
Problem following the diet 0 0 0 1 (4.55%)
Vomiting or diarrhea 0 0 0 0
More than 2 changes 0 0 0 1 (4.55%)
Note: The specific details of answers of Yes were recorded and exanimated. No
event can be classified as having a significant impact on study progress.
Figure 4-9 Box plot showing the variety of 24-h urinary excretion of intact quercetin
among study population and compared between that affected by treatment.
24-h urinary excretion of intact quercetin was 0.810 ± 0.150 µmol and 0.200 ± 0.078
µmol for quercetin and placebo respectively (mean ± SEM, n=22). Quercetin
supplementation is significantly improving quercetin intake in 22 free living
subjects.
Figure 4-10
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.
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4.3.4 Uric acid level in plasma
A two-way repeated measures ANOVA was run to determine the effect of different
treatments over time on plasma uric acid concentration. Analysis of the studentized
residuals showed that there was normality, as assessed by the Shapiro-Wilk test of
normality and no outliers, as assessed by no studentized residuals greater than ± 3
standard deviations. There was sphericity for the interaction term, as assessed by
Mauchly's test of sphericity (P > 0.05). There was a statistically significant
interaction between treatment and time on plasma uric acid concentration, F (2, 42) =
3.387, P = .043, partial η2 = .139. Therefore, simple main effects were run for
treatments. Plasma uric acid concentration was not statistically significantly different
in the control trial (315 ± 45 µM) compared to the intervention trial (330 ± 56 µM) at
the baseline of the trials, F (1, 21) = 1.709, P = .205, partial η2 = .075. Plasma uric
acid concentration was not statistically significantly different in the control trial (325
± 52 µM) compared to the intervention trial (314 ± 55 µM) at 2-week of the trials, F
(1, 21) = 1.315, P = .264, partial η2 = .059. However, plasma uric acid concentration
was statistically significantly different in the control trial (320 ± 47 µM) compared to
the intervention trial (304 ± 48 µM) at the 4-week of the trials, F (1, 21) = 4.894, P =
.038, partial η2 = .189, with a mean difference of 16.5 (95% CI, 1.0 to 32) µM. Also,
simple main effects were run for time. There was no statistically significant effect of
time on plasma uric acid concentration in the control trial, F (2, 42) = 0.589, P = .59,
partial η2 = .027. Plasma uric acid concentration was statistically significantly
reduced along time during quercetin treatment, F (2, 42) = 6.166, P = .004, partial η2
= .227.
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Table 4-6 Effect on plasma uric acid (µM) of quercetin and placebo during
intervention (n=22)
Note: All values are presented as mean ± SD. Data were tested by paried sample t test since the data is
normally distributed * indicates 0.01<P<0.05 and ** indicates P<0.01.
Plasma uric acid improved progressively over time among participants during 4
weeks of quercetin supplementation. From baseline to 2 weeks, plasma uric acid
showed a downward trend by -15.9 µM (95% CI, 0.9 to -32.8; P = 0.063). From
baseline to 4 weeks, plasma uric acid was decreased significantly by mean ± SEM
from 330 ± 12 µM to 304 ± 10 µM (95% CI, -7.6 to -45.5; P = 0.008). Plasma uric
acid by mean ± SEM remained unchanged throughout the treatment period when
participants received placebo from baseline of 315 ± 10 µM to 325 ± 11 µM (mean
change of 10.6 µM; 95% CI, -8.9 to 30.0; P = 0.273) at 2-week interval and to 320 ±
10 µM by mean change of 5.2 µM (95% CI, -15.1 to 25.5; P = 0.598) at 4-week
interval. No difference was observed between the baselines of each arm (P = 0.205).
(Table 4-6, Figure 4-11). The magnitude of plasma uric acid reduction was higher in
individuals with higher baseline plasma uric acid in both treatments. Plasma uric acid
in the majority of subjects declined after 4 weeks in treatment by quercetin (17/22)
but not by placebo (10/22) (Figure 4-12).
Treatment
Study Period ANOVA P
(effect of
time)
2-Week 4-Week
Baseline 2-Week 4-Week Change(95% CI) P
Change
(95% CI) P
Quercetin 330 ± 56 314 ± 55 304 ± 48 .004 ** -15.9(0.9, -32.8) .063
-26.5
(-7.6, -45.5) .008 **
Placebo 315 ± 45 325 ± 52 320 ± 47 .559 10.6(-8.9, 30.0) .273
5.2
(-15.1, 25.5) .598
ANOVA P
(effect of
treatments)
.205 .264 .038 * .043 *
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Figure 4-11 Distribution of plasma uric acid concentration (µM) in 22 healthy man
before, during and after the 4-week supplementation or placebo. Data are
presented by mean and 95% confidence interval.
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Figure 4-12 Regressions of changes of plasma uric acid after treatment of quercetin
or placebo within subject compared to baseline reading.
Compared to the placebo which does not affect the plasma uric acid in population
(n=22), supplementation have reduced the plasma uric acid level in majority of the
subjects (n=17 of 22). Correlation coefficient r was calculated by the Pearson test.
Due to the huge between-subjects variation of quercetin absorption and renal
excretion, compliance cannot be check by urinary excretion alone. Therefore, as
shown in Figure 4-13, each subject was reviewed by comparing the change of
concentration of plasma uric acid from baseline to the 24 h urinary excretion of total
quercetin during each arm. This plot helped to explain some of the outliers and
unexpected effects of the placebo.
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Figure 4-13 Relevance between blood uric acid reduction and quercetin
supplementation is presented for each individual. The mean value ± SD were
calculated by averaging the data from 2-week and 4-week samples.
The optimised coherence of efficient sample size and efficient inclusion criteria. In
consider of the U-shape association between plasma uric acid levels and mortality
risk (180) indicating that lower uric acid level subjects should be carefully excluded
because treatment might cause hypoururicemia in them.
4.3.5 Resting blood pressures
Blood pressure measures are presented in Table 4-7. Subjects were grouped
according to guidelines of World Health Organization-International Society of
Hypertension (WHO-ISH). Subjects with SBP lower than 120/80 mm Hg (n=10)
were considered as normotensive, between 120/80 and 140/90 mm Hg as pre-
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hypertensive (n=10), higher than 140/90 as hypertensive (n=2). The DBP in the
normotensive group (n=10) were significantly reduced after quercetin
supplementation (P<0.05) but not in the placebo group (Table 4-7). SBP was not
changed significantly in either group (Figure 4-14 and Figure 4-15).
Figure 4-14 Comparison of changes in blood pressure from baseline (mm Hg) in
subgroups.
Comparison to baseline observation after a double-blinded, placebo-controlled trial
compared 4 week of 500 mg d-1 quercetin versus placebo in 22 healthy males. MAP,
mean arterial pressure; PP. pulse pressure. Error bar indicates 95% CI. *Difference
from baseline; P<0.05.
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Figure 4-15 Regressions of changes of blood pressures compared to baseline reading
after 4 week of quercetin or placebo. Correlation coefficient r was calculated
by the Pearson test.
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Table 4-7 Resting systolic blood pressure (SBP), diastolic blood pressure (DBP), and
pulse rate in male subjects before and after 4-week supplementation with
quercetin (500 mg d-1) or placebo
Study period Changea P value
Baseline 4-week (95% CI)
Systolic blood pressure, SBP (mm Hg)
Total (n=22)
Quercetin 123.2 ± 1.5 122.0 ± 1.9 -1.1 (-4.0, 1.7) .412
Placebo 122.5 ± 2.1 124.6 ± 2.3 2.1 (-0.8, 5.1) .143
Normotensive (n=10) b
Quercetin 117.6 ± 1.5 115.3 ± 1.5 -2.3 (-7.9, 3.3) .378
Placebo 114.4 ± 1.6 115.9 ± 1.8 1.5 (-3.8, 6.8) .536
(Pre-) Hypertensive (n=12) c
Quercetin 127.8 ± 1.6 127.7 ± 2.2 -0.2 (-3.3, 3.0) .910
Placebo 129.3 ± 2.2 131.9 ± 2.3 2.7 (-1.2, 6.6) .161
Diastolic blood pressure, DBP (mm Hg)
Total (n=22) d
Quercetin 73.8 ± 2.0 71.8 ± 1.9 -2.0 (-4.1, 0.1) .067
Placebo 73.1 ± 1.7 72.7 ± 2.1 -0.4 (-2.9, 2.0) .794
Normotensive (n=10) b
Quercetin 71.4 ± 0.9 68.3 ± 1.0 -3.1 (-6.2, 0.0) .048 *
Placebo 69.2 ± 1.1 70.8 ± 0.8 1.6 (-1.4, 4.6) .264
(Pre-) Hypertensive (n=12) c
Quercetin 75.8 ± 3.5 74.8 ± 3.2 -1.1 (-4.3, 2.2) .479
Placebo 76.4 ± 2.6 74.3 ± 3.7 -2.1 (-6.0, 1.8) .261
Mean arterial pressure, MAP (mm Hg)
Total (n=22)
Quercetin 90.3 ± 1.6 88.6 ± 1.7 -1.7 (-3.5, 0.0) .055
Placebo 89.6 ± 1.6 90.0 ± 1.8 0.4 (-1.8, 2.6) .683
Normotensive (n=10) b
Quercetin 86.8 ± 0.8 84.0 ± 0.9 -2.8 (-5.6, -0.1) .044 *
Placebo 84.3 ± 1.1 85.8 ± 1.0 1.6 (-2.1, 5.2) .355
(Pre-) Hypertensive (n=12) c
Quercetin 93.2 ± 2.6 92.4 ± 2.5 -0.8 (-3.3, 1.7) .511
Placebo 94.0 ± 2.2 93.5 ± 3.0 -0.5 (-3.6, 2.6) .730
Pulse pressure, PP (mm Hg)
Total (n=22)
Quercetin 49.4 ± 1.9 50.2 ± 2.0 0.9 (-2.4, 4.3) .602
Placebo 49.4 ± 1.7 51.9 ± 2.3 2.5 (-0.5, 5.6) .093
Normotensive (n=10) b
Quercetin 46.2 ± 1.7 47.0 ± 1.8 0.8 (-5.6, 7.2) .785
Placebo 45.2 ± 1.3 45.1 ± 1.4 -0.1 (-3.1, 3.1) .944
(Pre-) Hypertensive (n=12) c
Quercetin 52.0 ± 3.1 52.9 ± 3.1 0.9 (-3.4, 5.2) .646
Placebo 52.8 ± 2.5 57.6 ± 3.1 4.8 (-0.2, 9.7) .058
Abbreviation: MAP, mean arterial pressure, MAP ≈ (2DBP+SBP) /3; PP, pulse pressure, PP = SBP -
DBP
a. mean ± SEM and mean change (95% CI). Paired t-test, 2 tailed, if not stated otherwise.
b. Subjects with blood pressure lower than 120/80 mm Hg (n=10) according to guidelines of World
Health Organization-International Society of Hypertension (WHO-ISH).
c. Subjects with blood pressure between 120/80 and 140/90 mm Hg are defended as pre-hypertensive
(n=10), higher than 140/90 as hypertensive (n=2).
d. Wilcoxon signed-rank test was used as the data is not normally distributed.
* indicates P<0.05 and ** indicates P<0.01 when compare to baseline by paired t test.
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4.3.6 Fasting glucose
The baseline concentration of fasting plasma glucose of the 22 healthy subjects was
5.04 ± 0.58 mM for 1st arm and 5.09 ± 0.51 mM for 2nd arm. Consistency of subjects
is good and carry-over effect was not observed. Figure 4-16 shows the effect of
quercetin supplementation on plasma glucose compared to control group, no
significant difference were observed in either group (Table 4-8). Two-way ANOVA
showed there was not a significant interaction between treatment and time (P=0.297),
maineffect of treatment was not significant (P=0.607) nor time (P=0.997).
Comparison of the effect on fasting plasma glucose of quercetin and placebo were
carried within each subject, as Figure 4-17 shows. Apparently, the quercetin intake had
increased the status of fasting plasma glucose level for some individuals but not for some
of the others. The number of each were very balanced, same was in placebo treatment.
Table 4-8 Concentration of fasting plasma glucose in male subjects before, during
and after 4-week supplementation with quercetin (500 mg d-1) or placebo.
C. glucose (mM), Mean ± SEM
Quercetin (P value, 2-tailed) Placebo (P value, 2-tailed)
Total (n=22) (P=.350) a
Baseline 5.04 ± 0.13 5.09 ± 0.11
2-week 5.01 ± 0.14 (.729) 5.13 ± 0.12 (.648)
4-week 5.10 ± 0.15 (.480) 5.02 ± 0.16 (.567)
Note: Mean value was compared with that at baseline (paired t test). a Change during quercetin
treatment was compared with that during placebo treatment (95% CI distribution is normal, paired t
test), b normal blood glucose level 3.9-5.9 mM, c pre-diabetes 5.9-7.0 mM
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Figure 4-16 Fasting plasma glucose concentration by mean ± SEM and individual
observations in 22 healthy man before, during and after the 4-week
supplementation placebo.
Figure 4-17 Linear regressions of changes of fasting plasma glucose after treatment
of quercetin or placebo within subject compared to baseline reading.
Correlation coefficient r was calculated by the Pearson test.
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4.3.7 Renal clearance of uric acid
The concentration of uric acid presented in urine was trendily reduced. 2-week of
quercetin supplementation reduced the urine uric acid concentration by mean ± SEM
from 1.23 ± 0.21 to 0.94 ± 0.18 mM (P<0.1, two tailed) but no change was observed
during placebo treatment (from 0.80 ± 0.12 to 0.84 ± 0.13 mM, SEM). Renal
excretion of uric acid was exanimated by total 24-h urinary uric acid level. It did not
significantly vary among the two time points for either treatment (Table 4-9).
Table 4-9 Urinary uric acid level of each visit (n=22) a
Day 14 Day 28 Asymp. P b
Concentration, mM
Quercetin 1.23 ± 0.21 0.94 ± 0.18 0.082 *
Placebo 0.80 ± 0.12 0.84 ± 0.13 0.673
24 h excretion, mmol
Quercetin 2.15 ± 0.38 1.61 ± 0.33 0.105
Placebo 1.41 ± 0.28 1.64 ± 0.31 0.348
a Data is presented by mean ± SEM *indicates 0.05<P<0.1
b Asymp. P is calculated by Wilcoxon signed-rank test, 2 tailed.
Renal excretion of uric acid was exanimated by total 24-h urinary uric acid level.
This data alone is not sufficient to draw any conclusion on whether kidney function
was affected, since this is usually indicated by glomerular filtration rate (GFR,
shown in Figure 4-18, 1). After all uric acid is mainly reabsorbed once was filtrated
(Figure 4-18, 2) while what we have detected is overall excretion (Figure 4-18, 4). It
is possible that quercetin can have an effect on kidney function (Table 4-9), but this
requires a biomarker that can accurately describe kidney function in vivo. Apparently
uric acid is not an ideal biomarker for such purpose.
Figure 4-18
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4.4 Discussion
4.4.1 Novelty
Previous nutritional intervention studies have not been designed for blood uric acid
level as their primary outcome, therefore the power estimation is not specific for uric
acid variation. Another overlooked issue of previous studies, is the method for uric
acid quantification may not be validated precisely engough to detect a difference
between samples. Besides, the U-shape association of uric acid level and mortality
requires a careful study design by conducting trial in subjects with blood uric acid in
the upper range. For this reason the human study has selected (screen) male
volunteers with uric acid level higher than average. For accurate measurements we
have modified an enzymatic spectrophotometric detection for uric acid assay
(Chapter 2).
4.4.2 Primary outcome
In this randomised controlled trial, supplementation with quercetin at 500 mg d-1 for
4 weeks progressively reduced plasma concentration of uric acid without inducing
changes in BMI, in fasting blood glucose or showing any adverse effects.
At the interval of 2 weeks, a mean change of -15.9 µM (95% CI, 0.9 to -32.8, P =
0.063) showed a trend towards decreasing. A significant decrease in plasma uric acid
level was observed at the end of 4-week treatment with mean change of -26.5 µM
(95% CI, -7.6 to -45.5, P = .008). On the basis of previous reports of lack of effect of
quercetin on blood uric acid after 2 weeks of dosage at 150 mg d-1 of quercetin
supplement in healthy subjects (89), 76-110 mg of flavonols (mostly quercetin
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glucosides) from 400 g onion with 6 cups of tea daily in type 2 diabetic patients (96),
or 15 mg d-1 quercetin glucoside from blueberry-apple juice for 4 weeks in healthy
subjects (98), the present study was purposely designed for a population with higher
uric acid level, with an apperently higher dosage and longer intervention period.
In vitro tests on bovine XOR showed that the inhibition constant for allopurinol is
0.34 ± 0.22 µM while that of quercetin is 1.40 ± 0.78 µM (181), indicating that intact
quercetin could be comparable to allopurinol in vivo based on this data, and
depending on the amount absorbed. Furthermore, quercetin in physiological fluids is
present in methyl-, glucuronosyl-, and sulfo- conjugated forms (see Figure 1-6,
Figure 1-7), some of which retain the inhibitory effects of quercetin (see Table 6-5)
(106, 111).
Besides the apparent inhibition of XOR, additional mechanisms are also possible,
including activated renal excretion of uric acid, which could be as a result of an
increased glomerular filtration of uric acid. Some drugs such as Losartan inhibit
directly URAT1, involved in uric acid reabsorption, and thereby decrease plasma
uric acid (182), whereas some treatments down regulate mURAT1 and mGLUT9 in
mice (183). Up-regulation of transporters (mOAT1 (183), rOAT1 (184) and hOAT1
(185)) which increase kidney urate secretion in the proximal tubules of the renal
cortex is also possible. Other additional mechanisms could involve an indirect
antioxidant effect that reduces microvascular ischemia in glomeruli and leads to
increased blood flow at the site, dilation of afferent arterioles, and competition for
reabsorption with ions such as sodium and potassium that exert osmotic effects
(186).
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It is worthy to notice in our study that the hypouricemic effect of quercetin is more
significant in subjects with higher uric acid level (Figure 4-12), which is in
accordance with animal tests (183). This suggests safety of quercetin compared to
allopurinol (154, 187), because quercetin may exhibit fewer side effects than
allopurinol in the amelioration of hyperuricemia. Alongside to the drugs used in gout
therapy, febuxostat and allopurinol, the uric acid lowering effect of 500 mg quercetin
(8.0 % reduction in mean plasma uric acid) during 14 d are not comparable to 10 mg
of febuxostat (26 % reduction in mean serum uric acid) (188). In comparison to daily
intake of 80 mg of febuxostat (253 µmol), which could decrease serum uric acid by
51 ± 14 % in healthy subjects by 6 days and reach the primary end point in 50~80%
of gout patients eventually, 300 mg d-1 of allopurinol (2204 µmol) cab only cure
20~40 % of the patients (Table 4-10). Apparently a 26.5 µM reduction (95% CI, -7.6
to -45.5) is not medically significant for gout patients. Therefore these findings are
especially beneficial: 1) to maintain a healthy population, i.e. preventing formation
of uric acid crystals (gouty arthritis) by preventing hyperuricemia defined as serum
uric acid concentration above its solubility limit 6.8 mg dL-1 (to convert milligram
per decilitre to micromoles per litre, multiply by 59.485) (189). Although
hyperuricemia alone is not sufficient to cause gout, a dose-response relationship
between serum uric acid and the risk of developing gout is well documented (190). 2)
For recovering gout patients: The primary treatment is to achieve an end point of
serum uric acid levels less than 6.0 mg dL-1 for a period of three months (189); this
includes the use of allopurinol to inhibit XO and uric acid production, or the use of
uricosuric drugs which increase renal excretion of uric acid. However for patients
also presenting kidney disease, liver disease, diabetes, congestive heart failure,
hypertension, etc., the dosage of allopurinol has to be adjusted in this stage (173).
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Once restored, patients are often advised on comprehensive dietary modifications for
prevention against recurrent gout attacks. In the above situations, adoption of one
quercetin tablet that has proven efficacy to reduce blood uric acid in the habitual diet
is easy to adhere to compared to a comprehensive dietary modifications. Therefore it
may be a promising behavioural approach to lower uric acid in individuals with
above-optimal blood uric acid either for those at high risk who have not yet
developed any disease, or for patients recovering after therapy.
- 102 -
Table 4-10 Summary of drug (febuxostat and allopurinol) usage and their effect on
blood uric acid level.
Subjects, n Design Duration Dailytreatment
Decrease in
mean serum
urate, %
Primary
result,
%
Reference
10 healthy
subjects
DR, PC 14 d
febuxostat
10 mg
26 Becker, 2004 (188)
10 healthy
subjects
DR, PC 14 d
febuxostat
70 mg
50 Becker, 2004 (188)
23 healthy
subjects
CO, DR 6 d
febuxostat
80 mg
51 ± 14
Khosravan, 2008
(191)
37 gout
patients
R, DB,
DR, PC
28 d
febuxostat
80 mg
76 Becker, 2005 (192)
267 gout
patients
R 28 wk
febuxostat
80 mg
48
Schumacher, 2008
(193)
598 gout
patients
R, DR 28 wk
febuxostat
80 mg
67 Becker, 2010 (194)
255 gout
patients
R, DB 52 wk
febuxostat
80 mg
81 Becker, 2005 (195)
268 gout
patients
R 28 wk
Allopurinol
300 mg
22
Schumacher, 2008
(193)
620 gout
patients
R, DR 28 wk
Allopurinol
300 mg
42 Becker, 2010 (194)
251 gout
patients
R, DB 52 wk
Allopurinol
300 mg
39 Becker, 2005 (195)
DB, double blind; DR, dose response; PC, placebo-controlled; CO, cross-over; R, randomized. Gout
patients are with gout and with serum uric acid concentrations of at least 8.0 mg dL-1 (480 µM); the
primary end point was a serum uric acid concentration of less than 6.0 mg dL-1 (360 µM) at the last
three monthly measurements. Molecular weight of allopurinol is 136.112 g mol-1 and of febuxostat is
316.374 g mol-1.
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4.4.3 Cardiovascular protective effects
A trend for reduction of diastolic blood pressure (P = 0.067) after quercetin
supplementation lends support to this hypothesis. The -2.00 mm Hg (95% CI, 0.11 to
-4.11) reduction is noteworthy, since this decrease has been calculated to result in a
17% decrease in the prevalence of hypertension in population studies (196, 197).
Uric acid-induced aging and death of human endothelial cells are mediated by local
activation of oxidative stress and the renin-angiotensin system, which provides a
novel mechanism of uric acid-induced endothelial dysfunction (198). It is alarming
that a recent estimates that ~25% of the US population has prehypertension, which is
defined as untreated blood pressure of 120-139 mm Hg systolic or 80-89 mm Hg
diastolic (199). Although hypertension could frequently exist with other
cardiovascular disease (CVD) risk factors such as metabolic syndrome, it is usually
asymptomatic. Importantly, there is a positive and direct correlation between
hypertension and the risk of other CVDs such as cardiac arrhythmia, coronary artery
disease, cardiac hypertrophy, myocardial infarction, and heart failure (200).
Significant reduction of -3.1 mm Hg (95% CI, 0.0 to -6.2) in DBP was observed in
normotensive group (n=10, P = 0.048) but not in (pre-) hypertensive group (n=12),
but no difference was found in SBP in either group. Although the magnitude of the
DBP reduction was small, the effects are clinically noteworthy, Cook et al. reported
that a 2-mm Hg reduction in the population average of DBP for white US residents
aged between 35 to 64 years would result in a 17% decrease in the prevalence of
hypertension, a 15% reduction in the risk of stroke and transient ischemic attacks,
and a 6% reduction in the risk of coronary heart disease (196, 197). Prolonged
decrease in usual DBP of 5-6 mm Hg is associated with about 35-40% less stroke
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and 20-25% less CHD (201). This is not consistent to previous findings. 150 mg of
daily quercetin supplementation decrease the systolic blood pressure significantly
after 6-week treatment in contrast to placebo (78). 730 mg of quercetin
supplementation for 4 weeks significantly reduced both SBP by -7 ± 2 mm Hg and
DBP by -5 ± 2 mm Hg (P<0.01) in stage 1 hypertensive patients but not in pre-
hypertensive subjects (81). The following limitation of blood pressure measurement
should be noted. Although blood pressure measurements were carefully taken, we
acknowledge that 24-h ambulatory blood pressure monitoring would have been more
accurate. The statistical calculation for subgroups as well as total might be
underpowered since subjects were not selected according to blood pressure, neither
was sample size estimated on it.
4.4.4 Blood glucose
Fasting glucose or BMI were not affected by either of 2 or 4-week quercetin or
placebo supplementation. This may be explained by the normal healthy status of
volunteers. Although many researches have confirmed the protective effects of
quercetin and other polyphenols in animal models of diabetes mellitus (202, 203),
this clinical trial still cannot prove the reduction of risk of diabetes effect of chronic
polyphenol supplementation. Volunteers in this study were recommended to take the
quercetin tablet (or placebo) with a meal. It might be able to lower the uptake of
glucose from a variety types of food by inhibiting the glucose transporters in small
intestine however simply relying on one dose of quercetin tablet per day, apparently,
may not be more helpful than a balanced diet rich of polyphenols and fibre.
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Concentration of glucose estimated by this external means will serve as internal
standard to obtain the absolute concentration of interested analytes for NMR
metabolic profiling of plasma, which is detailed in Section 5.2.7
4.4.5 Correlation between diastolic blood pressure and fasting glucose
We have found a moderate correlation between age and BMI (Figure 4-3) but no
correlation between concentration of plasma uric acid with either age or BMI (Figure
4-4) in our early stage. Previous study among Chinese ethnic reports that chance for
hyperuricemia of people aged 18-24 years is 2.01 fold (95% CI, 1.52 to 2.64) and
people aged 45-64 years is 0.56 fold (95% CI, 0.45 to 0.71) compared to age group
25-44 years and shows that age group 25-34 years has the highest blood uric acid
level. BMI became a risk factor for hyperuricemia only if above 30 (22).
The mean arterial pressure correlates with plasma glucose, insulin, and body weight
in type 2 diabetic mice (204). Purnamasari, D., et al. reported the most weighed
metabolic component contributing to the prevalence of insulin resistance among
siblings of T2DM patients is central obesity (56.7%), hypertension (46.7%),
decreased HDL cholesterol level (26.6%), hyper-triglyceridemia (26.6%) and
hyperglycemia (20%) (205). It was commonly believed that DBP and fasting glucose
in non-hypertensive, non-diabetic population was not related. This is the first time
bringing up interest in testing this hypothesis since a moderate correlation between
DBP and fasting glucose (Pearson Correlation =0.811, P<0.01, n=22) was observed
among males whose fasting glucose level were mostly below 6.0 mM while their
DBP were mostly below 90 mm Hg (Figure 4-8). However the sample size (n=22) is
small and can hardly draw any conclusion while a biological reason of this
correlation was not clear yet. This hypothesis cannot be tested within this study since
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the population was selective (males with higher blood uric acid level). Cohort studies
with representative population and larger sample size are required to test this
hypothesis. Apparently, the presumption of “non-hypertensive non-diabetic
population” has limited the test to be conducted in this subgroup. Another possible
explanation is that an unidentified confounding factor was affecting both DBP and
fasting blood glucose. Again, this requires a carefully designed cohort study. This
confounding factor could be the key to understanding diabetes and heart disease risk
and relevant metabolic syndromes.
4.4.6 Subjects compliance
24-h urinary excretion of intact quercetin was 0.81 ± 0.03 µmol (SEM, n=22) in
present study (Chapter 4) and was 1.17 ± 0.18 µmol (SEM, n=6) in previous study
(Chapter 3) after taking the same amount of quercetin dihydrate supplement tablet.
They are significantly different (P=0.04 by two-sample t test with non-equal
variance). Firstly, the purpose of the studies are different therefore the means of
sample collection were different. Our previous study (Chapter 3 or (177)) indirectly
detect the bioavailability of quercetin by quantifying 24-h urinary excretion of intact
quercetin in urine immediately started from quercetin intake. In contrast, present
study detected the 24-h urinary excretion of intact quercetin to reflect the habitual
intake of quercetin during the past several days. Besides, only one volunteer
participated in both studies, therefore, a difference in population may also contribute
to this difference. Even though Egert, S., et al. showed that habitual quercetin intake
can accumulate plasma quercetin, our result does not support or disagree that finding
(89).
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As shown in Figure 4-10, a high variance between subjects of 24 hour urinary
excretion of quercetin with mean of 0.810 ± 0.704 µmol during quercetin treatment
and 0.200 ± 0.366 µmol during placebo suggests that the variability in response to
quercetin is most likely associated with differences in absorption and tolerance, also
individuals varying in their dietary or exercise might modify the effect. Because of
the small size of this study, we were unable to identify the reason of the variable
response. Future studies may face the same situation and it is suggested to involve a
food frequency questionnaire (FFQ) as compliance check to make sure their own diet
does not contain significantly higher amount of quercetin in placcebo period.
However, the study population was very homogenous because strict eligibility
criteria and participant surveillance were used to prevent confounding influences of
gender, medications, diet, or other lifestyle factors. This was further confirmed by
plasma profiling (1H-NMR) in Chapter 5. Hence, our result may be valid only for
male individuals who are mildly hyperuricemic but otherwise healthy and we do not
know if the findings will extend to populations that include lower plasma uric acid
level, females, hypertensive, older or younger population or different ethnic or
geographic mixture. More clinical trials are needed to determine the re-productivity
of the data and whether it can be generalised to the larger population.
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4.4.7 Application
The role of habitual diet should also be considered. Similar effects might be achieved
by consuming quercetin-rich foods, which may provide more bioavailable quercetin.
We (Chapter 3) recently showed that, for example, quercetin (as glycoside
conjugates) in 100 g fresh red onion provides a similar amount of bioavailable
quercetin to the tablet used here (500 mg of pure quercetin aglycone) (177). This
preliminary study provides proof of principle and only one dosage was tested.
Further clinical research should determine the minimal and maximal dosage of
quercetin to establish a new therapy by evaluation of clinical efficacy and safety.
However, the present study adopted 500 mg d-1 of quercetin supplement, may
provide much more microbial metabolites to be absorbed into the blood stream and
have a physiological effect. This study did not evaluate the concentration of plasma
phenols thus did not identify the relationship to the observed effect. The lack of
adverse events for participants receiving quercetin in this study is promising, but the
absence of side effects cannot be extrapolated to higher doses or longer times.
However, quercetin is part of the normal diet and is consumed in very different
amounts according to the individual′s dietary pattern. 
In summary, quercetin seems to be an attractive alternative to available anti-
hyperuricemia medications. Adoption of one querctin tablet that has proven efficacy
to reduce blood uric acid in the habitual diet is easy to adhere to compared to a
comprehensive dietary modifications. Therefore it may be a promising behavioural
approach to lower uric acid in individual with above-optimal blood uric acid.
Establishment of effective amount of quercetin in diet may lead to recommendation
for serving of vegetables and fruits on a daily basis to take advantage of this benefit.
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Chapter 5. Metabolic Profiling of Plasma by 1H NMR Spectroscopy
from Randomised Controlled Trial
Abstract
The consumption of quercetin supplement at dosage of 500 mg d-1 has been proven
effective in lowering blood uric acid concentration and diastolic blood pressure in
pre-hyperuricemic males. The objective in this chapter is to investigate changes in
the plasma metabolite profile caused by 4-week intervention of 500 mg quercetin d-1,
using proton nuclear magnetic resonance (1H-NMR) spectroscopy-based
metabolomics. In this double-blinded randomised placebo-controlled cross-over
study, 22 healthy males received 500 mg quercetin d-1 for 4 weeks. Blood plasma
samples were collected at the baseline (day 0), 2-week (day 14) and 4-week (day 28)
of the treatments. The metabolic profiles were compared across samples using PCA,
PLS-DA and OPLS-DA to analyse the multivariate spectral data. Absolute
concentrations of corresponding signals (matabolites) were interpreted by external
measurement of glucose for each sample. Lipoproteins, amino acids and
carbohydrate profiles that related to metabolic pathways responsible for energy
metabolism can be detected. PLS-DA revealed a significant difference in plasma
profiles after administrations of quercetin and placebo. Glutamine and acetoacetate
were significantly reduced after quercetin supplementation compared to placebo
treatment. Valine, alanine, β-hydroxybutyrate and lactate levels were not affected by 
either treatment. 4-week intervention of 500 mg quercetin d-1 in healthy males
significantly alters the metabolite composition of plasma therefore has an effect on
metabolic progress.
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5.1 Introduction
As the metabolite composition within living tissue and its waste management reflects
the physiological or pathophysiological state of the total organism, a fast and reliable
analysis of metabolites within a specimen or the intact living system will supplement
medical diagnosis as well as basic research in various biochemical aspects.
Metabolic profiling, metabolomic and metabonomic studies encompass the
comprehensive and simultaneous systematic profiling of multiple metabolite
concentrations and their cellular and systemic fluctuations in response to drugs, diet,
lifestyle, environment, stimuli and genetic modulations, in order to characterise the
beneficial and adverse effects of such interactions (206). 1H-NMR (proton nuclear
magnetic resonance) spectroscopy provides structural and conformational
information on multiple metabolite classes without prior isolation of individual
chemical compounds. The obtained spectra of biofluids such as plasma and urine, or
of tissues and tissue extracts, provide metabolic patterns corresponding to the
metabolic status of the organism as a function of genetic, environmental or
toxicological influence (Figure 5-1).
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of the metabolites and pathways (G). Figure is personally drawn by Yuanlu Shi with
part adapted from (208, 209).
This technique permits a non-targeted comparison of physiological variation in
experimental animals/humans, such as male/female differences, healthy/patients
classification, age-related changes, dietary modulation, diurnal/nocturnal effects and
phenotyping of mutant and transgenic animals. Development of pharmaceutical
applications in which metabonomic biofluid profiles were used to identify specific
biomarkers of organ toxicity, an important economic factor of attrition in the
preclinical pharmaceutical discovery process has led to a quick diagnose at early
stage of the likelihood of developing disease (210, 211). Metabonomics and
metabolomics have found application not only in the study of diseases like
cardiovascular disease (212), multiple sclerosis (213), hypertension (214), breast
cancer (215), diabetes (216) and epithelial ovarian cancer (217), but also of
personalised medicine (218) and nutritional factors on gut microflora (219), in
animals fed by different grains (220), in humans given soy isoflavones (221), soya
milk (222), tea (223), grape products (224, 225), proteins (226), vitamins (227) or
fatty acids (228). The application of pattern-recognition techniques have been used in
nutrition and metabolomics research and challenges have been discussed extensively
(229-232).
Knowing the effect of lowering plasma uric acid, proton nuclear magnetic resonance
(1H-NMR) spectroscopy-based metabolite profiling was adopted to investigate
changes in plasma metabolomics caused by daily supplementation of 500 mg
quercetin for 4 weeks. The aim of this study is to investigate the possibility of
predicting postdose quercetin effects from predose metabolic profiles thus identify
potential biomarkers or toxicity through this pharmaco-metabonomics approach. It is
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particularly of interest in identifying other potential metabolites that may be
associated with uric acid reduction or to quercetin supplementation.
5.2 Materials and methods
5.2.1 Subjects and study design
22 healthy males were eligibly assigned and successfully compliant for the complete
study. They were healthy adult males aged 29.9 ± 12.9 y with BMI of 24.8 ± 3.0 kg
m-2, blood pressure of normal to (pre-) hypertensive (Systolic 123 ± 8 mm Hg,
diastolic 74.3 ± 9.0 mm Hg), and fasting blood glucose of normal to impaired fasting
glycemia of 5.04 ± 0.56 mM and plasma uric acid of 339 ± 51 µM (Table 4-2). They
were non-smokers and not a heavy drinker (less than 3 units of alcohol regularly per
day). The study was conducted according to the guidelines laid down in the
declaration of Helsinki of 1975 as revised in 1983 and all procedures involving
human subjects were in accordance with the ethical standards of the University of
Leeds, MaPS and Engineering joint Faculty Research Ethics Committee (MEEC12-
019), UK. Written informed consent was obtained from each of the subjects before
commencement of the study. All data were collected and analysed in the University
of Leeds, UK.
The study was a randomised, double-blinded, placebo-controlled, cross-over, 4-week
intervention trial with 2 treatment groups, with daily consumption of either quercetin
dehydrate tablet (500 mg stated, actual measured 544 mg, purchased from Nature′s 
Best, Kent, UK) (177) or placebo (the placebo formulation is a white oval tablet and
contain lactose monohydrate, magnesium stearate and cellulose, purchased from
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Fagron, Barsbuttel, Germany). There was a 4-week washout period between each
treatment. Blood and urine samples were taken before, during and the end of each
study phase. Each participant was independently and randomly assigned in one of
two groups, receiving both treatments in one order or another.
5.2.2 NMR sample preparation
Fasting plasma were collected at day 0, 14 and 28 of each arm and were stored at -
80 ̊C until analysis. 300 µL of plasma was mixed with 350 µL of deuterium oxide 
(D2O, Sigma-Aldrich, USA), flicked to remove bubbles and then vortexed at level 5
(Stuart vortex mixer, Bibby Scientific Limited, Staffordshire, UK). The mixture was
then centrifuged at 12 000 g (equivalent to 11 300 rpm) (MIKRO 120, Andreas
Hettich GmbH & Co.KG. Tuttlingen, Germany) for 5 min at room temperature. 600
µL of supernatant was transferred into a 5 mm, 7" select series NMR tube (S-5-500-
7; Norell. Inc).
5.2.3 1H NMR spectra acquisition
1H-NMR spectra were acquired on a Varian Unity Inova 500 spectrometer operating
at 499.97 MHz proton frequency at 20 ̊C. A standard NMR pulse sequence, Carr-
Purcell-Meiboom-Gill (CPMG) spin-echo sequence, was used to selectively
highlight the signals from the small molecule metabolites where the observed peak
intensities are edited on NMR T2 relaxation times. The Carr-Purcell-Meiboom-Gill
(CPMG) pulse sequence [RD - 90°- (τ - 180° - τ)n - acq] was used, with a relaxation
delay (RD) of 2 seconds, during which the water resonance was selectively irradiated
with a τ of 1.5 ms and an n of 150. For each FID (free induction decay), 256 
transients were collected into 16 384 data points with a spectral width of 6 000.2 Hz.
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5.2.4 Data binning/spectra fitting
Spectral data were processed with ACD/Spectrus Processor 2014 (Advanced
Chemistry Development Labs software 14, Toronto, Canada). An exponential line
broadening of 1 Hz was applied to the FIDs before zero filling with a transform size
of 32 768 (32 K) data points. The resulting spectra were phased, baseline corrected,
and referenced to the α-glucose signal at 5.23 ppm. The spectra sections were then 
divided into bins (frequency windows) of 0.005 ppm over the range 0.5-9.0 ppm, and
the integrals (areas; directly relating to concentration) of the signals within each bin
calculated. This serves to stabilise effects of physicochemical environment
differences (pH, ionic concentration, etc.) that may cause peak position variation and
allow a smaller, more manageable, number of variables for statistical processing. The
chemical shift region 4.2-6.0 ppm was set to zero to eliminate the effects of varying
water resonance suppression efficiency. Prior to principal components analysis
(PCA), the integrals were normalised to the total spectral area (hence total
concentration of all metabolites) and was converted into a numerical format,
consisting of observations (the actual samples) and variables (the individual intensity
and chemical shift pairs symbolising individual chromatographic peaks).
5.2.5 Chemometric analysis of NMR data
Analysis was then carried out using chemometric tools, such as principal component
analysis (PCA) and projection to latent structure also called partial least squares data
analysis (PLS-DA), to discover the variables describing the metabolic variation
involved in the particular study or to allow categorization of the samples.
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5.2.5.1 Multivariate analysis (Ordinary PCA)
The NMR data were Pareto-scaled and mean cantered before PCA was carried out
with the use of SIMCA-P+ 13.0.0.0 (Umetrics,Umea, Sweden). PCA reduces
multivariate data into a set of variables (principal components, PCs) which each
describe the variability in the data under the constraints that each PC is orthogonal to
the last and each accounts for the greatest source of variation remaining after
previous PCs have been established. In brief, multivariate data was plotted in multi
dimensions where the position of the data points represents the numerical intensity of
each variable. Having plotted out all the data points, a structure is visible and a new
latent variable, principal component (PC) 1, can be drawn through the centre of the
data swarm. However, there is still significant variance across the data points and a
second PC is generated at 90° to the first PC. In this manner three variables was
reduced down to 2 new PCs. PCA typically reduces datasets of thousands of
variables down to 10-11 PCs.
Two plots are produced in PCA: first, a scores plot, which displays how individual
samples relate to one another as a point on the plot (score, t) and allows intrinsic
clustering among individuals to be examined; and second, a loadings plot which
describes which variables are most influential in producing the scores plot (loadings,
p). The parts of the spectra corresponding to the most discriminatory variables are
displayed in order to allow identification of the varying metabolites or biomarkers
for a particular condition. For 1H-NMR spectral data, the variables are the chemical
shifts corresponding to the centres of the bins containing metabolite signals. The
quality of the model can be assessed based on the goodness of fit (R2X value, where
X refers to the original variable matrix) and the model′s ability to predict the class 
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membership of new samples (Q2 value). PCA only investigates the general variance
structure of the blood plasma spectral data.
5.2.5.2 Multilevel data analysis (MLPCA)
A further data mining approach, multilevel PCA (233) was used to analyse individual
contrast between quercetin intervention and placebo treatment. Let for example:
xiQ-w0, xiQ-w2 and xiQ-w4 be samples from subject i at week 0 (baseline), 2-week,
and 4 week of quercetin (Q) intervention. Further, let xiP-w0, xiP-w2 and xiP-w4 be
the corresponding samples during placebo (P) intervention.
The purpose is to investigate between the supplementary response, defined as the
difference between plasma composition after intervention and at baseline (dxiQ-w4-w0
= xiQ-w4 - xiQ-w0, dxiQ-w2-w0 = xiQ-w2 - xiQ-w0) for quercetin and the same for placebo, as
illustrated in Figure 5-4 of the baseline adjustment scheme. This corresponds to
comparing dxiQ-w4-w0 and dxiQ-w2-w0 with dxiP-w4-w0 and dxiP-w2-w0 across all individuals
(i=1, 2, 3, …, 22). Following analysis was carried on with normal PCA.
Figure
concatenation of
5.2.6 O
Orthogonal p
confirm any class separations identified in the PCA.
technique, which means a model is built with a priori knowledge of the class
membership of a set of samples and so acts to try to find the variation in the data that
best describes the difference between the classes. Because it is supervis
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original model. In the present study, it was not possible to obtain any more samples
and there were not enough samples to leave out a set for prediction. Therefore, the
OPLS-DA models were validated with the use of “leave-one-out” cross-validation,
where one third of the samples were excluded from the model and the OPLS-DA
model built from the remaining two third of the samples was used to predict the class
membership of the excluded samples. This step was repeated until all samples had
been excluded. Furthermore, OPLS-DA models were validated using permutation
testing. This involved randomly permuting the class memberships of the samples,
and remodelling the data to see whether the resulting models were of similar quality
to the original model (in terms of R2Y and Q2, where Y refers to the classification).
If permuted models are of similar or better quality than the original model, then the
original model could be spurious.
5.2.7 Quantification of metabolites
In order to quantify the absolute concentration of interesting metabolites, all NMR
spectra data were normalised to the whole spectrum integral. With α-glucose referred 
to δ 5.23 ppm, the baseline of regions of δ 5.20-5.25, 0.80-4.66 were phased to 
remove the interference of signal of water.
Then the spectra were binned into windows of 0.01 ppm width. The area of peaks of
metabolites of interest were checked to make sure that all bins that were covered in
the signal region were combined (Table 5-1). For example, peaks at 5.23 d α-glucose 
covers from 5.217-5.236 ppm with width of 0.019 ppm and the two bins cross 5.220-
5.240 ppm were combined for α-glucose integral.   
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Table 5-1 1H-NMR resonance assignments with chemical shifts for signals identified
in human plasma
Metabolite
δ (ppm) 
multiplicity
Peak region
(ppm)
Bin width
(ppm)
Selected and
combined
bins (ppm)
α-glucose 5.23 d 5.217 - 5.236 0.019 5.220 - 5.240 
β-glucose 4.65 d 4.626 - 4.653 0.027 4.620 - 4.660 
Valine 0.99 d 0.968 - 0.991 0.023 0.970 - 0.990
Valine 1.04 d 1.020 - 1.045 0.025 1.020 - 1.050
Lactate 4.11 q 4.091 - 4.117 0.026 4.090 - 4.120
Lactate
And threonine
1.334 d
1.332 d
1.303 - 1.338 0.035 1.300 - 1.340
Glutamine 2.13 q 2.090 - 2.147 0.057 2.090 - 2.150
Glutamine 2.46 m 2.415 - 2.466 0.051 2.410 - 2.470
Acetoacetate 2.27 s 2.265 - 2.275 0.010 2.260 - 2.280
Alanine 1.48 d 1.457 - 1.480 0.023 1.450 - 1.480
β-hydroxybutyrate 1.20 d 1.179 - 1.205 0.026 1.180 -1.210 
Note: s: singlet; d: doublet; q: quadruplet; m: multiplet.
For each sample, integrals of α-glucose and β-glucose were combined and this was 
referred to glucose concentration (mM) that was measured by external mean
(detailed in Section 2.2 and Section 0). The conversion factor (F) was used to predict
the concentration of other metabolites. In brief, the combined peak area of the
combined resonance at δ 4.65 ppm and δ 5.23 ppm (Aglucose) is used to normalise the
raw NMR signals integrals (X) in each spectrum.
F = C.glucose/Aglucose /number of 1H.
e.g. C. valine = F × Avaline / 3 (since doublet signal at 1.04 ppm was contributed by the
protons of 3 hydrogen of -CH3 of valine). A list of metabolites and their structure was
used for this calculation (Table 5-2).
Table 5-2
Metabolite
α, β-glucose
Valine
Lactate
Lactate
Threonine
Glutamine
Acetoacetate
Alanine
β-hydroxybutyrate
Metabolite chemical information
Chemical shift
(ppm)
4.65 d, 5.23 d
1.04 d
4.11 q
1.334 d
1.332 d
2.46 m
2.27 s
1.48 d
1.20 d
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Structure Identicalproton
(2)
(7)
(2)
(3)
(8)
(7)
(7)
(6)
(3)
N
of
-CH-
-CH3
-CH-
-CH3
-CH3
-CH2-
-CH3
-CH3
-CH3
umber
1H
1
3
1
3
3
2
3
3
3
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5.2.8 Univariate analysis
PCA and OPLS-DA statistics were performed in SIMCA and other data comparison
were performed in SPSS. After tests of normality, the paired Student t test or the
Wilcoxon signed-rank test was performed to compare the mean values of the
integrals from influential regions of the NMR spectra, using SPSS.
5.3 Results
5.3.1 1H NMR spectral analysis of plasma profiles
Lipoproteins, amino acid and carbohydrate profiles that relate to metabolic pathways
responsible for energy metabolism can be detected. Figure 5-5 shows a 500 MHz 1H-
NMR spectrum of plasma sample from an apparently heathy man. The reference
table from (234) and the Human Metabolome Database (235) were used for peak
assignment for resonances in the spectrum. Among them, the resonances of broad
lipid signals around 0.9 ppm (-CH3) and 1.3 ppm (-CH2-) stemming from the
lipoprotein contents of triglycerides, cholesterol compounds and phospholipids can
be assigned (Table 5-1). Spikes at δ 1.18 ppm of β-hydroxybutyrate (BHB), methyl 
group (δ 1.33 ppm, e.g. lactate or threonine; δ 1.48 ppm, e.g. alanine; δ 2.22 ppm, 
e.g. acetone, propionate) can be assigned and δ 2.46 ppm is glutamine, the most 
abundant free amino acid in human blood (236).
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Figure 5-5 500 MHz 1H-NMR Carr-Purcell Meiboom-Gill (CPMG) spectrum (δ 0-6 
ppm) of plasma from a healthy volunteer (samplecode 5792) with spectral
region δ 3-6 ppm dominated by sugars and δ 0-3 ppm dominated by lipids. 
Assignment of the most prominent peaks are included (234).
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In the spectral region δ 0.5-2.5 ppm, the biological variations between the data-pairs 
are illustrated (Figure 5-6). dxiQ-w4-w0 and dxiP-w4-w0 were calculated for each subject
and a mean and standard deviation for the NMR spectra of aliphatic region (δ 0.5 - 
4.5 ppm) is shown in Figure 5-6. A comparison of the changes brought about by
interventions on each region of chemical shift shows clearly the changes of
concentration of correspondent chemicals and a summary is listed in Table 5-3.
From visual inspection of the 1H NMR spectra of plasma samples, a high degree of
inter-subject and temporal variability which obscured the more subtle metabolic
changes related to dietary intervention was observed (Table 5-3). To be able to detect
more subtle treatment and related metabolic differences, pattern recognition
techniques were applied. Chemometric analysis was used to aid interpretation and to
detect latent variables associated with quercetin intervention.
Table 5-3 Visual inspection of comparison of dxiP-w4-w0 and dxiQ-w4-w0.
Chemical shift
(ppm)
Quercetin Placebo Comparison
VLDL, LDL 0.90   
Leucine 0.98   
Valine 1.03   
β- hydroxybutyrate 1.18  o 
Lactate 1.31   
Alanine 1.48   
Acetate 1.90 o o o
Acetoneacetate 2.22 o  
Glutamine 2.46 o  
Carbohydrate, sugar 3.4-3.7  o 
Glycerol of lipid 3.7-3.9 o  
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A
B
Figure 5-6 Spectra of dxiP-w4-w0 and dxiQ-w4-w0 (A) and mean difference between
spectra of dxiP-w4-w0 and dxiQ-w4-w0 (B) for 22 subjects in the region of δ 0.5 - 4.6 
ppm. Line and shadow show mean ± SD. Lactate was reduced significantly
(paired t test P<0.05) after quercetin treatment compared to placebo.
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5.3.2 PCA and unsupervised classification
PCA was performed on all plasma metabolite profiles. Two plasma samples were
recognised as outliers and were removed from the analysis because of the presence of
a substantial signal of ethanol. The PCA score plot (Figure 5-7) of the plasma
profiles did not display intrinsic clustering related to supplementations in the 1st and
2nd PCs. Initial PCA does not take the experimental design into account, therefore the
power of this multivariate method is not fully employed. However, this demonstrates
that the study population was in healthy condition and was homogenous.
Apparently huge variance between subjects made it impossible to compare within
subject (Figure 5-8) with ordinary PCA that overwhelm the variance with subject
even though we have accounted for the BMI and gender, two of the most important
factors on plasma metabolic variations (237). Figure 5-8 presents that the variation
within subject is much smaller than that between subjects making it difficult to
identify the changes within subject. In conclusion, multilevel data analysis is
necessary in cooperating interventional cross-over study in order to draw any
meaningful conclusion.
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Figure 5-7 PCA score plot of human plasma 1H-NMR spectra.
The presence of outliers was investigated using PCA-Hotelling T2 Ellopse (95% CI)
and the normality of multivariate data using the normal probability plot of PCA
model. Samples were classified into three groups. They are control (open circle)
contains samples of xiP-w0, xiP-w2, xiP-w4 and xiQ-w0; 2-week (black filled circle) of xiQ-w2
and 4-week (red filled circle) of xiQ-w4 (i=1, 2, 3, …, 22). This plot shows 38.9% of
the total difference. Component 1 represents 24.2% of the variance. The 4
observations representing samples from each laboratory visit for subject 339 who
has the highest fasting glucose level among all subjects fell outside the Hotelling′s 
T2 Ellopse (95% CI). Hotelling′s T2 is a multivariate t-test to assign a probability that
the predicted score value of any given observation is different from the mean of the
distribution (238).
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Figure 5-8 Scoring plot of each subject of first three major components. Note how
much less variable the human plasma is when is compared with other
individuals.
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5.3.3 Chemometric techniques with multilevel data analysis
After sample transformation detailed in section 5.2.5.2, examination of the scores
and score plots for PC1 vs. PC2 (Figure 5-9). The PCA model discriminating
between groups was not significant (α=0.05, Figure 5-9 A). Apparently blood sugars 
(δ 3-4 ppm) contribute to the major variance between samples. Interestingly we have 
not discovered any significant change of blood glucose level by external
measurement. However, some visual clustering in the second comment
(PC2:R2X=19.6%) suggests an association between quercetin intake and lower level
of plasma lactate (1.31 ppm) and LDL (0.90 ppm) and higher levels of glutamine
(2.46 ppm) and acetoneacetate (2.22 ppm) (Figure 5-9 B). The scores of PC2 were
significantly different between control and 4-week for quercetin treatment (P =
0.021, Figure 5-10)
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B
Figure 5-9 (A) 1H-NMR score plot of subtracted data. Inner circle indicates mean
95% CI ellipse and out circle is predicted 95% CI. (B) Loadings plot of
component 1 (top, 20.7%) and component 2 (bottom, 19.6%) across δ 0.5 to 4.2 
ppm and 6.0 to 9.0 ppm.
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Figure 5-10 Subtracted scoring plot of each subject of first two major components.
Statistic was conducted by two sample non-equal variance t test. Panel A, C shows
the within-subject variance and between subject variance of scores of component 1
and component 2. Panel B, D shows the box plot of scores of component 1 and
component 2, showing the difference between interventions. Bar with whisker
represent median and 5-95%.
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5.3.4 OPLS-DA and supervised classification
The OPLS-DA analysis revealed a model for comparison of changes of quercetin and
placebo (Figure 5-11). Validation procedures indicate that for a two-component
OPLS-DA model the sample classification could be predicted accurately in 59.5 ±
6.3% (mean ± SEM) of the cases, indicating that the observed quercetin-induced
plasma changes were robust. The OPLS-DA loading plot (Figure 5-12) highlighted
the metabolites that weighs most in describing the difference between classes. They
are valine, alanine, glutamine, acetoacetate, β-hydroxybutyrate and lactate. 
Figure 5-11 OPLS-DA score plot of human plasma 1H-NMR spectra substracted
from baseline spectra: dxiP-w4-w0 (placebo) and dxiQ-w4-w0 (quercetin).
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Figure 5-12 OPLS-DA loading plot of component 1 (9.8 %) across δ 0.5 to 4.2 ppm 
and 6.0 to 9.0 ppm.
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5.3.5 Changes in metabolites
Metabolites that were caught in chemometric analysis were quantified by the proton
numbers comparing to concentration of glucose as indicated in Table 5-2 and result
is shown in Table 5-4 and Figure 5-13. Valine, glutamine, acetoacetate and lactate
were significantly reduced after quercetin supplementation compared to placebo
treatment. Alanine and β-hydroxybutyrate were not affected by either treatment 
(Table 5-5, Figure 5-14).
Table 5-4 NMR quantification of these metabolites (n = 6*12-2 = 130).
Plasma concentration (µM)
Mean ± SD Median (95% CI) Range
Ref.
Mean ± SD
Valine 207 ± 90 179 (121-412) 37-579 212 ± 63
Acetoacetate 62.2 ± 42.7 55.0 (26.6-105.8) 12-350 40.6 ± 36.5
Alanine 389 ± 115 373 (248-603) 99-911 427 ± 84
β-hydroxybutyrate 52.1 ± 64.6 42.3 (12.1-106.4) 6.4-559 76.9 ± 66.3
Glutamine 607 ± 171 581 (421-957) 136-1 280 510 ± 118
Lactate 943 ± 449 837 (392-1886) 101- 2 896 1 490 ± 371
Note: The predicted concentration of those metabolites were consistent with previous
report (239).
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Figure 5-13 Data distribution of each metabolites shown in boxplots. (A) Valine, (B)
Alanine, (C) Glutamine, (D) Acetoacetate, (E) β-hydroxybutyrate and (F)
Lactate. Open square shows mean value and box represents upper quintile,
median and lower quintile with whiskers showing 1.5 × interquartile range
(IQR). Q1, Q2, Q3, P1, P2 and P3 represents baseline, 2-week and 4-week of
quercetin arm and baseline, 2-week and 4-week of placebo arm, respectively.
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Table 5-5 Metabolites quantified by NMR to glucose reference (n=22 or 20).
Quercetin Placebo
P by one way
ANOVA
main effects
Measures P Measures P of time
of
treatment
Glucose, mM Between baseline P (.35) .99 .61
Baseline 5.04±0.60 5.09±0.49
2-week 5.01±0.65 .73 5.13±0.58 .65
4-week 5.10±0.69 .48 5.02±0.77 .57
Valine, µM Between baseline P (.08 *) .006 * .10
Baseline 253 ± 23 281 ± 27
2-week 165 ± 11 .01 * 170 ± 10 .02 *
4-week 178 ± 11 .02 * 191 ± 12 .07
Alanine, µM Between baseline P (.83) .42 .33
Baseline 410 ± 35 403 ± 21
2-week 372 ± 27 .28 381 ± 20 .45
4-week 365 ± 20 .25 402 ± 21 .96
Glutamine, µM Between baseline P (.13) .01 * .02 *
Baseline 676 ± 45 723 ± 49
2-week 532 ± 27 .008 ** 577 ± 26 .03 *
4-week 542 ± 25 .008 ** 588 ± 22 .02 *
Acetoacetate, µM Between baseline P (.71) .02 * .51
Baseline 86.6 ± 17.4 73.5 ± 9.1
2-week 52.5 ± 3.9 .02 * 55.8 ± 4.5 .06
4-week 49.0 ± 4.4 .006 ** 55.2 ± 4.8 .08
β-hydroxybutyrate, µM Between baseline P (.71) .05 .76
Baseline 90.7 ± 30.4 57.4 ± 7.5
2-week 36.9 ± 4.0 .001 ** 44.2 ± 5.9 .12
4-week 40.6 ± 5.0 .13 42.1 ± 4.7 .13
Lactate, µM Between baseline P (.37) .44 .54
Baseline 1093 ± 118 989 ± 98
2-week 827 ± 59 .08 965 ± 107 .53
4-week 792 ± 76 .03 * 993 ± 105 .94
Note: All data are presented as mean ± SEM. There was not a statistically significant
interaction between treatment and time on any metabolites which was determined by
two-way ANOVA. Alanine and glutamine were tested by paried sample t test since
the data is normally distributed and others were tested by paired sample Wilcoxon
signed-rank test since the data were not normally distributed. * indicates
0.01<P<0.05 and ** indicates P<0.01.
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Figure 5-14 Concentration of metabolites at each visit by mean ± SD.
(A) Valine, (B) Alanine, (C) Glutamine, (D) Acetoacetate, (E) β-hydroxybutyrate 
and (F) Lactate. * indicates P<0.05 and ** indicates P<0.01. (B) Alanine and (C)
Glutamine were tested by paired sample t test since the data is normally distributed
and others were tested by paired sample Wilcoxon signed-rank test since the data
were not normally distributed.
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5.4 Discussion
The principle objective of the present study was to assess the effect of long term
intake of quercetin supplement on the plasma uric acid and one of the secondary
outcomes was plasma metabolic profiles.
Among the 132 analysed plasmas, two samples displayed an unexpected biochemical
profile (2362 and 9282). When their spectra were examined, triplet and quadruplet
resonances at 1.18 and 3.65 ppm, for the methyl and methylene groups of ethanol
were unexpectedly detected. Contamination during handling was ruled out as a
potential source of ethanol. Endogenous ethanol is known to be produced in small
quantity in mammalian tissue via the reduction of acetaldehyde, itself derived from
the decarboxylation of pyruvate (240), as an intermediate step for the elimination of
excess energy-releasing substrates from mitochondria (241) during intense physical
effort. But cases in this study may be caused by alcohol intake before donating their
fasting blood because results of other visits of these two volunteers do not show such
abundant ethanol loads. For these assumptions, those two samples were excluded
from analysis because this may show the most negative scores (outlier of the score
plot).
The peak integrals relate directly to the number of protons giving rise to the peak and
hence to the relative concentrations of the substances in the sample. Absolute
concentration was obtained for glucose quantified by a conventional biochemical
assay (assay protocol is detailed in Section 2.2 and result is in 4.3.6). Trimethylsilyl
propionic acid (TSP) was not used as reference standard in plasma samples, since the
compound binds to high molecular weight proteins (primarily albumin) resulting in a
much reduced signal with a very broad line width.
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Generally, NMR-based metabolomics studies of biofluids have shown a high
reproducibility (206), therefore it is sufficient to have one sample per time point. We
also tested two or three aliquots of three representative plasma samples across the
whole run and this serves as a quality control measure. As each plasma sample was
prepared between each test individually, carry-over was avoided. Metabolites like
uric acid is NMR invisible. This is a result of a very rapid exchange of protons on the
metabolite with matrix protons (242).
Apparently we have exposed two challenges in nutritional metabolomics studies.
These metabolic responses are often small and subtle since the volunteers are
generally healthy and in metabolic homeostasis. Moreover, the effect of the
nutritional treatment tend to be much smaller than the biological variation that exists
between the individuals. Suhre et al. (243) and Gieger et al. (244) showed that
changes in the concentration levels of biochemically related metabolite pairs are
often highly correlated with genetic variance in the general population. Humans are
extremely diverse beings and it is not surprising that most human metabolomics
studies have found that spectral outputs are strongly influenced by inter- and intra-
individual variation. For example, dietary intervention with isoflavone (245) or with
barley (237). Some other have been undertaken involved clinical cases and controls
(246) which is probably making it more difficult to detect the changes in metabolic
profiles resulting from dietary intervention as the contrast between the metabolic
profiles variances produced from individuals with a clinical disease compared with
the healthy controls.
Ongoing analytical developments include development of cryogenic probes and
increases in magnetic field strength and resolution for NMR. The enhanced
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sensitivity and resolution gained by these developments increases the capability for
biomarker detection, at the expense of increased spectral complexity. Spectral
complexity was traditionally addressed by peak picking or by binning signals across
the spectra in order to generate a smaller or more manageable data set (247). In this
study, 1340 buckets of 0.005 ppm resolution was generated and the analysis was
performed using the full data set rather than a peak-picked selection, which increase
the information recovered, for example potential biomarker, from the statistical
modelling.
Soft Independent Modelling of Class Analogy (SIMCA) (248) is an established
method for multivariate classification. Principle Component Analysis (PCA) (249)
models are fitted for each class, and model residents are utilised to classify unknown
observations to no class, one class or several classes (250). However, each disjoint
PCA model is generated based on the direction in the data demonstrating the higher
variation, which might be distinctly different from the direction separating the
classes. Consequently, maximum class separation is not explicitly the objective
function of the method.
A new method for identifying multiple NMR peaks from the same molecule in a
complex mixture, based on the concept of Statistical Total Correlation Spectroscopy
(STOCSY) takes advantage of the multicolinearity of the intensity variables in a set
of spectra to display the correlation among the intensities of the various peaks across
the whole spectra (251). However this technique would require the biological
samples to be carefully prepared to prevent the disturbance of pH or temperature that
causes variation on chemical shift of metabolites. For current study, binning spectra
has avoided this problem caused by unadjusted pH of plasma samples.
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The particular strength of the cross-over design is that interventions are evaluated on
the same subjects, allowing comparison at the individual level rather than on the
group level. Taking advantage of cross-over design and the underlying data structure
can be useful to uncover minor treatment effects. Unfortunately, most traditional
multivariate data analysis techniques such as Principle Component Analysis (PCA),
Partial Least Squares (PLS) and Partial Least Square - Discriminant Analysis (PLS-
DA) do not optimally exploit the paired data structure in cross-over design. A
specific limitation of using PCA and PLS-DA in cross-over designed experiments is
that the net treatment effect is not separated from the biological variation between the
subjects. As a result, subtle treatment effects within the subjects are often largely
overwhelmed by the strong biological variation between subjects (Figure 5-8). Figure
5-15 summarises the extrinsic and intrinsic factors affecting to metabolome. With a
cross-over study design, the extrinsic factors can be simplified down to treatment and
the intrinsic variation such as resting metabolite rate can be accounted when compare
results. Therefore, a hypothesis of a metabolic shift was proclaimed from our finding
that quercetin varies the balance between substrates metabolised, both acutely and
chronically, according to plasma substrate concentrations, including fatty acids,
glucose, ketone bodies, lactate and amino acids hormones, oxygen availability,
workload and disease difference in plasma.
Figure
nutritional metabolome
Blood lactate is a measure of not only energy imbalance but also oxidative capacity.
Prior work suggested that lactate is elevated among obese, insulin
(252) and decreases with weight loss
that serum lactate may be an independent risk factor for the development of type
diabetes
metabolism in mitochondrial oxidative metabolism and thus diminish the production
of lactate. In fact, lactate is m
used as a metabolic fuel by oxidative cancer cells
resembles processes that have been characterised in tumour cells
tumour tissues
known as intracellular lactate shuttles
lactate dehydrogenase (LDH) that convert lactate into pyruva
on the specific monocarboxylate transporters (MCTs) of lactate into and out of cells
(258). Quercetin inhibits glucose uptake by breast cancer cells independently from
oestrogen signalling
5-15 Exogenous and endogenous factors likely to influence the human
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Under normal biochemical circumstances, lactate is shuttled into gluconeogenesis
and thus is not maintained at high concentration in the plasma. Since, as shown by
our data, plasma concentration of lactic acid was found to be lowered by quercetin
supplementation, we postulate that an activation in the gluconeogenic pathway
caused by quercetin activated the consumption of lactic acid by liver cells. The
observed change in plasma concentrations of the glucogenic amino acids like
glutamine would also support this hypothesis. In humans, the main gluconeogenic
precursors are lactate, alanine, glycerol and glutamine, accounting for over 90% of
the overall gluconeogenesis (221) and their blood levels were all reduced along
quercetin treatment.
In conclusion, the study population was, as expected, homogenous. Some changes
were observed through plasma profiling if by 1H NMR when analysed after
subtraction from baseline without being confounded by the other variation source
(mainly between subject variation). 4-week intervention of 500 mg quercetin d-1 in
healthy males significantly altered the metabolomics of plasma therefore has a
significant effect on metabolism.
Figure 5
Figure is personally drawn by Yuanlu Shi.
-16 Schematic chart of metabolites that may relate in glucose regulation.
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Chapter 6. Kinetics of Inhibition of Enzymes Involved in Uric Acid
Metabolism by Quercetin and its Metabolites
Abstract
Various dietary flavonoids have been evaluated in vitro for their inhibitory effect on
xanthine oxidase (XO), the final step in uric acid metabolism. This study investigated
the inhibition of enzymes involved in uric acid metabolism by quercetin and its
metabolites: quercetin-3-O-glucuronide, quercetin-3′-sulfate, quercetin, 3,4-
dihydroxyphenylacetic acid (DOPAC), phloroglucinol, 3-hydroxyphenylacetic acid,
3-methyoxy-4-hydroxyphenylacetic acid (homovanillic acid), homovanillic acid
sulfate, 3,4-dihydroxybenzoic acid and 4-hydroxyphenylacetic acid; as well as the
mechanisms involved based on studies ex vivo and in vitro. Enzyme activity was
determined by direct measurement of product formation by HPLC. The result shows
that healthy human plasma contains the activities of adenosine deaminase (ADA) and
purine nucleoside phosphorylase (PNP), but not xanthine oxidoreductase (XOR)
activity. There was a dose-dependent inhibitory effect of quercetin (IC50, 23.6 ± 8.1
µM), quercetin-3′-O-sulfate (IC50, 2.4 ± 1.1 µM) and 3,4-dihydroxyphenylacetic acid
(IC50, 124 ± 16 µM) on bovine XO and an inhibition of quercetin on plasma ADA.
None showed interaction with plasma PNP activity. These results suggest that
quercetin and its microbial-derived metabolites may suppress the formation of uric
acid in vivo.
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6.1 Introduction
XOR catalyses the oxidation of hypoxanthine to xanthine and of xanthine to uric acid
in the metabolic pathway of purine degradation in humans. It appears in two inter-
convertible forms of the same gene product: xanthine oxidase (XO; E.C.1.17.3.2)
using oxygen as the electron acceptor, and xanthine dehydrogenase (XD;
E.C.1.17.1.4) which predominates in vivo in non-pathological conditions, using FAD
as a flavin cofactor and NAD+ as the preferred electron acceptor (110). Under
physiological conditions XOR exists in the form XD, but can convert to XO by
pathological events such as ischemia in vivo. Because XO produce the cytotoxic
intermediates, active oxygen species like superoxide anion radicals and hydrogen
peroxide, the irreversible conversion from XD to XO (D-to-O conversion) has been
implicated in ischemic injury to intestine, heart, kidney, skin, pancreas, liver, and
brain, as well as in the pathogenesis of inflammatory and virus-induced tissue injury.
It has, moreover, been suggested that these active oxygen species interact with nitric
oxide synthesised by the endothelia. XOR also catalyses the metabolism of some
other naturally occurring heterocyclic compounds (261).
Excess activity of XOR in XD form produces excess cytosolic concentration of
NADH which may leads to metabolic disorders such as fatty liver, similar to
alcoholism (262) and, in XO form, produces ROS (reactive oxygen species).
Inhibition of XOR is a primary objective in treating hyperuricemia, for example
using allopurinol or febuxostat. However, as shown in Figure 1-2, which summarises
the pathway of uric acid formation from purine degradation and the enzymes
involved with their inhibitors Figure 6-1, these enzyme were also of interest.
Adenosine deaminase (ADA, E.C.3.5.4.4) catalyses the deamination of adenosine
and to inosine
adenine (EHNA, CAS#59262
deoxyribose
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control of the inhibition of this reaction.
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Quercetin and many other polyphenols and food extracts were tested for their
inhibitory effect on xanthine oxidase. However, none of them have detected those
compounds (Figure 6-2). When considering the effect of oral intake of quercetin, or
of other polyphenols, studies have mainly focused on intact polyphenol present in
blood or in urine, for example, the aglycone or their conjugates. The colonic
microflora may transform a polyphenol to a more potent biologically active
compound (265), and its effect may be crucial. The potential biological activity of
quercetin in vivo is dependent on the intestinal absorption and subsequent interaction
with target tissues, and the absorption, metabolism, distribution, and excretion of
quercetin have been extensively studied. To fully assess the health benefits of dietary
quercetin, the biological properties of both the aglycone, conjugates and microbial
metabolites was investigated. As shown in Figure 6-2, the proposed pathway for
colonic bacterium-mediated catabolism of quercetin in the human large intestine
results in the production of 3,4-dihydroxyphenylacetic acid (DOPAC) and
phloroglucinol (123), smaller quantities of 3,4-dihydroxybenzoic acid, 4-
hydroxyphenylacetic acid (124), 3-hydroxyphenylacetic acid, with subsequent
hepatic conversion of 3,4-dihydroxyphenylacetic acid to 3-methyoxy-4-
hydroxyphenylacetic acid (homovanillic acid) (126, 127, 266) and further to
homovallinic acid sulfate. The tested compounds include the two initial quercetin
metabolites found in human hepatic portal vein: quercetin-3-O-glucuronide and
quercetin-3′-sulfate (112). Those compounds (include but not limited to) can be 
found in human organ after ingesting quercetin. They all may play a crucial part in
interfering uric acid metabolites in liver (Figure 1-8) and this study tested this
hypothesis.
Figure 6-2
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We have previously reported that daily supplementation of 500 mg quercetin for 4
weeks significantly reduces plasma uric acid concentrations in healthy males
(Chapter 4). This could be a result of intact quercetin circulating in blood that
inhibits XOR. Hypothetically, this may also be caused by the large amount of penolic
acids released by microbial from unabsorbed quercetin. Besides XO, present study
also tested the interaction of these compounds with human ADA and PNP.
6.2 Materials and methods
6.2.1 Chemicals and equipment
Substrates and inhibitors were dissolved in PBS pH 7.4. Substrates: adenosine,
inosine, hypoxanthine, xanthine and uric acid; co-enzymes: NAD+, FAD (Flavin
adenine dinucleotide disodium salt hydrate) are all from Sigma-Aldrich (St. Louis,
MO, USA). Internal standard adenine was from Alfa Aesear (Ward Hill, MA, USA);
inhibitors: EHNA hydrochloride was from Calbiochem (Merk KGaA, Darmstadt,
Germany); 9-benzylguanine was from AldrichCPR and allopurinol from Sigma
(Sigma-Aldrich).
Potential inhibitors were dissolved in DMSO at a stock concentration of 20 mM
and stored at -20 ̊C. Quercetin-3-O-glucoronide and quercetin-3′-O-sulfate (70%
purity) were sythesised in our lab and the following were purchased: quercetin
(Extrasynthese, France), 3,4-dihydroxyphenylacetic acid (Alfa Aesar), 3-
hydroxyphenylacetic acid (Alfa Aesar), 4-hydroxyphenylacetic acid (Alfa Aesar),
homovanillic acid (Alfa Aesar), phloroglucinol (ACROS organic, Fisher Scientific,
UK), 3,4-dihydroxybenzoic acid (Sigma-Aldrich), 3,4-dihydroxyphenethylamine
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(Sigma-Aldrich), homovanillic acid sulfate (Santa Cruz Biotechnology, Dallas, TX,
USA). Experiment was carried on a digital incubator (Dry Block Heater,
AccuBlockTM Digital Dry bath, Labnet) at 37 C̊. 
6.2.2 Enzyme preparation
Venous blood was obtained in EDTA K3 tube form a healthy subject with written
consent. Whole blood was 1:1 (vol:vol) diluted with PBS buffer pH 7.4 before
centrifugation at 3 000 g, 4 ̊C for 10 min. The supernatant plasma was stored at -80 ̊C 
till analysis. About 2 mL of plasma was dialysed in PBS pH 7.4 buffer with a slide-
A-Lyzer dialysis Cassettes, 20 K molecular weight cut off (MWCO) (Thermo Fisher
Scientific, Waltham, MA, USA) to purify the plasma enzymes from abundant small
molecules such as uric acid. 20 K MWCO was chosen because molecular weight of
ADA is about 42 kDa (267); PNP is 87-92 kDa (268) or 32-33kDa (269); XO is 300
kDa (270) and they will be caged in the dialysis membrane with 20 K MWCO.
Xanthine oxidase from bovine milk and human adenosine deaminase and purine
nucleoside phosphorylase (recombinant and expressed in E.coli) were from Sigma-
Aldrich
6.2.3 Kinetic analyses and determination of the inhibitory effect
A protocol for the experiment of enzyme inhibitory analysis is displayed in Figure
6-3. In brief, a reaction mixture consisted of 200 µL of processed plasma and 100 µL
of testing compound at certain concentration were pre-incubated at 37 C̊ for 5 min. 
An enzyme reaction was initiated by adding 200 µL of 37 ̊C pre-incubated 1 mM 
substrate. At 15 and 30 min after the enzyme reaction was initiated, 200 µL of
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reaction mixture was taken and mixed to another test tubes containing 40 µL of 5 M
HCl (ice-cold) and was then vigorously shaken by vortex. 10 µL of 1 mM of adenine
was then added as internal standard (10 nmol). The resulting solution was
centrifuged at 17 000 g at 4 ̊C for 10 min. The supernatant solution was transferred to 
another clean test tube and was frozen at -20 ̊C. On the day of analysis, samples were 
thawed and centrifuged at 17 000 g at 4 ̊C for 15 min to remove the precipitated 
lipids-protein sediment. Supernatant was injected to HPLC without further
processing. The freeze-thaw cycle was essential for samples containing plasma
otherwise the sample become cloudy after 24 h at 4 ̊C. Determination of the 
inhibitory effect against XO in bovine milk, against human plasma purine nucleoside
phosphorylase (PNP) and against human plasma adenosine deaminase (ADA)
activity were performed using this protocol with their correspondent substrates,
inhibitors and tested compounds.
Inhibition of each enzyme is measured by decreased product production. Quercetin
and its metabolites (Figure 6-2) were initially tested, and from those, only the
compounds which expressed inhibitory capacity were explored further.
Figure 6-3
of XO is not from plasma, it is purified from
Protocol of enzyme kinetic experiments for ADA, PNP and XO. Enzyme
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bovine milk.
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The human plasma ADA and PNP activity were analysed in the plasma matrix
instead of purified form. Because the enzyme products were diverse (Data not
shown), indicating that other enzyme activities were present in bacterial recombinant
enzymes when same assays were conducted with them. It is possible that the tested
compounds prefer to bind to other proteins in plasma thus the actual IC50 could be
lower than the concentration estimated. Compared to intact poplyphenols, higher
amounts of phenolic acids are found in plasma up to 200 nM at 1.5 h (271) and 34.2
µg mL-1 at 8-10 h (272) following flavonoids intake. The actual concentration in the
hepatic portal vein might be higher than the rest of the circulation and it is vital to
understand whether the plasma enzyme could be highly active and affected.
Therefore, using human plasma enzyme ex vivo is an advantage compared to
purified/recombinant enzymes.
XO activity is normally low in healthy human plasma and we confirmed this in study
plasma sample. Therefore the inhibitory effect of testing compound on XO was
determined using XO purified from Bovine milk. 300 µL enriched buffer containing
5 µL of 1 mM FAD, 10 µL of 5 mM EDTA, 40 µL of 10 mM NAD+, 120 µL of air
saturated PBS buffer, pH 7.4 and 0.01 U XO were pre-incubated at 37 ̊C with or 
without test compound or inhibitor (in this case, allopurinol). To initialise the
reaction, 200 µL of 37 ̊C pre-incubated hypoxanthine was added to the mix. The XO 
activity was also studied in the absence of NAD+, FAD or EDTA and was compared
to that at optimal condition. The inhibition of XO by tested compounds is expressed
as the concentration that results in half-maximal enzyme velocity (IC50).
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6.2.4 HPLC reverse phase separation of nucleosides
The corresponding products were analysed using HPLC method as detailed in
Section 2.6. Uric acid production represented XO activity from hypoxanthine;
hypoxanthine production represented plasma PNP activity from inosine (bacause of
the lack of XO activity in plasma, hypoxanthine was not further converted to
xanthine or uric acid); ADA activity was defined by the total production of inosine
and hypoxanthine since PNP activity was also presented in human plasma.
6.2.5 Purity of quercetin-3-O-glucoronide and quercetin-3′-O-sulfate
Quercetin-3-O-glucuronide and quercetin-3′-O-sulfate were synthesed in the lab.
According to the product specification record of quercetin-3′-O-sulfate, the purity is
70% and this was corrected. Quercetin-3-O-glucoronide and quercetin-3′-O-sulfate
stock solutions were diluted in 50% ethanol and was identified by RP-HPLC. The
HPLC method is detailed in Section 2.3. As shown in Figure 6-4, both standard
samples were free of quercetin and they are identical according to the overlay UV
spectra (Figure 6-5).
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Figure 6-4 HPLC chromatogram of individual standard (1 nmol) of quercetin (A, Rt,
13.8 min), quercetin-3-O-glucoronide (B, Rt, 6.44 min) and quercetin-3′-O-
sulfate (C, Rt, 11.5 min).
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Figure 6-5 Overlay of UV spectra of quercetin, quercetin-3-O-glucoronide and
quercetin-3′-O-sulfate standard from the chromatogram.
6.2.6 Statistics
Statistical calculation in this Chapter was carried in Excel 2010 (Microsoft, USA) by
independent t test (2 tailed, non-equal variance). Comparison was made between
100% enzyme activity (control) and percentage of inhibition/activation. Replicate
number was 4 for tested compounds and 8 for known inhibitors. The Curve fitting in
achieving IC50 value was gained in using OriginPro 9.1 (OriginLab, USA).
6.3 Results and discussion
6.3.1 Experimental concentrations
To achieve the same amount of intact quercetin in urine to fresh red onion meal,
quercetin dehydrate supplement tablet was adopted as study meal. However, a
dosage of 544 ± 45 mg d-1 (500 mg d-1 stated) of quercetin is much higher than usual
intake (3.3 ± 2.4 mg d-1) (273). Even though, the maximum concentration of intact
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quercetin in circulatory blood from majority studies cannot exceed 2 µM (Table 6-3,
Figure 6-6). It is possible that the extensive quercetin was metabolised into smaller
phenolic acids by colon bacteria and the plasma peak concentrations of those
phenolic acid may reach higher than intact quercetin after quercetin intake (Table 6-2
in comparison to Table 3-3), thus may play a more important role in physiological
system. However, the concentration of subsequent compounds might be higher in
hepatic portal vein and/or, most importantly, in hepatocytes.
Table 6-1 Plasma Cmax of total quercetin after quercetin intake.
Quercetin
intake
(µmol)
Plasma Cmax
(µM)
Ref
Onion 225 ± 43 0.74 ± 0.15 (143)
Onion 331 7.65 ± 4.83 (149)
Quercetin-4′-glucoside 331 7.02 ± 5.40 (149)
Onion 411 ± 74 1.34 ± 0.30 (116)
Quercetin-3-O-rutinoside 26.2 0.078 (274)
Quercetin-3-O-rutinoside 65.6 0.158 (274)
Quercetin-3-O-rutinoside 164 0.298 (274)
Quercetin-3-O-rutinoside 331 ± 7 0.30 ± 0.30 (143)
Quercetin-3-O-rutinoside 662 1.06 ± 1.13 (149)
Quercetin aglycone 26.5 0.137 (274)
Quercetin aglycone 66.2 0.219 (274)
Quercetin aglycone 166 0.285 (274)
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Figure 6-6 Plasma Cmax of intact quercetin against quercetin intake by food form.
Data are extracted from Table 6-1.
Table 6-2 Excretion of phenolic acids in the urine (µmol) of human subjects 24 h
after consumption by mean ± SD.
Phenolic acids Quercetin-3-rutinoside
supplemented tomato
juice (per 176 µmol)
by mean ± SD (127)
Quercetin-3-rutinoside
Supplement (per 100
µmol) by
mean ± 95% CI (275)
3,4-Dihydroxyphenylacetic acid 16 ± 3 5.0 ± 1.9
3-Methoxy-4-hydroxyphenylacetic acid 19 ± 6 7.8 ± 4.2
3-Hydroxyphenylacetic acid 4.4 ± 1.1 36.1 ± 16.1
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6.3.2 Inhibition of human plasma adenosine deaminase
Plasma ADA activity was quantified by the total production of inosine and
hypoxanthine after a certain duration of time incubating with adenosine. The plasma
used in all enzyme assays was taken from one healthy male subject at one time point.
The plasma ADA activity was 5.14 ± 0.76 U L-1 (mean ± SD, n=12) and this is used
as the control value. 1 unit of ADA produces 1 μmol of inosine and hypoxanthine per 
min at 37 ̊C pH 7.4. 
The total amounts of inosine and hypoxanthine produced in assays with 50 μM of the 
interested compounds were compared to that of absence (control) and the result is
shown as a ratio (Figure 6-7). EHNA, as positive inhibitor of ADA, efficiently
inhibits the production of inosin at the rate of 90.6 ± 3.9% (P<0.001). At 50 µM,
quercetin (inhibition of 6.54 ± 3.17%, SEM, P = 0.022) shows significant inhibition
of plasma ADA activity. 3,4-dihydroxyphenylacetic acid (inhibition of 4.62 ± 3.95%,
SEM) and homovanillic sulfate (inhibition of 3.44 ± 2.90%, SEM) shows a mild
potential inhibition. Quercetin-3-O-glucuronide and quercetin-3′-O-sulfate at 50 µM
have activated human plasma ADA by 2.32 ± 1.34% (SEM) and 2.46 ± 1.94%
(SEM), respectively. However, none of these were significant. 9-benzylguanine, as
PNP inhibitor and allopurinol, as an XO inhibitor, failed to inhibit plasma ADA.
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Figure 6-7 Inhibition of human plasma ADA of tested compounds at concentration of
50 µM. Data are presented by mean ± SEM, n=4. ** indicates P< 0.05 and ***
indicates P< 0.01.
To evaluate the dose dependency of the observed inhibitory effect, a higher
concentration of quercetin and of 3,4-dihydroxyphenylacetic acid was tested at 200
µM and homovanillic acid sulfate at a series of concentrations at 5, 50, 500 µM.
Result is as shown in Figure 6-8. A dose dependent inhibition of quercetin on human
plasma ADA was proven for the first time (Figure 6-9). 3,4-dihydroxyphenylacetic
acid was an activator of plasma ADA activity at high concentration (200 µM) while
had no effect at low concentration (50 µM). Homovanillic acid sulfate does not
inhibit or activate plasma ADA activity.
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Figure 6-8 Inhibition of human plasma ADA. Data are presented as mean ± SEM.
(A) EHNA, as positive control, efficiently inhibites the production of inosine at the
rate of 90.6 ± 3.9%. (B) 200 µM of quercetin (inhibition of 13.3 ± 2.4%) and 50 µM
of quercetin (inhibition of 6.54 ± 3.17%) (C) 200 µM of 3,4-dihydroxyphenylacetic
acid (inhibition of -18.8 ± 3.4%) and 50 µM of 3,4-dihydroxyphenylacetic acid
(inhibition of 4.62 ± 3.95%). (D) the inhibition of homovanillic acid sulfate were
0.30 ± 2.24%, 3.44 ± 2.90% and -1.30 ± 2.14% of the concentration at 500 µM, 50
µM, and 5 µM. ** indicates P< 0.05, *** indicates P< 0.01 and NS indicates not
significant.
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Figure 6-9 Dose dependent inhibition of quercetin on plasma adenosine deaminase.
Data are presented by mean ± SEM.
Adenosine deaminase (ADA) is an enzyme present in cells of the immune system,
and ADA activity is considered an indicator of cellular inflammation (276, 277).
Plasma ADA activity is mainly contributed by ADA 2, the major isoenzyme in the
serum of normal individuals. Normal serum ADA activity varies among studies,
ranging from 2.38 ± 1.43 to 17.05 ± 3.75 U L-1 (278) and 10.11 ± 2.01 U L-1 (279).
The mean ADA activity in fasting plasma was higher in T2DM patients (23.1 ± 0.6
U L-1 SE) compared with that in non-diabetic control subjects (18.6 ± 0.8 U L-1 SE;
P<0.05) (280), higher in pulmonary tuberculosis patients (35.5 ± 6.93 U L-1)
compared to 16.20 ± 2.85 U L-1 in healthy subjects (281) and higher in patients with
systemic vasculitis (20.6 ± 6.3 U L-1) than age-matched and gender-matched healthy
subjects (12.8 ± 1.8 U L-1; P<0.001) (282). A positive correlation between plasma
uric acid and plasma ADA activity was found in women with preeclampsia (p <0.01)
with a significant higher ADA activity compared to normotensive pregnant women
or non-pregnant women (283). The levels of ADA and uric acid were simultaneously
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found to be significantly higher in patients of head and neck cancers as compared to
the levels in controls (P<0.001) and a positive correlation was also observed between
ADA and uric acid (P<0.001) (284).
6.3.3 Interaction of plasma purine nucleoside phosphorylase (PNP)
Plasma activity was quantified by the production of hypoxanthine after incubation
with inosine. The plasma used in all enzyme assays was taken from one healthy
subject with plasma PNP activity of 21.4 ± 3.1 U L-1 (n=6). 1 unit of PNP produces 1
μmol of hypoxanthine per min at 37 ̊C pH 7.4. The total amounts of hypoxanthine 
produced in assays in the presence of 50 μM of the test compounds were compared 
to control and the result is shown as a ratio (Figure 6-10). 20 µM 9-benzylguanine, as
positive control, efficiently inhibited the production of inosine at a rate of 26.5 ±
1.9% (P<0.001). At 50 µM, none of the tested compounds showed inhibition of
human plasma PNP activity (P>0.05). However, a higher concentration was tested of
3,4-dihydroxyphenylacetic acid at 200 µM and homovanillic acid sulfate at 500 µM
and 5 µM were tested. The result is shown in Figure 6-11. Neither compounds
showed any significant effect on plasma PNP activity.
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Figure 6-10 Inhibition of purine nucleoside phosphorylase by 50 µM of indicated
compound. Data are presented by mean ± SEM. 3,4-dihydroxyphenylacetic
acid inhibits by 2.40 ± 1.74% (NS) and homovanillic acid sulfate activate 2.30
± 2.10% (NS) and quercetin-3-O-glucuronide activated 2.7 ± 1.5% (NS) of
plasma PNP activity. *** P<0.01.
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Figure 6-11 Inhibition of plasma purine nucleoside phosphorylase of 3,4-
dihydroxyphenylacetic acid and homovanillic acid sulfate.
Inhibition is not dose dependent even though at high concentration. Data are
presented by mean ± SEM. (A) 20 µM of 9-benzylguanine, as positive control,
efficiently inhibited the production of hypoxanthine by 26.5 ± 1.9%. (B) The
inhibitory effect of homovanillic acid sulfate was -1.79 ± 0.79%, -2.30 ± 2.10% and
2.49 ± 2.79% of the concentration at 500 µM, 50 µM, and 5 µM. (C) The inhibitory
effect of 3,4-dihydroxyphenylacetic acid was 0.25 ± 0.90% at 200 µM and 2.40 ±
1.74%) at 50 µM. *** indicates P< 0.01 and NS indicates not significant.
It was proven that none of the testing compound can effectively inhibit plasma PNP
activity, therefore do not contribute to the prevention of uric acid production.
However, PNP activity is 3.26 ± 1.63 µmol min-1 L-1 in gout patients, 3.91 ± 2.15
µmol min-1 L-1 in asthma which were all lower than 6.69 ± 3.92 µmol min-1 L-1 in
healthy subjects (285).
Inhibitors of PNP have been used for the treatment of T-cell cancers and autoimmune
disorders where T-cell clones are misdirected against self-antigens causing disorders,
including psoriasis, rheumatoid arthritis, and multiple sclerosis. A rare genetic
deficiency of PNP reveals that the enzyme is essential for recycling d-guanosine and
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formation of free purines leading to uric acid synthesis (286). This finding is
showing for the first time the enhancing function of quercetin metabolites on plasma
PNP.
6.3.4 Inhibition of xanthine oxidase
6.3.4.1 Assay parameters
This experiment was conducted with enzyme purified from bovine milk (XO from B.
taurus) instead of from human biological samples. Experiments were conducted with
hypoxanthine as substrate in either human plasma (dialysed) or red blood cells
(induced hemolysis) from several other subjects but failed to produce uric acid or
xanthine. This indicates that plasma XD activity cannot be found in this blood
sample (Figure 6-12).
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Figure 6-12 LC-MS detection of uric acid production from hypoxanthine by ex vivo
plasma and none was found within 15 min (D) or 30 min (F) of incubation.
Panels on left show chromatograms of 1-2MS (E-) 135 m/z with arrow indicates
hypoxanthine and panels on right show chromatograms of 1-2MS (E-) 167 m/z with
arrow indicates uric acid. MS chromatograms of standards sample (A, B), plasma
incubated with hypoxanthine for 15 min (C, D) and plasma incubated with
hypoxanthine for 30 min (E, F) are shown.
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The contribution of co-factors, EDTA, FAD and NAD+, was investigated by
excluding them in assay system (Figure 6-13). Result shows that neither EDTA or
FAD affects the overall performance of XO. NAD+ inhibited XO activity
astonishingly and FAD is not essential whenever NAD+ is present or not.
Figure 6-13 Comparison of uric acid production through XO when co-factor was
absent. Error bar indicates SEM.**P < 0.05.
EDTA was administered during blood sampling as an anticoagulant agent so it is
normally present. By adopting a commercial enzyme instead of a human biological
sample, it is considered for examination of XO activity to scavenging metal ions so
to deactivate metal-dependent enzymes (287). However, it is not essential in
contributing to the enzyme activity (Figure 6-13).
FAD and NAD+ were involved in this experiment for the purpose of generating
comparable results to conditions in liver in vivo or in liver extract (ex vivo) where
XD takes the main role of producing uric acid (288) and was found to be more
sensitive to flavonoid treatment (289). XO and XD are composed of two identical
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subunits of approximately 145 kDa. Each subunit contains one molybdenum centre,
one flavin (FAD), and two non-identical [2Fe-2S] iron-sulfur centres. The oxidative
hydroxylation takes place at the molybdenum centre with a concomitant reduction of
NAD+ for XD at the flavin centre (290). The absence of NAD+ significantly
(P<0.01) enhanced the enzyme activity by ~1.23 fold and 1.20 fold at 15 min and 30
min, respectively. These evidences all suggest that the nature of bovine milk XOR is
mainly in the form of XO, either of a result of readily conversion from XD to XO
either irreversibly by proteolysis or reversibly by oxidation of Cys residues to form
disulﬁde bridges (291) or of the nature of enzyme processing. The enzyme could be 
puriﬁed in its XD form from species such as chicken, whereas it was always isolated 
in its XO form from mammalian sources such as bovine milk (292).
However, results of present inhibition assay were determined with all co-factors. The
100% enzyme activity in this assay setting can convert 400 μM of hypoxanthine to 
101 ± 3 μM (mean ± SEM) of uric acid in 15 min and 153 ± 4 μM (mean ± SEM) in 
30 min. Inhibition was defiended as the proportion (%) of less uric acid produced
with presence of each testing compound at certain concentrations compared at the
same condition except without presence of testing compound.
6.3.4.2 Inhibition of bovine milk xanthine oxidase
The XO activity was reflected by the formation of uric acid when hypoxanthine
serves as substrate, since we have not detected stable accumulation of xanthine
during incubation. Results are as shown in Figure 6-14. Allopurinol, as a positive
control, inhibits the XO activity by 97.6 ± 0.3% (mean ± SEM). Among the tested
compounds, quercetin (91.6 ± 1.2%, mean ± SEM, P<0.001), 3,4-
dihydroxyphenylacetic acid (24.3 ± 5.1%, mean ± SEM, P = 0.017) and quercetin-3′-
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O-sulfate (93.4 ± 0.4%, mean ± SEM, P<0.001) were found to significantly inhibit
XO activity.
Inhibition was further determined for quercetin, 3,4-dihydroxyphenylacetic acid,
quercetin-3′-O-sulfate, phloroglucinol and homovanillic acid sulfate at other
concentrations (Figure 6-15). 3,4-dihydroxyphenylacetic acid dose dependently
inhibited XO but at a relatively high concentration (Figure 6-15 B). Quercetin and
quercetin-3′-O-sulfate were found to be inhibitors showing activating effects at low
concentration (Figure 6-15 C, D, Table 6-3) while phloroglucinol at high
concentration (Figure 6-15 F). Homovanillic acid sulfate did not affect XO activity
either at high or low concentration (Figure 6-15 E).
Table 6-3 Dose dependent inhibition of xanthine oxidase by quercetin and quercetin-
3′-O-sulfate (mean ± SEM)
Concentration (µM)
Quercetin Quercetin-3′-O-sulfate
Inhibition (%) P value Inhibition (%) P value
0.08 -9.87 ± 3.78 0.080 -3.15 ± 6.33 0.652
0.4 -9.63 ± 4.72 0.134 -12.78 ± 2.96 0.050
2 -2.90 ± 1.34 0.118 36.25 ± 3.35 0.008
10 20.66 ± 7.57 0.072 72.14 ± 5.16 0.001
50 91.62 ± 5.08 <0.001 93.44 ± 0.36 <0.001
Note: P value was calculated by t test (2-tailed, two sample non-equal variance)
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Figure 6-14 Inhibition of xanthine oxidase by 50 µM of each compound against 400
µM of hypoxanthine. Data are presented as mean ± SEM.
Quercetin, 3,4-dihydroxyphenylacetic acid, quercetin-3′-O-sulfate and
phloroglucinol were found to significantly inhibit XO activity. 3,4-dihydroxybenzoic
acid were found to be a activator at a mild promotion level. ** indicates P< 0.05 and
*** indicates P< 0.01.
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Figure 6-15 Comparison of inhibition of xanthine oxidase at series of concentrations.
Data are presented by mean ± SEM.
(A) 50 µM of allopurinol by 97.65 ± 0.28%; (B) 200 µM and 50 µM of 3,4-
dihydroxyphenylacetic acid by 70.72 ± 3.11% and 24.34 ± 5.08%,
respectively; (C) quercetin ranging from 0.08 µM to 50 µM; (D) quercetin-
3′-O-sulfate ranging from 0.08 µM to 50 µM; (E) homovanillic acid of 5
µM, 50 µM and 500 µM; (F) phloroglucinol of 200 µM and 50 µM by -8.51
± 2.25% and 4.30 ± 3.04%, respectively. * indicates 0.05 < P < 0.1, **
indicates P< 0.05, *** indicates P< 0.01 and NS indicates not significant.
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6.3.4.3 IC50
Half maximal inhibitory concentration (IC50), IC10 (if apply) and IC90 (if apply) of
XO were determined from plots of dose dependent inhibitors: quercetin (Figure
6-16), quercetin-3′-O-sulfate (Figure 6-17) and 3,4-dihydroxyphenylacetic acid
(Figure 6-18) and are summarised in Table 6-4.
.
Figure 6-16 Dose dependent inhibition of quercetin on xanthine oxidase. Data are
presented by mean ± SEM. Parabola polynomial fitting was generated in
OriginPro 9.1, R2 > 0.99
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Figure 6-17 Dose dependent inhibition of quercetin-3′-O-sulfate on xanthine oxidase.
Experimental polynomial fitting with instrumental weight was generated in
OriginPro 9.1, Adjusted R2=0.95.
Figure 6-18 Dose dependent inhibition of 3,4-dihydroxyphenylacetic acid on
xanthine oxidase. Data are presented by mean ± SEM. Experimental
polynomial fitting was generated in OriginPro 9.1. Adjusted R2 is not
applicable for this plot due to the small number of data.
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Table 6-4 IC10, IC50, IC90 of quercetin, quercetin-3′-O-sulfate, and 3,4-
dihydroxyphenylacetic acid on xanthine oxidase from bovine milk
Compound IC10 (µM) IC50 (µM) IC90 (µM)
Quercetin 6.06 ± 2.08 23.6 ± 8.1 48.9 ± 16.7
Quercetin-3′-O-sulfate -- 2.4 ± 1.1 40.1 ± 19.3
3,4-dihydroxyphenylacetic acid 18.2 ± 2.3 124 ± 16 --
Note: when [E] is producing 5.91 ± 0.25 µmol min-1 L-1 at 37 ̊C from hypoxanthine 
to uric acid and initial [S] is 400 µM. All data are presented by mean ± SEM
It is worthy to mention that quercetin-3′-O-sulfate inhibits XO by 50 % at the
concentration of 2.4 ± 1.1 µM which, theoretically, can be easily achieved in
circulation blood by quercetin intake, for example, plasma peak concentration of
quercetin-3′-O-sulfate can be 0.665 ± 0.082 µM (SEM) (112). As an inhibitor,
quercetin-3′-O-sulfate activates bovine milk XO by 12.8 ± 3.0 % at concentration of
0.4 µM and similar behaviour was also observed for theaflavin-3-gallate and
epicatechin gallate (134). Therefore, without knowing the physiological activity of
XD/XO in healthy living liver cells, the physiological concentration of quercetin-3′-
O-sulfate in liver cells and the comparability between human XD in living hepatic
cells and bovine milk purified XO, it is difficult to link this result to human trials.
Table 6-5 summarises various studies and their findings on the Ki and IC50 of
quercetin or quercetin conjugates on bovine milk xanthine oxidase. This incosistancy
could be caused by the way they quangtify uric acid All of them were using
abosrbance 295 nm in detecting uric acid production, as mentioned before in Section
2.6.1, this may be interfered by many other compounds especially polyphenols. The
studies also varies in reaction temperature and pH. Present study was conducted at
37  ̊C, pH 7.4, whilst the maximum activity of bovine milk xanthine oxidase is 25  ̊C, 
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pH 7.5. Also it was possible that the manufactured xanthine oxidase contains
(usually <0.1% ) of uricase activity at 25  ̊C, pH 8.5. Those are the possible reasons 
that Ki value cannot be consistantly measured.
In Table 6-5, it is worthy to mention that quercetin-3′-O-sulfate and quercetin-3′-O-
glucuronide are better inhibitors of bovine milk XO than quercetin and other
quercetin 3-O-conjugates. As shown in Figure 6-19 C, The 3′-sulfo-conjugates of 
quercetin rotate the B ring towards A/C rings thus forms a dihedral angle which is
similar to that of febuxostat and luteolin.
Table 6-5 Ki and IC50 of quercetin and quercetin metabolites on xanthine oxidase
from bovine milk in vitro.
Ki (µM) IC50 (µM) Ref
Allopurinol 0.34 ± 0.22 (181)
Quercetin 1.40 ± 0.78 (181)
Quercetin 2.08 (293)
Quercetin 1.5 (294)
Quercetin 1.2 ± 0.7 (295)
Quercetin 0.28 0.44 (106)
Isorhamnetin/ tamarixetin 0.17 0.40 (106)
Quercetin 0.2 (111)
Isorhamnetin 0.25 (111)
Quercetin-4′-O-glucuronide 0.25 (111)
Quercetin-3′-O-glucuronide 1.4 (111)
Quercetin-3-O-sulfate 78 (111)
Quercetin 23.6 ± 8.1 Present study
Quercetin-3′-O-sulfate 2.4 ± 1.1 Present study
3,4-dihydroxyphenylacetic acid 124 ± 16 Present study
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Figure 6-19 Three-dimensional (3D) structures of quercetin, quercetin-3′-O-sulfate, 
febuxostat and luteolin are found in PubChem Substance and PubChem
Compound Database (296). (A) shows the full view of A/C rings; (B) shows
the full view of B ring and (C) shows the dihedral angle between A/C ring and
B ring formed by O1C2C1′C2′ (Figure 1-5).  
Xanthine oxidoreductase (XD, not XO) is also known as a crucial upstream regulator
of activity of PPAR-γ, a master-regulator of adipogenesis, expression of adiponectin, 
and an anti-inflammatory factor in adipocytes. Adipose tissue could produce and
secrete uric acid through XOR and the production was enhanced in obesity (297).
XOR-/- mice showed 50% reduction of adipose mass compared to wild type whilst
obsess mice demonstrated higher level of XOR mRNA and uric acid in adipose
tissue (298).
XO, which has been reported to increase its activity during oxidative stress (299,
300), produces uric acid and superoxide (Figure 6-1). In healthy individuals, XO is
present in appreciable amounts only in the liver and jejunum; only in various liver
disorders the enzyme is released into circulation (300). Plasma XO activity were
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reported to be 2.1 ± 0.3 µmol min-1 L-1 in infant (301), 2.1 ± 0.8 µmol min-1 L-1
(302), 0.3 ± 0.2 µmol min-1 L-1 (303) and 0.32 ± 0.09 µmol min-1 L-1 (304) in healthy
subjects and 0.36 ± 0.05 µmol min-1 L-1 in in healthy males (304). According to
Yamamoto et al., there was no significant difference between healthy subjects and
gout patients of plasma XO activity (305). Jawed et al. firstly purified human XOR
from plasma using protein A beads coated with rabbit antihuman XOR polyclonal
antibody. They found 75% of the plasma NADH oxidase activity was contributed by
XOR, and it is significantly higher in rheumatoid arthritis patients (306). Our study
has not found plasma XOR activity, since the plasma was collected from an
apparently healthy subject. The produced uric acid, in reflecting of plasma enzyme
activity, could not reach the limit of quantification (detailed in section 2.6.3.3). Brief
calculation, plasma XO activity was reported, at highest, to be 2.1 ± 0.8 µmol min-1
L-1 (302) in healthy subjects. In each assay, 200 µL diluted plasma [2 ] was added
to 500 µL reaction system.
2.1 µmol min-1 L-1 × 200 µL / 2 = 210 pmol min-1
Plasma provides 210 pmol min-1 enzyme activity. By the end of reaction, 200 µL of
mixture was taken then be terminated by adding 50 µL of acid and methanol to 250
µL. If allow reacting for 30 min, the 250 µL of sample would contain:
210 pmol min-1 × 200 µL × 30 min / 500 µL = 2.520 nmol
10 µL of sample was injected to HPLC. So the amount of uric acid in 10 µL sample
would be:
2.520 nmol / 250 µL × 10 µL =100.8 pmol
And 100.8 pmol is close to the limit of quantification (78.2 pmol) of uric acid.
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Healthy human erythrocytes XD activity is reported by µmol min-1 g-1 of
haemoglobin is abundant than that of plasma (307) and is 0.61 ± 0.15 µmol min-1 g-1
of haemoglobin (308). We have also used healthy human erythrocytes for the
experiment. Results show that healthy human erythrocytes show XO activity
however the activity varies from sample to sample. Therefore the plan was
terminated. It might because of a limit of current treatment which cannot validate the
reproducibility. The treatment was, in brief, that erythrocytes were obtained from the
blood sample of the human study MEEC 12-019 with mononuclear leukocytes
isolated by Ficoll centrifugation (GE Healthcare, USA) and destroyed with detergent
(DECON 90, Decon Laboratories Limited, UK) according to (308). The remain
erythrocytes were harvested and washed in PBS, pH 7.4 (Sigma, USA) three times
and aliquots were stored at -80 ̊C till use.  
IC50 of quercetin on milk XO was reported to be 0.44 µM (106), 1.5 µM (294) and
2.08 µM (293). Ki of quercetin on milk XO varies from 1.40 ± 0.78 µM (181), 1.2 ±
0.7 µM (295), 0.28 µM (106) to 0.2 µM (111). By which, a comparison of the
inhibitory effect between isorhamnetin and quercetin can be made. Ki of
isorhamnetin is about 0.6 fold (0.17 µM (106)) and 1.25 fold (0.25 µM (111)) of Ki
of quercetin (Table 6-5). Results from the present study provide comparisons of IC50
between quercetin-3′-O-sulfate and quercetin and 3,4-dihydroxyphenylacetic acid
and quercetin. At inhibiting XO activity, quercetin-3′-O-sulfate is almost 10-fold
more efficient than quercetin and 3,4-dihydroxyphenylacetic acid is about 0.2-fold.
Quercetin-3′-O-sulfate was found to be an effective inhibitor of XOR, like
isorhamnetin and quercetin-4′-O-glucuronide (111) whilst quercetin-3-O-glucuronide
was found not able to inhibit, like quercetin-3-O-sulfate (111). This finding agreed
with previous findings that the position of conjugation is much more determinant on
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the function than the conjugated groups because of the exposure of the crucial
structure O1C2C1′C2′ angle (Figure 1-5). It can be concluded that the intact 
quercetin is more likely to inhibit XO than derived phenolics. This is probably due to
the loss of O1C2C1′C2′ structure where XOR favours (110). 
Some parameters of this assay brought limits. Besides the presence of NAD+
exhausted the enzyme, the adoption of hypoxanthine but not of xanthine as substrate
(as high concentration of xanthine is not stable in reaction buffer) introduced various
factors that may interfere with the observation since xanthine and uric acid inhibits
enzyme activity as well (309). Therefore Km and Ki of assay was not determined.
In conclusion, quercetin and its microbial-derived metabolites may suppress in vivo
the formation of uric acid by inhibiting XO and ADA. This finding may also provide
hypothesis of the relationship between quercetin supplement and other diseases
related to ADA activity.
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Chapter 7. Summary and Future Perspectives
7.1 Purpose of investigation and novelty
The primary hypothesis is that blood uric acid concentration can be modulated by
quercetin supplementation, especially in pre-hyperuricemic subjects. We investigated
the effect of oral supplementation of quercetin at 500 mg d-1 on blood uric acid level
by a randomised, double-blinded, cross-over human study. The result shows that the
blood uric acid levels were lowered after 4 weeks of quercetin supplementation
without affecting BMI, systolic blood pressure or fasting blood glucose level. The
lack of association of blood uric acid with other biomarkers during recruitment and
the lack of effect of quercetin treatment on BMI, systolic blood pressure or fasting
blood glucose suggest that hyperuricemia advances or at least is independent from
metabolic syndromes (Chapter 4). But this does not propose that metabolic
syndromes are independent from hyperuricemia.
The uric acid lowering effect was chronic (effect did not show significance until 4
weeks) so it might be caused by a more complex mechanism other than a simple
direct enzyme inhibition (Chapter 6). In Chapter 6, ex vivo characterisation of the
interaction of quercetin and its microbial and mammalian metabolites with enzymes
that are involved in uric acid metabolism, ADA, PNP and XOR was discussed to
advance previous knowledge that quercetin and some of its metabolites efficiently
inhibited XO in vitro (Chapter 6). Results showed that XO activity in vitro was
inhibited by not only quercetin, but also by quercetin-3′-O-sulfate and 3,4-
dihydroxyphenylacetic acid, dose-dependently. Also quercetin inhibits human
plasma ADA activity, dose-dependently, Therefore, this justifies the mechanism of
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the uric acid lowering effect of quercetin and its metabolites by direct inhibition of
the production of uric acid and its precursors.
Since blood uric acid is independent from other targeted biomarker levels (all within
healthy range) and it does not respond to quercetin immediately, as mentioned above,
we therefore explored the potential changes in all detectable plasma metabolites
using 1H-NMR spectroscopy and pattern-recognition techniques (Chapter 5). This
methodology was adjusted specifically for the study design and successfully
recognised several carbohydrate metabolites responding to quercetin treatment. For
example, lactate was significantly reduced after 4 weeks of quercetin treatment, but
not of placebo. The untargeted scanning of the differences in 1H-NMR spectra was
powered by the cross-over design of this study thus providing two study groups that
were matching in phenotype yet controlled by placebo. This randomised trial with
sufficient sampling points provided a valuable data set to explore potential
biomarkers that may have been affected by quercetin supplementation.
However, the effects of functional foods are not always as significant as
pharmaceutical strategies and usually they do not affect a healthy system as much as
an unhealthy system. Therefore, one of the advantages of the current study is that a
careful selected population were involved in this randomised controlled trial. It was
designated to use a male pre-hyperuricemic population to investigate the uric acid
lowering effect of quercetin. Similar to what we might anticipate, the effect was
found to be more remarkable in subjects with a higher initial uric acid level. Also this
lack of influence can be confirmed in other outcomes respectively, such as BMI,
fasting glucose and blood pressure since none of those were correlated to plasma uric
acid level and were normally distributed in normal range. Therefore the lack of effect
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on these biomarkers could be partially due to the normal healthy status. After all the
function of functional foods may be to dramatically protect against stress. The
development of disease is usually a result of years of accumulation of stress caused
by either an unhealthy lifestyle or lifelong susceptibility due to typical genetic
predisposition. Therefore a reasonably long exposure to the beneficial treatment must
be safe. This elongated treatment period is another advantage of present study
allowing a repeated supplementation chronically simulates diet.
A dosage 500 mg d-1 quercetin aglycone might be difficult to be efficiently delivered,
since quercetin aglycone yields less quercetin in urine as portion of intake than
quercetin glucosides from food. A pilot human study compared the renal excretion of
intact quercetin from aglycone supplement and quercetin glucoses from food. We
have found out that one 500 mg quercetin aglycone tablet is comparable to 100 g
fresh onion (Chapter 3). This result provided the confidence of the delivery
efficiency of supplement tablet for human study and provided a constant to compare
the previous results from humans studies conducted with different form of quercetin.
7.2 Discussion of outcomes
The key findings in this study is a favourable reduction in blood uric acid and blood
lactate after the habitual consumption of quercetin supplements, in healthy male
subjects with higher range of blood uric acid level, without affecting fasting glucose
blood pressure or BMI. This is probably not a result of reduced production of uric
acid through the inhibition of quercetin and its metabolites on XOR activity and
ADA, two important enzymes in purine metabolic pathways. Although we have
found the inhibitory effect of quercetin on both enzymes, the effective concentration
(IC50) are apparently higher than the physiological concentration (see
Table 6-2
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plasma antioxidant capacity (311, 312). This is not surprising given the high
concentration of urate in human plasma (160–450 μM) and its powerful reducing and 
free radical scavenging activities (313). In the extracellular environment, urate can
scavenge hydroxyl radical, singlet oxygen, and peroxynitrite, especially when
combined with ascorbic acid or thiols (314-316). However available data suggest that
uric acid is not essentially a biological antioxidant and, depending on the chemical
milieu, may become a prooxidant. Uric acid loses its antioxidant ability in the
hydrophobic environment (317) and even becomes a strong prooxidant in the
presence of lipid peroxides (318).
The products of XO, superoxide (•O2−) and hydrogen peroxide (H2O2) would surely
cause oxidative stress. In healthy human liver and jejunum, only 21% of XOR
activity was XO (319). However an irreversible conversion from XD into XO
happens in cell death in isolated hepatocytes subjected to ischemia (320) and in acute
minimal liver damage when XOR leaks into the blood. Like other cytoplasmic and
mitochondrial enzymes (321), the dehydrogenase form of XOR could be rapidly
converted into the oxidase form which may then produce extracellular oxygen
radicals (322). As XO produces •O2− and H2O2, the conversion from the XD to the
XO is hypothetically proposed to be responsible for causing oxidative stress. If this is
true, inhibition of XOR by allopurinol would not reduce oxidative stress when the
enzyme was mainly dehydrogenase since allopurinol/oxypurinol blocks the
production of uric acid and of •O2− and H2O2 by shutting down the enzymatic system
(Figure 7-2) (323). Allopurinol is an irreversible mechanism-based inhibitor of the
enzyme XOR in both forms (Figure 7-2). The enzyme commits suicide by initially
activating allopurinol into a transition state analogue, oxypurinol, that bind very
tightly to the molybdenum-sulfide (Mo-S) complex at the active site (324). It is
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uric acid is followed by an increase in the production of chemokines. In animal tests,
accumulation of uric acid in blood induced by means other than XOR inhibition
cause acute inflammation (by injection of uric acid solution) (329) and insulin
resistance (by inhibition of uricase) (68). An example for the mechanism is the effect
of hyperuricemia might be partially responsible for the low-grade inflammation and
insulin resistance in the adipose tissue and for increased risk of cardiovascular
disease induced by obesity.
Development of renal disease, endothelial dysfunction, and activation of the renin-
angiotensin system might also be the underlying cause of hyperuricemia-induced
hypertension. Since uric acid inhibits the expression of renin (330) and stimulates
renin release via a macula densa dependent mechanism (331) causing decreased
internal renin. This suggests a promising protective function for the endothelial cells
and smooth muscle cells by quercetin intake. Quercetin interrupts the renin-
angiotensin system signalling pathway by inhibiting the angiotensin-converting
enzyme activity and decreasing its mRNA production (332). This direct inhibition of
quercetin on the renin-angiotensin system may explain the antihypertensive effects of
quercetin.
Despite a long standing association between increased XOR activity and negative
clinical outcomes, recent report described a paradigm shift where XOR mediates
beneficial actions by catalysing the reduction of NO2− to •NO in both forms (Figure
7-4) (333).
R-C-H + 2NOO− + H+  R-C-O− +2•NO + H2O (Figure 7-4 C)
NADH + 2NOO− + 3H+  NAD+ + 2•NO + 2H2O (Figure 7-4 D)
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The synchronised decrease of blood urate and lactate after chronic oral consumption
of quercetin may indicate a relationship of their metabolism or a multi-functional
intervention by quercetin. Uric acid and lactic acid share the renal transport system
of organic acids (341) so that increased blood level of one may lead to accumulation
of another in blood because of the competition on transporters in renal excretion.
This hypothesis is also consistent with the known association of fructose induced
hyperuricemia and simultaneous generation of lactic acid (56) and the association of
hyperuricemia with other conditions of excessive generation of acid in the liver, like
diabetic acidosis (342) and alcoholism (343). Judging by the fact that allopurinol
treatment does not prevent lactic acid elevation caused by exercise in rats (344) or in
humans (345), uric acid formation is not likely to affect physiological lactic acid
balance. Therefore, hypothetically, the increase in serum concentration of uric acid is
due to the decreased urinary excretion of uric acid. It was demonstrated that ethanol
induced excessive production of lactic acid and NADH was accompanied by
decreased urinary excretion of uric acid, as well as the increase of serum uric acid
(346) especially when NADH inhibits production of uric acid (347). This may
indicate that uric acid excretion may be dependent on blood lactic acid. It is possible
that quercetin improved the efficiency of renal anion transporters however this needs
to be further investigated.
To summarise, as a key factor for gout, blood uric acid levels were significantly
reduced by oral supplementation of quercetin. The observed effect might be a result
of inhibition of uric acid production, or indirectly activated renal excretion of uric
acid through the reduction of lactate production or increase of lactate usage. The
downstream effects, as hypothesis, could involve a reduction of oxidative stress in
adipose, endothelial cells, etc., and a mediation on insulin delivery.
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7.3 Overall conclusion and future perspectives
Among healthy male subjects with a higher range of blood uric acid level, we
observed favourable reduction in blood uric acid and blood lactate after the habitual
consumption of quercetin supplements, without affecting fasting glucose or BMI.
This is probably a result of the inhibitory effect on XO/XD or other purine metabolic
enzymes.
We did not identify the role of the phenolic breakdown products of quercetin and
their metabolites in lowering blood uric acid. However bearing this goal in mind, a
series of quercetin metabolites, both microbial and mammalian, were tested on the
enzymes that were involved in uric acid metabolism, both ex vivo and in vitro.
Unfortunately we could not detect ex vivo human plasma XOR activity so the
relevant knowledge about XOR cannot advance beyond in vitro. The gap between
requires several more specific experiments to be performed.
Three hypotheses were proposed through the results of this thesis.
1) Quercetin may affect energy metabolism that activates gluconeogenesis in liver or
glycolysis in muscles by reduced oxidative stress and insulin tolerance;
2) Quercetin may inhibit MCTs (monocarboxylate transporters) thus reduced blood
lactate and improved renal excretion of uric acid.;
3) Quercetin may inhibit renal transporters in reabsorption of uric acid and
consequently cause a depletion of blood uric acid.
In conclusion, this research has exposed many potential functions of polyphenols in
vivo, for example, on energy metabolism, on cancer prevention, on kidney function
and on general healthy well-being.
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On the basis of these results, it is highly recommended that plasma/serum uric acid
level should be considered as an outcome or a risk factor in future nutrition cohort
study in public health research. Basic science research is still required in confirming
the causal relationships between metabolic syndromes and development of diseases.
To our hesitation, investigation of quercetin on kidney function is not included in this
study, as multiple lines of evidence suggest that kidney dysfunction is the
fundamental cause of hyperuricemia (348). A study looking into the interaction of
quercetin with human URAT1 (SLC22A12) and GLUT9 (SLC2A9) would be
helpful to better understand the in vivo effect of quercetin and may provide a new
approach in preventing gout and other metabolic disease.
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